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ABSTRACT 
 
Papua New Guinea (PNG) is a country of great diversity. The landscape and geography 
ranges from volcanic and mountainous highlands to coastal and floodplain lowlands, as well 
as more than 600 islands. There are more than 800 cultural and language groups 
countrywide, with more than 80% of the population living in rural areas (National Research 
Institute 2010). In 2016, tuberculosis (TB) in PNG was estimated to have caused more than 
30,000 cases countrywide (World Health Organization 2017a), with control challenged by 
the emergence of drug resistance, and complicated by a resource-limited health system. The 
situation faced by PNG due to TB and drug-resistant TB (DR-TB) has been described as an 
emergency (Eccles 2016; IRIN 2010). 
Research from regional settings in PNG has described a TB burden much higher than the 
national average, including in Western Province where this study was based (Aia et al. 2018; 
Cross et al. 2014; McBryde 2012). However, there is limited epidemiological data from areas 
outside the South Fly and provincial capital of Daru, despite evidence of a heavy TB and 
drug-resistant TB (DR-TB) burden (Aia et al. 2016; Furin & Cox 2016; Kase et al. 2016; 
McBryde 2012). The research presented in this thesis describes and characterises the 
distribution and determinants of TB in the rural Balimo region of Western Province. It is 
hoped that this study will provide epidemiological data about TB in the region that can 
inform local TB control strategies. 
This study used retrospective data analysis and laboratory techniques to describe TB in the 
Balimo region. The Balimo District Hospital (BDH) TB patient register was analysed, and 
laboratory diagnostic results were examined. A molecular assay was used to describe genetic 
evidence of DR-TB, and an interferon (IFN)-ɣ release assay (IGRA) was used to investigate the 
population-level latent TB burden and Mycobacterium tuberculosis complex (MTBC) 
infection in TB patients. 
A very high burden of TB was identified, with an estimated incidence of 727 TB cases per 
100,000 people per year. Approximately 25% of TB patients were children, and more than 
xv 
75% of all patients had extrapulmonary TB. Spatial analysis of TB across the region identifed 
a high TB burden in the area immediately surrounding Balimo. Lower rates of TB were 
identified in more remote areas, likely due to the challenges faced by people from rural 
regions in accessing health facilities. However, the spatial analysis also provided evidence of 
potential under-diagnosis of TB in more remote areas. 
DR-TB was described in the region, based on molecular evidence of rifampicin (RIF) 
resistance. In addition, the challenges of diagnosing TB in this region, where laboratory 
facilities are limited, are highlighted based on validation of the smear microscopy method 
used at the BDH laboratory. In combination, these results emphasise the importance of 
implementing a molecular method of TB diagnosis and detection of drug resistance in the 
Balimo region. 
Given the high burden of TB described in the Balimo region, an unexpectedly low proportion 
of latent TB was identified. Analysis of the IGRA results provided support for the accuracy of 
extrapulmonary TB diagnoses at BDH, which is important given more than 90% of the 
extrapulmonary TB diagnoses in the TB register analysis were made clinically based only on 
presenting signs and symptoms. 
Overall, this study emphasises the very high burden of TB present in the Balimo region. The 
results highlight the critical importance of investing in the hospital at Balimo, and ensuring 
that resources and facilities at the hospital are of a high standard adequate for accurate 
diagnosis and effective management of TB in the region. This need is especially important in 
the context of a region where other infectious diseases are also endemic. As a broad 
epidemiological study of TB in the Balimo region, the results presented in this thesis 
contribute important contextual information and baseline data on which future TB control 
efforts can be based. 
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GENERAL INTRODUCTION 
 
Tuberculosis (TB) is an ancient disease, with both archaeological and molecular evidence of 
TB occurring in Egypt more than 5000 years ago (Cave 1939; Daniel 2006; Nerlich et al. 1997; 
Zimmerman 1979; Zink et al. 2003). In more recent times, but before the advent of 
antibiotic-based treatment, one of the best-known approaches to the management of TB 
was the sanatorium. These facilities promoted TB care through exposure to the open air, 
exercise, and a healthy diet (Murray et al. 2015). Later public health measures included the 
introduction of the Bacille Calmette-Guérin (BCG) vaccine in 1921 (Daniel 2006). However, 
chemotherapeutic management of TB was only developed relatively recently, with the 
introduction of streptomycin (STR) in 1944 (Daniel 2006). TB treatment is effective with a 
treatment success rate greater than 85% (and frequently higher) for drug-susceptible cases 
(World Health Organization 2017a). The development of drug-resistant TB (DR-TB) is 
therefore of critical importance, as it poses numerous challenges to TB control, requiring 
more expensive medications and longer treatment durations. Furthermore, treatment 
efficacy is lower for DR-TB strains, with treatment success rates in 2014 of only 54% globally 
for multidrug-resistant TB (MDR-TB) (resistance to rifampicin (RIF) and isoniazid (INH)) and 
rifampicin-resistant TB (RR-TB) (World Health Organization 2017a). 
In a social context, TB is known to disproportionately affect vulnerable populations, 
including certain ethnic groups, prisoners, homeless people, refugees, and people living in 
lower socioeconomic settings (Centers for Disease Control and Prevention 2016; Figueroa-
Munoz & Ramon-Pardo 2008). As a result, people living in countries with decreased 
socioeconomic levels, measured by indicators such as the human development index (HDI), 
as well as vulnerable groups situated within higher HDI countries, face an increased risk of 
TB. Additionally, such settings face a double challenge – control and management of drug-
susceptible TB, as well as growing burdens of DR-TB. 
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Papua New Guinea (PNG) is a lower-middle-income country (based on 2018 fiscal year 
classifications), defined as having gross national income (GNI) of USD 1006 – 3955 per capita, 
and is ranked 154 (out of 188) on the HDI (United Nations Development Programme 2016; 
World Bank Group n.d.). PNG is also a high-burden country for TB, with incidence estimated 
to be 432 cases per 100,000 people per year (World Health Organization 2017a). DR-TB is 
considered to be high-burden, officially estimated to affect 3.4% of new TB patients, 
although other research has found higher rates in some settings (Aia et al. 2016; Gilpin et al. 
2008; Simpson et al. 2011; World Health Organization 2017a). By comparison, Australia, 
which is one of PNG’s nearest neighbours, is a high-income country (GNI of USD 12,236 or 
more per capita), ranked at 2 on the HDI (United Nations Development Programme 2016; 
World Bank Group n.d.). Australia has an estimated TB incidence of only 6.1 cases per 
100,000 people per year, and DR-TB in 3.6% of new TB patients (World Health Organization 
2018c). Furthermore, local transmission of TB is very low, with approximately 86% of TB 
patients diagnosed in Australia having been born overseas (Toms et al. 2017). 
It is thought that TB became established in PNG in the late 1800s and early 1900s (Ley et al. 
2014b). The first national TB control program using modern treatment was implemented in 
the 1950s, and management of TB across PNG became the responsibility of Dr. S. C. Wigley 
in 1957, who remained the specialist medical officer for TB for more than 20 years (Kennedy 
ca.1978; Levy et al. 1998; Ley et al. 2014b; Wigley n.d.). In the 1970s, a national policy for TB 
management was developed, in consultation with the World Health Organization (WHO) 
(Kennedy ca.1978). This policy outlined a plan for TB control and management, through 
case-finding, treatment, health education, contact tracing, and immunisation; and included 
clear and specific instructions for the recording and management of TB patients (Kennedy 
ca.1978). 
Despite the long history of TB in PNG, there continues to be limited published data 
describing the TB burden in many settings. Additionally, there is limited insight into the 
factors that influence TB epidemics in local settings. These factors must be understood in the 
context of the geographic and cultural diversity that defines PNG – a country with a 
mainland area ranging from volcanic and mountainous highlands to coastal and floodplain 
lowlands, as well as about 600 islands located to the north, south, and east of the mainland 
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(Commonwealth 2018) (Figure 1.1). Furthermore, the country is populated by more than 800 
different language groups, with 88% of people living in rural areas (Commonwealth 2018; 
National Statistical Office 2015). This diversity emphasises the importance of understanding 
TB in a local context. 
 
 
Figure 1.1: The Fly River region in the South Fly District of Western Province, PNG. (Image 
credit: Tanya Diefenbach-Elstob) 
 
For Western Province, a number of studies have described various aspects of the 
epidemiology of TB (Aia et al. 2016; Bainomugisa et al. 2018; Gilpin et al. 2008; Guernier et 
al. 2018; McBryde 2012; Pandey et al. 2018; Simpson et al. 2011). This data has described 
the substantial burden of TB in the province, with incidence higher than the estimated 
national average (McBryde 2012). The provincial capital of Daru is in the South Fly District, 
and is located on an island to the south of the mainland. Daru is the site of the referral 
hospital for presumptive DR-TB patients in the province (Department of Health 2011), and 
has a very high burden of DR-TB (Aia et al. 2016; Furin & Cox 2016; Kase et al. 2016). 
However, as the provincial capital, the island of Daru has an urban and more transient 
population. Additionally, the population dynamics and source of flow of TB patients into the 
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provincial capital has not been described. The lack of comprehensive studies from the North 
and Middle Fly districts of the province have resulted in a situation where the broader 
provincial TB burden is uncertain, and the impact of TB cases from other regions on Daru is 
unknown. 
This research presented in this thesis will describe and characterise TB in the Balimo region, 
the urban centre of the Middle Fly District of Western Province. TB in the region is managed 
at Balimo District Hospital (BDH), a rural hospital with no resident physician, and limited 
diagnostic laboratory facilities. TB is known to occur in this region, and there is evidence that 
the burden of disease is substantial (McBryde 2012). Research from our group has identified 
potential under-diagnosis of TB, particularly for pulmonary smear-negative TB patients 
(Guernier et al. 2018). Furthermore, our earlier work has described numerous barriers and 
facilitators of TB treatment adherence, although many of these factors are influential 
throughout the entire TB journey (Diefenbach-Elstob et al. 2017). In this region, it is 
important to understand the burden of TB, but also to appreciate the context in which TB 
occurs, as understanding these factors will help to guide the design and implementation of 
TB control measures that are appropriate for this setting. This research will address the 
epidemiological knowledge gap of TB in the Balimo region, placing it in the context of social, 
cultural, behavioural, and geographic factors. Taking this broad approach is important to 
provide data that is setting-specific and appropriate to local TB management, and also to 
further understanding of the impact of TB from the Balimo region on the greater Western 
Province area.  
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LITERATURE REVIEW – CHALLENGES FOR 
TUBERCULOSIS CONTROL IN RESOURCE-LIMITED SETTINGS 
 
2.1. Introduction 
Tuberculosis (TB) is a global disease epidemic. In 2016, TB was estimated to have caused 
about 10.4 million cases and 1.6 million deaths worldwide (World Health Organization 
2017a). These numbers are despite TB being both treatable and curable in drug-susceptible 
cases. In Papua New Guinea (PNG), TB contributes substantially to disease burden. Incidence 
data from 2016 estimated TB to have caused almost 35,000 cases and more than 4300 
deaths in PNG (World Health Organization 2017a), and more than 28,000 TB cases were 
notified (Aia et al. 2018). The country has the third-highest incidence of TB in the Western 
Pacific Region, behind Kiribati and Timor-Leste (World Health Organization 2017a). 
Increasing case notification rates, and a treatment success rate of only 74% in new cases and 
63% in previously treated cases, signal an urgent need for improved TB control strategies 
countrywide (World Health Organization 2017a). 
In 1994, the World Health Organization (WHO) first proposed the directly observed 
treatment, short-course strategy, known as DOTS, as a framework for TB control (World 
Health Organization 2006). The DOTS strategy was originally based on five key components: 
political commitment, a passive case-finding approach to detecting cases, standardised 
treatment with proper case management, a regular drug supply, and a monitoring system to 
enable program evaluation (World Health Organization 1999, 2006). However, the 
challenges facing DOTS, particularly in settings with poor support and inadequate 
infrastructure, led the WHO to release expanded DOTS guidelines in 2006, known as the 
‘Stop TB Strategy’ (World Health Organization 2015c) (Figure 2.1). The ‘Stop TB Strategy’ 
reinforced and further defined the original components of DOTS, and emphasised 
community involvement and the need to consider increasing drug resistance (World Health 
Organization 2002). The ‘Stop TB Strategy’ was made up of six components. The first, to 
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pursue high-quality DOTS expansion and enhancement, included the original aims of the 
DOTS strategy (World Health Organization 2006). The other components included addressing 
increasing challenges to TB control, such as TB-HIV and drug resistance; strengthening health 
systems; engaging with all care providers, both public and private; empowerment of people 
with TB and their communities; and enhancing research activities (World Health 
Organization 2006). In 2014, the ‘End TB Strategy’ was implemented, parallel to the goal of 
ending TB that was included as part of the new sustainable development goals (SDG) 
adopted in 2015 (United Nations n.d.-a, n.d.-b; World Health Organization 2015c). The new 
strategy is built on three pillars: (1) integrated, patient-centred care and prevention, (2) bold 
policies and supportive systems, and (3) intensified research and innovation (World Health 
Organization 2015e). 
 
 
Figure 2.1: TB treatment poster from PNG linked to the ‘Stop TB Strategy’ and DOTS. (Image 
credit: Tanya Diefenbach-Elstob) 
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Many resource-limited settings, including PNG, base their TB control programs on the 
strategies endorsed by the WHO. However, the implementation of these strategies is 
influenced by a variety of setting-specific factors, including limited resources, staff shortages, 
and funding short-falls (Dimitrova et al. 2006; Khan et al. 2016). In addition, treatment 
approaches often focus on the ‘direct observation of treatment’ (DOT) aspect that was 
historically part of the strategy, and which emphasised the need for patients to have their 
treatment observed by a health worker or treatment supporter (World Health Organization 
1999). The focus on DOT can be problematic due to the economic burdens placed on 
patients when treatment observation requires travel, and results in lost time for work and 
food production activities (Diefenbach-Elstob et al. 2017; Gebremariam et al. 2010; 
Sagbakken et al. 2013; Tadesse et al. 2013). As a result of local challenges, TB control 
programs have by necessity adapted TB management strategies to accommodate their own 
setting-specific demands (Massey et al. 2012; Newell et al. 2006; Wei et al. 2008). 
This literature review will introduce TB, and examine aspects of TB control strategies in 
resource-limited settings, with a particular focus on the challenges that are faced. The 
influence of such challenges on TB epidemiology will then be described. Finally, the burden 
of TB in PNG will be described, including the factors influencing TB epidemiology in this 
region. 
 
2.2. Tuberculosis 
2.2.1. The organism: Mycobacterium tuberculosis 
Mycobacterium tuberculosis (MTB), the causative organism of TB, is part of the M. 
tuberculosis complex (MTBC) that comprises at least seven genetically similar species 
(Rodriguez-Campos et al. 2014; Wirth et al. 2008). Human TB cases are primarily caused by 
M. tuberculosis, with a smaller number of cases caused by M. africanum, and M. bovis 
(Forrellad et al. 2013; Rodriguez-Campos et al. 2014; Torres-Gonzalez et al. 2016). Other 
species responsible for disease primarily in animals include M. bovis, M. canettii, M. caprae, 
M. microti, and M. pinnipedii, and potentially M. orygis and M. mungi (Forrellad et al. 2013; 
Hershberg et al. 2008; Rodriguez-Campos et al. 2014).  
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Molecular analysis techniques have led to the sub-division of M. tuberculosis and M. 
africanum into seven lineages, which are further divided into a number of strains (Table 2.1) 
(Brites & Gagneux 2015; Nebenzahl-Guimaraes et al. 2016). The discovery of all lineages in 
Africa has resulted in an ‘out of Africa’ hypothesis describing the evolution and spread of TB 
throughout the world (Brites & Gagneux 2015; Gagneux & Small 2007; Nebenzahl-Guimaraes 
et al. 2016). 
 
Table 2.1: The sub-division of M. tuberculosis and M. africanum lineages, including the 
geographic region associated with each lineage, and some of the well-known strains. 
(Sources: Blouin et al. 2012; Gagneux et al. 2006; Gagneux & Small 2007; Nebenzahl-
Guimaraes et al. 2016) 
Lineage Species Geographic region Included strains 
1 M. tuberculosis Indo-Oceanic EAI 
2 M. tuberculosis East-Asian Beijing 
3 M. tuberculosis East-African-Indian CAS 
4 M. tuberculosis Euro-American Haarlem, LAM, T, X 
5 M. africanum West-African 1  
6 M. africanum West-African 2  
7 M. tuberculosis Ethiopian  
CAS: Central Asian; EAI: East-African-Indian; LAM: Latin American-Mediterranean 
 
2.2.2. Transmission and infection 
The transmission of MTB is predominantly airborne, via the aerosolisation of respiratory 
droplets from infected individuals, primarily through coughing (Pai et al. 2016; Yates et al. 
2016). If an infected person’s immune system has an adequate response, MTB bacilli that 
reach the lungs are contained in granulomas, resulting in a non-symptomatic and non-
infectious latent infection (Pai et al. 2016). If the bacilli are not able to be contained, they 
replicate and spread throughout the body, resulting in active TB (Knechel 2009). Active TB 
may occur in up to 15% of people who have been latently infected (Trauer et al. 2016). 
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Active pulmonary TB, which is restricted to the lungs, is characterised by non-specific signs 
and symptoms such as fever, fatigue, weight loss, and night sweats; as well as more specific 
symptoms including a prolonged cough and haemoptysis (Pai et al. 2016). 
Extrapulmonary TB refers to infection in any site of the body apart from the lungs. The most 
common sites of infection are the lymph nodes, pleura, gastrointestinal tract, bones, central 
nervous system, and genitourinary system (Peirse & Houston 2017). Presentation is often 
non-specific, and the condition may go unrecognised, with case reports describing 
misdiagnoses of extrapulmonary TB as conditions such as metastatic disease and Crohn’s 
disease (Makhani et al. 2013; Riedel et al. 1989). 
 
2.2.3. Identification and diagnosis 
Phenotypic diagnosis of TB is generally performed by liquid or solid culture of clinical 
samples, frequently sputum. However, the slow replication time of MTB means that this 
technique is lengthy (Chien et al. 2000; Lawn & Zumla 2011). Furthermore, culture is 
expensive, carries the risk of generating infectious aerosols, and requires sophisticated 
laboratory infrastructure (World Health Organization 2012). In resource-limited settings, 
microscopy of sputum smears is the most common method of diagnosis (Figure 2.2). 
However, microscopy is increasingly being replaced by the Xpert MTB/RIF. The Xpert 
MTB/RIF is a semi-automated and rapid nucleic acid amplification test (NAAT) that can 
detect MTB infection, as well as rifampicin (RIF) drug resistance, based on amplification of 
the rpoB gene (Helb et al. 2010; Ioannidis et al. 2011; World Health Organization 2013c). 
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Figure 2.2: Photomicrograph of M. tuberculosis visualised with an acid-fast Ziehl-Neelsen 
stain. (Image source: CDC PHIL/ Dr George P. Kubica – Public Domain) 
 
The diagnosis of extrapulmonary TB is frequently challenging, with the technique used 
dependent on the site of infection. Culture or microscopy may be used if fluid samples are 
available, while tissue samples may be examined using histology or cytology (Purohit & 
Mustafa 2015). However, the inability to collect a suitable clinical specimen, or a lack of 
diagnostic infrastructure even if samples are available, means that the diagnosis of 
extrapulmonary TB is frequently clinical, based solely on presenting signs and symptoms 
(Dangisso et al. 2014; Purohit & Mustafa 2015). The WHO diagnostic guidelines for TB allow 
for the clinical diagnosis of both pulmonary and extrapulmonary TB, using the classification 
of a ‘clinically diagnosed TB case’, based on the decision of a clinician to commence a patient 
on a full course of TB treatment (World Health Organization 2013a). 
 
2.2.4. Treatment of tuberculosis 
The discovery of antibiotics led to the first drug treatments for TB, beginning in 1944 with 
injectable streptomycin (STR) (Daniel 2006). Oral treatment followed with isoniazid (INH) in 
1952, and the rifamycins in 1957 (Daniel 2006). RIF, still in use today, was discovered in 1962 
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(Zumla et al. 2013). The other two first-line drugs, pyrazinamide (PZA) and ethambutol 
(EMB), were discovered in 1954 and 1961 respectively (Zumla et al. 2013).  
Six-month four-drug combination treatment regimens were introduced in the 1970s (Zumla 
et al. 2013), and have now been the first line of defence in TB treatment for more than 40 
years. The recommended standardised treatment regimen for new TB patients consists of 
daily medication, with a two-month intensive phase of INH, RIF, PZA, and EMB; followed by a 
four-month continuation phase of INH and RIF (World Health Organization 2017b) (Figure 
2.3). This regimen is often abbreviated as 2HRZE/4HR. 
 
 
Figure 2.3: RIF, INH, PZA, and EMB drugs in fixed dose combinations. (Image credit: Tanya 
Diefenbach-Elstob) 
 
2.2.5. The emerging crisis of drug-resistant tuberculosis 
The problem of drug-resistant TB (DR-TB) emerged soon after effective antibiotic treatments 
were developed. Resistance to STR was first reported in 1948, only four years after the drug 
was first used in TB treatment (Crofton & Mitchison 1948). This pattern continued, with 
drug-resistant cases occurring in response to other anti-TB drugs as they were developed 
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and put into use (Fox et al. 1999; Keshavjee & Farmer 2012). The result of ongoing and 
emerging drug resistance was the implementation of the multi-drug regimens still used 
today. 
Drug resistance can occur in response to any of the anti-TB drugs. However, DR-TB is usually 
described in relation to two main categories. Multidrug-resistant TB (MDR-TB) is resistance 
to both INH and RIF, while extensively drug-resistant TB (XDR-TB) is MDR-TB with additional 
resistance to any fluoroquinolone (FLQ), plus at least one of three listed injectable antibiotics 
(capreomycin, kanamycin, and amikacin) (World Health Organization 2013a) (Table 2.2).  
 
Table 2.2: Definitions used to describe DR-TB (World Health Organization 2013a, 2017a). 
Note that the definitions of XXDR and TDR are unofficial (World Health Organization 2018e). 
Type of resistance Associated drugs 
Mono-resistant Any one drug 
Rifampicin-resistant Only RIF (susceptible to INH) 
Multidrug-resistant (MDR) Both INH and RIF (resistance to other drugs may 
also be present) 
Extensively drug-resistant (XDR) MDR, plus 
Any fluoroquinolone, plus 
Any one of capreomycin, kanamycin, or amikacin 
Extremely drug-resistant (XXDR) 
Totally drug-resistant (TDR) 
All first- and second-line drugs 
INH: isoniazid; RIF: rifampicin 
 
Two different pathways may lead to the development of DR-TB. Acquired drug resistance 
develops in a case of active drug-susceptible TB, as a result of insufficient treatment allowing 
the selection of resistant mutant strains (World Health Organization 2014b). Primary drug 
resistance occurs as a result of direct transmission of a drug-resistant TB strain (World 
Health Organization 2014b). For many years, management of DR-TB in TB control programs 
focused on acquired drug resistance and previously treated TB patients (Dheda et al. 2017). 
However, there is growing evidence highlighting the large proportion of DR-TB cases that 
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result from direct transmission of DR-TB strains (Dheda et al. 2017; Sarita et al. 2017; Zhao et 
al. 2012). 
Globally in 2016, 4.1% of new TB cases and 19% of retreatment cases were identified as 
either RIF-resistant TB (RR-TB) or MDR-TB (World Health Organization 2017a). It has also 
been estimated that about 8.5% of TB cases have INH resistance, without concurrent RIF 
resistance (World Health Organization 2017a). Furthermore, it was estimated that about 
6.2% of MDR-TB cases had XDR-TB (World Health Organization 2017a). Extremely drug-
resistant TB (XXDR-TB) and totally drug-resistant TB (TDR-TB), while not officially recognised 
terms, generally refer to resistance to all of the tested first- and second-line drugs (Kanabus 
2016; Udwadia et al. 2012; Velayati et al. 2009; World Health Organization 2018e) (Table 
2.2). Cases of XXDR-TB and TDR-TB have been described in Italy, the United States of 
America, Iran, and India (Kanabus 2016). 
In addition to these estimates for DR-TB, in some settings the proportion of TB drug 
resistance is thought to be much higher. The World Health Organization (WHO) has 
designated 30 countries as high MDR-TB burden countries (Figure 2.4). Of those countries in 
the MDR-TB high-burden list, the best estimate of MDR/RR-TB ranges from 1.3% (Kenya) to 
38% (Belarus) in new cases; and from 7.1% (South Africa) to 72% (Belarus) in previously 
treated cases (World Health Organization 2017a). In 2014 only 54% of MDR/RR-TB cases and 
30% of XDR-TB cases were successfully treated worldwide (World Health Organization 
2017a). DR-TB has become a global crisis. 
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Figure 2.4: High-burden countries for TB, MDR-TB, and TB/HIV. (Image source: World Health 
Organization 2017a) 
 
2.2.6. Global epidemiology of tuberculosis 
In 2016, TB incidence globally ranged from a low of 0 cases per 100,000 people per year in a 
number of countries (British Virgin Islands, Monaco, Montserrat, Saint Kitts and Nevis, San 
Marino, Sint Maarten (Dutch part), Tokelau, and the Wallis and Futuna Islands) to a high of 
781 cases per 100,000 people per year in South Africa (Figure 2.5) (World Health 
Organization 2017a). Five countries were the origin of 56% of incident TB cases; these were 
India, Indonesia, China, the Philippines, and Pakistan (World Health Organization 2017a). 
Approximately 600,000 new cases of TB were either RR-TB or MDR-TB, and of these, 47% 
occurred in China, India, and the Russian Federation (World Health Organization 2017a). 
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Figure 2.5: Estimated TB incidence rates per 100,000 people in 2016. (Image source: World 
Health Organization 2017a) 
 
The proportion of bacteriologically confirmed cases of TB varies widely by region. For 
example, for pulmonary TB cases in 2016, bacteriological confirmation ranged from 38% in 
the Western Pacific region to 78% in the Americas (World Health Organization 2017a). 
Extrapulmonary TB proportions are also variable, ranging from 8% in the Western Pacific 
region to 24% in the Eastern Mediterranean region (World Health Organization 2017a). 
However, rates of extrapulmonary TB are often substantially higher in setting-specific 
studies. For example, studies have described extrapulmonary TB in 22.7% of TB patients in 
Kassala, Sudan, 49.4% of TB patients in Van, Turkey, and 24.9% of TB patients in Fiji 
(Abdallah et al. 2015; Pezzoli et al. 2016; Sunnetcioglu et al. 2015). In addition, the presence 
of TB-HIV coinfection may influence local TB epidemiology, with a number of studies 
describing increased risk of extrapulmonary TB in people with HIV infection (Gomes et al. 
2014; Wilkinson & Moore 1996; Yang et al. 2004).  
 
2.3. Working Towards Tuberculosis Control: Challenges in Resource-Limited Settings 
Despite the implementation of the expanded ‘End TB Strategy’, there are still significant 
barriers to TB control in many settings; some of these barriers are described following. Local 
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identification of such barriers, and the adaptation of the ‘End TB Strategy’ to address them, 
is essential to ensuring that broad TB control guidelines are actually useful in the settings 
where they are implemented. 
 
2.3.1. Diagnosing tuberculosis with limited laboratory infrastructure 
The WHO-recommended approach to TB diagnosis is sputum smear microscopy in primary 
health care facilities; and culture, drug susceptibility testing (DST), and molecular detection 
of drug resistance in health care facilities where clinical laboratories are available (World 
Health Organization 2018f). However, techniques such as culture and DST are reliant on 
extensive laboratory networks with the necessary equipment and trained staff, as well as a 
national reference laboratory (World Health Organization 2006). Furthermore, access to 
multiple diagnostic approaches is important, to ensure that more difficult-to-diagnose cases 
are properly assessed, including those that are smear-negative, have HIV co-infection, and 
with possible drug resistance (World Health Organization 2006). 
Solid and liquid culture methods, as well as DST, require moderate- and high-risk (TB-
containment) laboratories (World Health Organization 2012) (Figure 2.6). However, such 
laboratories may not be readily accessible, with clinical samples requiring culture and DST 
often needing to be sent to reference laboratories that may be located in another country. 
The length of time required to achieve culture results is also problematic, with solid culture 
taking about seven weeks, while automated or semi-automated liquid culture systems such 
as the BACTEC 960 take about seven to eleven days (Battaglioli et al. 2013; Scarparo et al. 
2004; Zhao et al. 2013). These factors mean that obtaining culture results is time-consuming. 
Thus, best-practice recommendations based on microscopy, culture, and DST are difficult to 
achieve where only limited laboratory facilities are available. These difficulties emphasise 
the importance of other more accessible techniques, such as the Xpert MTB/RIF platform 
recommended by the WHO (World Health Organization 2018f). However, as noted 
previously, although the platform has been rolled out across numerous settings there are 
limitations to its use due to cost, accessibility, the need for stable electricity and 
temperature control requirements, and the inability to identify resistance to other anti-TB 
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drugs (Boehme et al. 2011). These are important considerations in resource-limited settings, 
and research is important in determining the best ways to prioritise and manage Xpert 
MTB/RIF testing in combination with other diagnostic and screening approaches (Muttamba 
et al. 2018; Muyoyeta et al. 2015; Philipsen et al. 2015). 
 
 
Figure 2.6: M. tuberculosis solid culture showing colony morphology. (Image source: CDC 
PHIL/ Dr. George Kubica – Public Domain) 
 
In resource-limited settings, often sputum smear microscopy is the only technique that is 
readily available. However, this technique is known to have low and variable sensitivity of 31 
– 98%, and poor sensitivity of the technique has been described in samples from patients 
who are HIV-positive (Cattamanchi et al. 2009; Elliott et al. 1993; Steingart et al. 2006a; 
Steingart et al. 2006b). Poor sensitivity, especially when combined with a lack of access to 
other bacteriological diagnostic facilities, may lead to increased false-positive clinical TB 
diagnoses. The challenges faced due to poor microscopy sensitivity have been described in a 
study from Ethiopia, where poor microscopy accuracy was noted as potentially contributing 
to empiric treatment of patients who did not actually have TB (Cowan et al. 2013). However, 
large numbers of smear-negative results may also contribute to substantial proportions of 
false-negative diagnoses, and potentially under-diagnosis of TB (Guernier et al. 2018). These 
outcomes create burdens for patients, who may be unnecessarily exposed to potentially 
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toxic drugs, or remain untreated despite actually having TB. Difficulties in TB diagnosis also 
create challenges for health workers, who may spend a considerable amount of time 
treating and managing misdiagnosed patients. 
 
2.3.2. Clinical diagnosis of tuberculosis 
The inability to accurately diagnose TB using laboratory-based methods may increase the 
likelihood of a patient receiving a clinical TB diagnosis, based solely on presenting signs and 
symptoms (Purohit & Mustafa 2015). This scenario may be particularly the case for 
presumptive extrapulmonary TB, where suitable diagnostic samples can be difficult to obtain 
(Norbis et al. 2014). Given the difficulties associated with bacteriological identification of TB, 
clinical diagnoses will undoubtedly continue to be common for the foreseeable future. 
Additionally, in resource-limited settings where minimal laboratory infrastructure is 
available, clinical diagnoses are likely to form a substantially higher proportion of the total 
identified TB cases. 
The growing burden of DR-TB is an additional complication in the use of clinical diagnoses for 
TB. In clinically diagnosed TB cases, a positive response to treatment may be the only 
evidence available to confirm that a TB diagnosis was correct, despite this approach being 
problematic due to treatment failure, acquired drug resistance, and the effectiveness of 
some TB drugs against other bacterial organisms (Chakravorty et al. 2005; Colebunders & 
Bastian 2000; Ryu 2015). However, for DR-TB patients, clearly there will be non-response to 
first-line treatment, even if the clinical diagnosis of TB was correct. This situation may lead to 
prolonged periods of ineffective treatment, ongoing transmission of DR-TB strains to others, 
and worsening of disease. 
 
2.3.3. Outcomes of delayed diagnosis and treatment 
Poor diagnostic and treatment outcomes may occur for TB patients due to delays in the 
diagnosis-to-treatment pathway, including delays in either the initial diagnosis or treatment 
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commencement, and loss-to-follow-up between diagnosis and treatment initiation. For 
example, delay in a TB diagnosis may lead to loss to follow-up. A systematic review of 
sputum smear- and culture-positive patients found pre-treatment loss to follow-up rates 
ranging from 4 – 38% in low- and lower-middle-income countries (MacPherson et al. 2014). 
A number of studies have explored this issue further. Delays in returning the results of 
sputum testing were specifically identified as pre-treatment barriers in studies from Malawi 
and Vietnam (Buu et al. 2003; Squire et al. 2005). Distance and access to a health facility 
have also been noted as important. In the study from Vietnam, people from urban areas 
were more likely to be lost prior to treatment (Buu et al. 2003). However, in studies from 
India and Cambodia people located in rural areas or further from a health facility were more 
likely to be lost (Lorent et al. 2015; Mehra et al. 2013). In the study from Cambodia, costs 
associated with transport and lost time from work were also cited as barriers (Lorent et al. 
2015). 
Diagnostic accuracy and prompt access to diagnostic testing are particularly important in the 
context of case detection and follow-up of people being investigated for TB. Patients who do 
not receive a diagnosis on the day that they attend a health centre may be left with no 
choice but to return home, and subsequently may not return for diagnostic results (Squire et 
al. 2005). Other problems in the diagnosis-to-treatment pathway may include confusion 
about testing and the need to return for results, and unavailability of results even if patients 
do return (Skinner & Claassens 2016). Delays in receiving results may mean that patients are 
not traceable by health workers, due to both a lack of records and staff time constraints, and 
will thus remain undiagnosed and untreated (Engel et al. 2015). This challenge is particularly 
concerning in the context of ongoing TB transmission to others, and also in understanding 
the true burden of TB in settings where pre-treatment loss to follow-up occurs (MacPherson 
et al. 2014). Furthermore, delayed diagnosis and treatment of TB patients has been 
associated with transmission of MTB to patient contacts, and death and treatment failure 
outcomes (Gebreegziabher et al. 2016; Golub et al. 2006). 
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2.3.4. Treatment of tuberculosis with limited health facilities 
The earlier ‘Stop TB Strategy’ called for standardised, short-course treatment regimens that 
used fixed dose combination (FDC) drugs (World Health Organization 2006). Supervision of 
treatment was advised, although it was stated that this should be flexible and sensitive to 
patient needs (World Health Organization 2006). The most recent TB treatment guidelines 
continue to recommend FDCs (World Health Organization 2017b). Treatment supervision is 
also advised, although this may be offered by a treatment supporter (friend, family, or lay 
person), health worker, or video observation if appropriate (Figure 2.7) (World Health 
Organization 2017b). 
 
 
Figure 2.7: Hospital-based health workers in Balimo, PNG. (Image credit: David Plummer) 
 
In practice, achieving treatment guidelines can be extremely difficult, particularly in 
resource-limited settings. Facilities that care for TB patients must contend with a lack of 
infrastructure and resources, and inadequate numbers of staff (Buregyeya et al. 2013; 
Zelnick et al. 2013). Furthermore, resource shortages may include the medications used to 
treat TB, with such shortages having been reported from a number of countries (Rusen et al. 
2010; Stop Stockouts 2016). 
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In resource-limited settings, there are often inadequate numbers of health workers, with 
existing staff overburdened (Buregyeya et al. 2013). It has been estimated that there is a 
global shortage of approximately four million health workers, and that sub-Saharan Africa 
needs to triple its workforce (Chen et al. 2004). In many settings, the mix of providers is 
unsuitable, with a particular shortage of community-based workers (Chen et al. 2004). The 
distribution of workers can also be problematic, with excess health worker numbers in urban 
locations, while rural areas are under-served (Chen et al. 2004; Figueroa-Munoz et al. 2005). 
In PNG, where more than 80% of the population live in rural areas, in 2009 it was estimated 
that 44% of the health service delivery workforce (doctors, health extension officers, nurses, 
midwives, community health workers, and dentists) were employed in urban areas, and 56% 
were working in rural areas (Morris & Somanathan 2011; National Statistical Office 2015). 
The ageing of health workforces is also an area of concern, particularly due to the large 
proportion of the workforce who are approaching retirement age (Morris & Somanathan 
2011). In PNG in 2009, 15.6% of the health service delivery workforce (as defined above) 
were aged 55 years or over, 37.7% were aged 45 – 55 years, and only 12.3% were aged 
under 35 years (Morris & Somanathan 2011). The challenges associated with staff shortages 
and health workforce distribution have the potential to compromise not only diagnosis and 
treatment of TB patients, but also the ability to conduct essential contact tracing and follow-
up activities. 
 
2.3.5. Treatment challenges for tuberculosis patients 
Challenges presented by access factors may be substantial barriers across all facets of TB 
management, including treatment-seeking, diagnosis, treatment, and follow-up. Financial 
and travel-related burdens have been described in a number of resource-limited settings, 
including rural China, Nigeria, and the Solomon Islands (Massey et al. 2012; Ukwaja et al. 
2013a; Wei et al. 2009; Xu et al. 2010). Access to medications in predominantly resource-
limited settings such as parts of Africa is complicated by the high proportions of the 
population living in rural areas, where access is limited (Tetteh 2009). This challenge will also 
be an important factor in a setting such as PNG, where more than 80% of the population live 
in rural areas, only 35% live within ten kilometres of a major road, and 17% have no road 
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infrastructure links at all (National Research Institute 2010; National Statistical Office 2015; 
Ongugo et al. 2011) (Figure 2.8). It is possible that these barriers may also prevent people 
with TB symptoms from seeking treatment in the first place. 
 
 
Figure 2.8: Travelling in a dugout canoe in the Balimo region of PNG, where there are very 
few roads, and travel is predominantly by boat or foot. (Image credit: David Plummer) 
 
The economic hardship that can result from TB is also a recognised problem, as 
demonstrated by one of the indicators of the ‘End TB Strategy’, which is to have no TB-
affected patients and families facing catastrophic costs due to TB by 2020 (Floyd et al. 2018; 
World Health Organization 2015c). Patients may face potentially devastating costs in 
accessing TB care. In South Africa, a study found that about 41% of costs associated with TB 
care were incurred before treatment had even been started, primarily due to loss of income 
(Foster et al. 2015). Income loss has also been described in Zambia, with TB patients 
reported to have delayed treatment-seeking due to money shortages, and having an average 
of 18 days of work lost prior to diagnosis (Needham et al. 1998). Among those patients who 
had ceased work due to TB, an average of 48 days of work were lost (Needham et al. 1998). 
In China and India, patients have described borrowing money and selling assets to cover 
costs (Jackson et al. 2006; Prasanna et al. 2018). In Nigeria, where TB laboratory tests and 
medications are free, substantial costs were still incurred for consultations with health 
38 
providers, medications and diagnostic tests unrelated to TB, as well as transportation 
(Ukwaja et al. 2013a). Additionally, the proportion of households who were classified as 
poor increased from 54% prior to the TB episode to 79% afterwards (Ukwaja et al. 2013a). In 
a study from India, 32.4% of households experienced catastrophic costs (TB costs that 
exceeded 20% of the household’s annual income) during diagnosis and the intensive phase 
of TB treatment (Prasanna et al. 2018). 
Large burdens may be placed on TB patients. For example, in some settings strict 
interpretation and implementation of DOT may mean that patients are not allowed to take 
their medications home with them, and will be expected to travel daily to a health facility to 
receive their treatment (Benbaba et al. 2015; Sagbakken et al. 2008). Such travel can be an 
insurmountable barrier for patients, with excessive transport costs, and lost time resulting in 
burdens in maintaining paid employment, even in settings where less frequent attendance 
at a health clinic is required (Benbaba et al. 2015; Chida et al. 2015). These examples 
demonstrate the increased burdens caused by TB diagnosis and treatment, which may 
disproportionately affect the vulnerable and disadvantaged populations who are least able 
to overcome such challenges. 
For many patients, TB treatment creates disadvantage, discrimination, and perpetuation of 
poverty. As already discussed, patients may be unable to retain employment due to needing 
to attend daily at a health facility for treatment observation, resulting in economic burdens 
on top of existing health burdens (Gebremariam et al. 2010; Sagbakken et al. 2013). 
Discrimination against TB patients is prevalent in many settings, which hinders both 
identification and treatment (Baral et al. 2007; Gebremariam et al. 2010). 
 
2.3.6. Achieving effective tuberculosis control despite resource challenges 
Although there are numerous barriers to TB control, especially in resource-limited settings, 
there are many achievements from such settings that should also be acknowledged. For 
example, extensive research from the Solomon Islands has described treatment barriers 
associated with taboos and traditional beliefs, but has also detailed community-based 
projects aimed at overcoming such challenges (Massey et al. 2011; Massey et al. 2012; 
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Massey et al. 2013). Community-based systems of care have been implemented in many 
resource-limited settings, with such approaches often successful. For example, in Ethiopia 
the community-based Health Extension Program was introduced in 2004 (Ketema et al. 
2014). This program offers decentralised TB services, with many TB-related activities being 
conducted by health extension workers (HEW) and TB supporters (Ketema et al. 2014). 
Where patients are unable to attend a health facility daily, medications are dispensed 
weekly, and treatment is observed by a HEW or treatment supporter (Ketema et al. 2014). 
The program found that treatment success was not significantly associated with either 
approach – patients had treatment success rates of 97.8% in the community and 93.5% at 
health facilities (Ketema et al. 2014), thus indicating the feasibility of community-based 
treatment support strategies. In Tanzania, a similar approach has been used, labelled 
‘patient centred treatment’ (PCT) (Egwaga et al. 2009). This strategy uses home-based 
treatment observation, and patients can choose their own treatment supporter (Egwaga et 
al. 2009). A study of this approach in comparison to health facility-based treatment found 
treatment success to be significantly better for the PCT cohort (Egwaga et al. 2009). 
Bangladesh provides an example of considerable efforts to deal with staffing challenges and 
service delivery. A Belgian non-governmental organisation (NGO), the Damien Foundation 
Bangladesh, has trained 12,525 informal village doctors to provide services in TB control in 
rural areas (Salim et al. 2006). These village doctors, known as gram dakter, usually practice 
‘alternative’ and mixed forms of medicine, and are either unqualified or only semi-qualified 
(Salim et al. 2006). However, with more than 75% of Bangladesh’s population living in rural 
areas, they are often the first contact that people with TB symptoms have with the health 
system (Salim et al. 2006). These village doctors were trained to provide TB services, 
including collection of sputum samples; providing treatment to patients, including DOT; and 
patient follow-up (Salim et al. 2006). The village doctors are in turn supervised by staff of the 
NGO, who visit the village doctors at least three times during each patient’s treatment 
course (Salim et al. 2006). This system has resulted in a treatment success rate of about 90% 
(Salim et al. 2006). Most importantly, the success of the strategy has led to it now being 
incorporated into Bangladesh’s national TB control policy (Salim et al. 2006). The approach 
used in Bangladesh provides an excellent example of how existing village health workers can 
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be trained and incorporated into TB control programs, to provide simple but essential 
services that also alleviate pressures on the health system. 
Many of the barriers facing TB control in resource-limited settings are similar worldwide. 
Examples include inadequate numbers of health personnel, a lack of resources, and 
challenging geography. There are also parallels in facilitators of control in many settings, 
such as strong community networks, and the presence of influential organisations such as 
churches and community groups (Cavalcante et al. 2007; Demissie et al. 2003) (Figure 2.9). 
All of these factors will influence the activities that are achievable within a local TB control 
program. 
 
 
Figure 2.9: Sister Bisato Gula providing TB awareness to a community music group involved 
in World TB Day activities in Balimo. (Image credit: Tanya Diefenbach-Elstob) 
 
2.4. Tuberculosis Control in the Era of Drug Resistance 
Ineffective TB control programs result in problematic management of TB patients, and can 
thus increase the risk of drug resistance in a number of ways: 
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(1) Delays in diagnosis increase the period of time that patients carry infection, and thus 
increase the risk of spontaneously developing drug resistance (Colijn et al. 2011). 
Such delays also increase the period of infectivity to others. 
(2) Improper treatment, through improper drug choice, or inadequate dosing or timing 
of treatment, increases the selection of drug-resistant clones, and thus acquired drug 
resistance (Mitchison 1998). 
(3) Patients with strains that are resistant to some drugs but not others will experience 
improper treatment even with full adherence. They are thus at risk of amplified 
resistance due to an incorrect combination of drugs not adequately suppressing the 
bacteria (Basu & Galvani 2008). 
(4) Where cases are drug-resistant, the use of inadequate treatment regimens increases 
the risk of primary transmission of drug-resistant strains to others due to ongoing 
infectivity. 
(5) Loss-to-follow-up of TB patients after they have commenced treatment may occur, 
and resultant incomplete treatment may drive the selection of drug-resistant 
organisms and development of DR-TB (Naidoo et al. 2017; World Health Organization 
2014b). 
An effective TB control program that ensures prompt diagnosis and treatment of TB 
patients, as well as effective contact tracing and case-finding activities, is thus essential in 
slowing the rise of drug resistance. 
Control of DR-TB is critical, and should be specifically addressed in TB programs. However, 
the complexities involved in control of drug-susceptible TB are amplified for DR-TB. Access to 
second-line drugs can be difficult, and drug shortages can be severe. For example, waiting 
times of 9 – 12 months have been reported from Russia, primarily due to the limited number 
of suppliers who were approved and registered to sell the required drugs (Olson et al. 2011). 
Treatment regimens for DR-TB are not standardised, with treatment duration and the 
antibiotics used dependent on factors such as treatment history and DST results (World 
Health Organization 2016). The treatment of DR-TB is an area undergoing regular revision, 
with a number of new and updated guidelines having been in use over the course of this 
study (World Health Organization 2013b, 2014a, 2014b, 2016). Additionally, despite 
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increasing rates of drug resistance, as well as identification of organisms with resistance to 
greater numbers of drugs, there has been slow uptake of new medications such as 
bedaquiline and delamanid (Cox et al. 2018). The management of DR-TB is also challenged 
by the centralisation of treatment facilities. Patients with presumptive or confirmed DR-TB 
may need to travel and spend extended periods at medical facilities distant from their usual 
home, which creates access challenges for patients that have already been discussed (see 
Section 2.3.5). 
 
 
Figure 2.10: Sister Bisato Gula and Mr Mauri Amadu navigating waterways in the Balimo 
region. (Image credit: Tanya Diefenbach-Elstob) 
 
2.5. Building on Current Strategies in Tuberculosis Control 
It is clear that in the implementation of the ‘End TB Strategy’ in resource-limited settings, 
there is no one-size-fits-all approach, and every setting will face unique sociocultural and 
structural challenges. Overcoming such challenges will require focused, setting-specific 
research, using the existing literature as a starting point and methodological guide. 
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Furthermore, flexibility in the approach to treatment, as well as TB outreach services, may 
play a role in supporting positive treatment outcomes. 
The ‘Stop TB Strategy’ and DOTS have been extremely successful in facilitating and enabling 
successful TB treatment and cure for many patients (Obermeyer et al. 2008; Shargie & 
Lindtjorn 2005; Subramani et al. 2008). Despite this success, the challenges faced by TB 
patients highlight the importance of TB control programs continuing to seek ways to enable 
treatment and prevent disadvantage of TB patients, and to encourage the development of 
culturally and regionally appropriate solutions to TB control. 
The extensive body of TB literature, recommendations, guidelines, and standards serve as 
guiding documents in the context of locally effective TB control programs. However, local 
conditions and resource availability mean that health care staff must often adapt these 
recommendations. The importance of local TB control and management highlights the 
importance of capacity building and research strengthening initiatives. Empowering local 
staff with the skills to conduct their own research will enable them to better understand and 
adapt control strategies to their local conditions. Furthermore, understanding of setting-
specific factors will contribute to contextualising local TB epidemiology. 
 
2.6. The Influence of Local Factors on Tuberculosis Epidemiology 
Section 2.3 of this literature review described a number of the local and program factors that 
result in challenges for TB programs. However, it is also important to note that these same 
factors will play a role in the recognition and diagnosis of TB, and thus local TB epidemiology. 
Costs are important in determining how and when people with TB symptoms will seek care, 
and the types of health care facilities at which they will present. This has been demonstrated 
in a study from China, where there was a high level of misunderstanding by participants 
about the availability of free TB services (Long et al. 2008). In addition, the most common 
reason given by migrants for not undergoing a recommended X-ray was cost (Long et al. 
2008). Economic factors, as well as factors such as TB education and awareness, will thus 
play a role in actual case detection (Long et al. 2008) (Figure 2.11). 
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Figure 2.11: TB education posters from PNG in Tok Pisin and English. (Image credit: David 
Plummer) 
 
A number of studies have linked increased distance to a health facility with delays in TB 
diagnosis (Bogale et al. 2017; Godfrey-Faussett et al. 2002; Lorent et al. 2015; Makwakwa et 
al. 2014; Mesfin et al. 2009; Tadesse et al. 2013; Ukwaja et al. 2013b). Such an association 
will affect TB epidemiology by resulting in under-diagnosis of TB in more distant regions. 
Additionally, diagnostic delay is associated with further progression of disease once 
diagnosis is actually achieved (Virenfeldt et al. 2014). Education can also play a role, with 
lower levels of schooling associated with diagnostic delay (Makwakwa et al. 2014; Segagni 
Lusignani et al. 2013). 
Structural factors may also influence gender differences in TB epidemiology. For example, a 
study of people being investigated for TB in Pakistan identified more females at local 
facilities that were accessible by foot; and more males at facilities that were open in the 
evening, and that undertook more TB investigations (Khan et al. 2012). Furthermore, 
another study from Pakistan has reported geographic differences in rates of TB, with more 
females in two provinces, and more males in the other two provinces (Khan et al. 2013). A 
study from Peru described the lower priority that was given to women’s health when 
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compared to men, and that women experienced economic barriers to obtaining healthcare 
services, despite having greater awareness of TB services (Onifade et al. 2010). These results 
suggest that behavioural and sociocultural factors, as well as health system availability, 
influence gender ratios in TB diagnoses. 
The influence of sociocultural and structural factors on local TB epidemiology is difficult to 
assess, but will almost certainly play a role in the distributions and characteristics of local TB 
burdens. These factors are important to consider in the context of local TB control programs. 
 
2.7. Health Indicators in Papua New Guinea 
Data from PNG demonstrates that poor health outcomes are experienced by much of the 
population. In 2012, the average life expectancy was 62 years of age (World Health 
Organization 2015a). Although likely to be variable by region, in 2013 the under-five 
mortality rate was 61 per 1000 live births (World Health Organization 2015a). Lower 
respiratory infections are the leading cause of death, and TB and malaria are both included 
in the top five (World Health Organization 2015d). In earlier data, infectious diseases 
including TB, pneumonia, malaria, and meningitis were in the top five causes of death for 
both urban and rural population strata (Riley 2009), highlighting the fact that health 
challenges affect urban and rural populations alike. In 2017 the prevalence of HIV in adults 
aged 15 – 49 years was 0.9%; and in 2012 TB, HIV, and malaria combined caused the second-
highest burden of years of healthy life lost due to disability (YLD) (UNAIDS 2018; World 
Health Organization 2015d). 
One of the biggest challenges to attaining positive health outcomes in PNG is the ability of 
limited health infrastructure to cope with the increasing disease problem. In 2010, it was 
estimated that there were only 6.2 health workers (physicians, nurses, and midwives) per 
10,000 people countrywide (World Health Organization Regional Office for the Western 
Pacific 2017b). By comparison, in 2013 Australia had 159 health workers per 10,000 people 
(World Health Organization Regional Office for the Western Pacific 2017a). The capacity of 
health facilities outside the PNG capital of Port Moresby is limited, and accessing healthcare 
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is challenging for much of the population, particularly in rural and remote areas (Diefenbach-
Elstob et al. 2017; Ongugo et al. 2011). 
 
2.7.1. Tuberculosis in Papua New Guinea 
In PNG, TB control programs are guided by the National TB Management Protocol (Figure 
2.12). This protocol is based on DOTS, and takes into consideration the WHO guidelines, as 
well as recommendations from the International Union Against TB and Lung Disease 
(Department of Health 2011). The protocol outlines the use of bacteriological methods of 
diagnosis, treatment regimens for various categories of patients, management algorithms 
for presumptive and confirmed drug-resistant patients, and guidelines for other 
considerations, such as infection control, TB-HIV coinfection; and advocacy, communication, 
and social mobilisation (ACSM) strategies (Department of Health 2011). 
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Figure 2.12: The PNG National TB Management Protocol, which outlines TB diagnosis, 
treatment, and reporting guidelines for the country's TB control program. (Source: 
Department of Health 2011) 
 
The impact of TB on PNG’s health outcomes is severe. The WHO estimates TB incidence in 
PNG to be 432 cases per 100,000 people each year (World Health Organization 2017a). With 
an estimated population of about 8.1 million people, this equates to almost 35,000 cases per 
year. Case notifications are lower, and in 2016 just over 28,000 TB cases were reported (Aia 
et al. 2018). By comparison, Australia, with a population of 24 million, has an incidence of 
only 6.1 cases per 100,000 people per year, equating to almost 1500 cases each year (World 
Health Organization 2017a). 
The incidence of TB in many areas of PNG is thought to be much higher than the national 
estimate (Cross et al. 2014; McBryde 2012), and this assumption is supported by case 
notification data. In 2016 the southern region of PNG, which includes Western, Gulf, Central, 
Milne Bay, and Oro Provinces, had a case notification rate of 615 cases per 100,000 people 
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per year (Aia et al. 2018). The five provinces with the highest case notification rates were the 
National Capital District (1117 per 100,000), West New Britain (907 per 100,000), Western 
(674 per 100,000), Gulf (669 per 100,000), and Oro (592 per 100,000) (Aia et al. 2018), with 
four of these being located in the southern region. 
Based on case notification data from 2016, 57% of TB patients in PNG had pulmonary TB, 
and of these 31% had bacteriological confirmation (World Health Organization 2017a). 
About 42% of TB patients had extrapulmonary TB, although the proportion was much higher 
in some provinces (78.5% in Eastern Highlands, 74.1% in Hela, 63.6% in Enga, 62.5% in 
Jiwaka, and 62.1% in Western) (Aia et al. 2018). With the exception of the reported case 
notification data, there is only one setting-specific study that describes extrapulmonary TB 
within a cohort of TB patients in PNG. This was a paediatric study undertaken at Modilon 
Hospital in Madang Province (Watch et al. 2017). Among 734 paediatric admissions with 
presumed TB, 384 (52.3%) had extrapulmonary TB (Watch et al. 2017). 
As already discussed, diagnosis of TB can be challenging, particularly in rural and remote 
areas. In recent years, there was a lack of culture facilities in PNG, necessitating samples 
being sent to the Queensland Mycobacterium Reference Laboratory (QMRL) in Australia for 
culture and DST. A number of Xpert MTB/RIF machines, which can identify M. tuberculosis 
infection, as well as detect RIF resistance, are available countrywide, including at Daru in 
Western Province (McBryde 2012). Rural centres that have laboratory facilities rely on 
microscopy-based identification of MTB infection. 
Diagnosis is even more challenging for extrapulmonary TB cases, where even if laboratory 
facilities are available, it may not be possible to collect a clinical specimen. These challenges 
may mean that some TB cases are missed, while some diagnosed cases may not actually 
have TB at all. The difficulties associated with positively identifying extrapulmonary TB in 
resource-limited settings are illustrated by its global epidemiology. In 2016, about 15% of TB 
notifications worldwide were for extrapulmonary cases (World Health Organization 2017a), 
although setting-specific rates are often much higher (see Appendix 1). Potentially high rates 
of clinical diagnoses and extrapulmonary TB cases make understanding the presentation of 
TB in PNG essential, and highlight the need for achieving clinician confidence in TB 
diagnoses. 
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Although DOTS has simplified TB treatment, there are still challenges to its implementation 
in PNG, and infrastructural factors mean that implementation must be flexible. The national 
management protocol states that TB treatment should be given using DOT (Department of 
Health 2011). However, daily travel to a health centre, or living away from home for the 
duration of treatment, may be prohibitively expensive for many patients, and therefore daily 
direct observation may not occur. This challenge is particularly relevant in a subsistence 
population, where patients may need to spend considerable amounts of time producing 
food, and income can be extremely limited (Diefenbach-Elstob et al. 2017) (Figure 2.13). 
 
 
Figure 2.13: Catching fish in the Aramia River near Balimo in Western Province, PNG. (Image 
credit: David Plummer) 
 
Sociocultural factors are also important, including social support, discrimination, religious 
beliefs, traditional healing, and the influence of witchcraft (Diefenbach-Elstob et al. 2017). 
There is some published literature describing the influence of sociocultural factors on health 
and illness in PNG (Diefenbach-Elstob et al. 2017; Lepowsky 1990; Macfarlane 2009; 
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Macfarlane & Alpers 2009; Ongugo et al. 2011; Whittaker et al. 2009), which provides a 
starting point for other PNG-based health research. As has been noted in this review, and as 
evidenced by prior Balimo-based research (Diefenbach-Elstob et al. 2017), such factors have 
a strong influence on the implementation of DOTS. Further understanding of these factors 
will influence the way treatment is delivered locally, particularly in rural and remote areas. 
 
 
There is a small but growing body of published data describing the epidemiology of TB in 
specific settings in PNG. Of the 22 PNG provinces, those with recently published data include 
Eastern Highlands (Ley et al. 2014a), Gulf (Cross et al. 2014), Madang (Aia et al. 2016; Ballif 
et al. 2012a; Ballif et al. 2012b; Ley et al. 2014a; Luke et al. 2008; Watch et al. 2017), Milne 
Bay (Ley et al. 2014a), Morobe (Aia et al. 2016), and Western (Aia et al. 2016; Bainomugisa 
et al. 2018; Gilpin et al. 2008; Guernier et al. 2018; McBryde 2012; Pandey et al. 2018; 
Simpson 2011) provinces, and the National Capital District (NCD) (Aia et al. 2016; Kasa Tom 
et al. 2018; Uluk et al. 2013). 
Cases of DR-TB have also been identified in PNG. In the Gulf Province study, three drug-
resistant cases were detected using Xpert MTB/RIF (Cross et al. 2014). Two studies 
conducted among Western Province patients seeking healthcare on Australian Torres Strait 
Islands estimated drug resistance to occur in up to 25% of cases, with evidence of primary 
transmission of DR-TB strains (Gilpin et al. 2008; Simpson et al. 2011). However, patients 
presenting at these clinics may be more likely to have advanced disease. Most recently, a 
multi-province study undertaken in four provinces identified MDR-TB in 20/999 (2.0%) new 
cases, and 24/146 (16.4%) previously treated cases (Aia et al. 2016). Daru in Western 
Province had the highest MDR-TB burden, with 34.1% of all TB cases being MDR-TB (Aia et 
al. 2016). Additionally, Daru has previously been noted as a hotspot for DR-TB, and recent 
research has provided evidence of transmission of DR-TB strains in this setting (Bainomugisa 
et al. 2018; Furin & Cox 2016; Kase et al. 2016; World Health Organization Representative 
Office: Papua New Guinea 2016). However, the proportion of DR-TB reported from Daru and 
Australian health clinics in the Torres Strait will not be representative of the province-wide 
51 
burden of DR-TB, as Daru Hospital is the only referral site for presumptive DR-TB patients 
across Western Province (Department of Health 2011) (Figure 2.14). As a result, there is 
limited understanding of the extent of DR-TB in the province more broadly, as well as in 
specific settings outside of Daru. 
 
 
Figure 2.14: The PNG and Western Province flags flying at Daru Airport. (Image credit: Tanya 
Diefenbach-Elstob) 
 
Although a number of studies from Western Province have been mentioned, the majority of 
TB data from the region is limited to the South Fly District and Daru areas. There is one 
province-wide evaluation study (McBryde 2012), while other data is from Daru and the 
South Fly District (Aia et al. 2016; Bainomugisa et al. 2018; Pandey et al. 2018), and from 
PNG patients presenting at Australian health clinics in the Torres Strait (Gilpin et al. 2008; 
Simpson et al. 2011). Published TB data from the Middle Fly District of Western Province is 
limited to the province-wide evaluation study (McBryde 2012), and a molecular investigation 
of TB diagnosis based on sputum smear slides (Guernier et al. 2018). Th evaluation study 
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included two sites in the Middle Fly District, estimating TB incidence to be 330 cases per 
100,000 people per year at Balimo, and 381 cases per 100,000 people per year at Awaba, 
suggesting a substantial burden of TB disease in the district (McBryde 2012). The province-
wide estimate of TB incidence was 549 cases per 100,000 people per year (McBryde 2012). 
This preliminary data provides a foundation for examining the TB burden in Western 
Province more closely. Furthermore, the data signals an urgent need for developing a better 
understanding of TB burden in the province (McBryde 2012). 
 
2.8. Conclusion 
The high burden of disease in PNG caused by TB makes national TB control critical. However, 
TB control across the country is made more challenging by geographic and access difficulties, 
limited resources, inadequate numbers of healthcare personnel, and the strong influence of 
sociocultural factors. Although there is a body of literature describing the epidemiology of 
TB in various regions of PNG, for other areas little is known. For these settings, 
understanding the burden of disease, the extent of drug resistance, diagnostic accuracy, and 
the challenges of treatment access, will be essential to the aim of locally-achievable TB 
management and care. 
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THE EPIDEMIOLOGY OF TUBERCULOSIS IN PATIENTS 
DIAGNOSED AT BALIMO DISTRICT HOSPITAL 
 
The majority of this chapter forms the basis of a manuscript published in Tropical Medicine & 
International Health, with publication details as follows: 
 
Diefenbach-Elstob T, Graves P, Dowi R, Gula B, Plummer D, McBryde E, Pelowa D, 
Siba P, Pomat W and Warner J (2018) The epidemiology of tuberculosis in the rural 
Balimo region of Papua New Guinea. Tropical Medicine & International Health. In 
Press. https://doi.org/10.1111/tmi.13118 © 2018 John Wiley & Sons Ltd 
 
Some data that was not published in the manuscript has been included in the thesis chapter. 
In addition, the thesis chapter has been updated for clarity and currency, and to incorporate 
comparison data from the recently published article describing the countrywide TB burden 
in PNG (Aia et al. 2018), that had not been published at the time our manuscript was 
submitted. 
 
3.1. Introduction 
Tuberculosis (TB) is an urgent health concern in Papua New Guinea (PNG). In 2016, incidence 
was estimated at 432 cases per 100,000 people per year, which in a population of 
approximately 8.1 million, equated to almost 35,000 people with TB (World Health 
Organization 2017a). The burden of TB cases resistant to standard treatment is also 
substantial, with drug resistance estimated to occur in 3.4% of new cases, and 26% of 
retreatment cases (World Health Organization 2017a). 
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Western Province is the largest province in PNG by area. The province has three districts – 
North Fly, Middle Fly, and South Fly (Figure 3.1). Middle Fly District, the most populous of 
the three districts, includes five local level government (LLG) areas. These are Balimo Urban, 
Gogodala Rural, Bamu Rural, Lake Murray Rural, and Nomad Rural (Figure 3.1). Balimo 
District Hospital (BDH) primarily serves the Balimo Urban and Gogodala Rural LLGs, and to a 
lesser extent the Bamu Rural LLG. In this study, the area served by BDH is generally referred 
to as the ‘Balimo region’, while the term ‘Gogodala region’ refers to the combined Balimo 
Urban and Gogodala Rural LLGs only. 
 
 
Figure 3.1: Western Province of Papua New Guinea (PNG), showing the North Fly, Middle Fly, 
and South Fly Districts. Balimo is located in the south-east of the Middle Fly District, and the 
provincial capital of Daru is on an island to the south-east of the provincial mainland. (Image 
attributions: (1) By Keith Edkins (Derived from File: Papua_New_Guinea_Districts.png) 
[Public domain], via Wikimedia Commons; (2) By Alaisd [Public domain], from Wikimedia 
Commons) 
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In Western Province, TB incidence has been estimated at 549 cases per 100,000 people per 
year (McBryde 2012). Drug resistance has been identified in 25% of Western Province-based 
TB patients presenting at Australian health clinics in the Torres Strait (Gilpin et al. 2008; 
Simpson et al. 2011), although patients presenting at these clinics may be more likely to 
have advanced disease. More recently, a multi-site study that included two sites in Western 
Province found multidrug-resistant TB (MDR-TB) in 34.1% of Daru Hospital TB cases (Aia et 
al. 2016). Cases with rifampicin (RIF) mono-resistance were also identified, including 7.3% of 
those from Daru, and 5.6% of those from Tabubil in the North Fly District (Aia et al. 2016) 
(Figure 3.1). However, data about the burden of TB in other areas of the province are scarce, 
particularly outside the South Fly District. Only one study examined TB in the province more 
broadly; this was an evaluation study which assessed the risks of TB across the province, and 
concluded that the provincial burdens of TB and MDR-TB were much higher than official 
estimates, and that improvements within the TB control programme were essential to limit 
the spread of drug resistance (McBryde 2012). 
A small number of health facilities across Western Province are able to provide TB diagnosis 
and treatment. However, the lack of roads and cost of travel makes access difficult 
(Diefenbach-Elstob et al. 2017). Furthermore, TB patients with evidence of drug resistance, 
based on a lack of response to first-line treatment, or persistent positive smear microscopy 
results, must travel to the provincial capital on the island of Daru to access second-line 
treatment. Daru is therefore at risk of becoming a hotspot for complicated TB cases, with 
high numbers of drug-resistant cases concentrated on a small and densely populated island 
that has already suffered from other health crises, including cholera (Horwood et al. 2014; 
National 2010). 
The known high rate of drug-resistant TB (DR-TB) cases in Daru, combined with the lack of 
research describing TB across the province more broadly, means there is an urgent need for 
epidemiological data describing TB patients from other areas of Western Province. This 
study describes the epidemiology of TB in the patient cohort of BDH located in the Middle 
Fly District of Western Province, PNG. 
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3.2. Materials and Methods 
3.2.1. Study setting and patient characteristics 
Balimo, located on the Aramia River floodplain in the Middle Fly District of Western 
Province, is a town of approximately 4400 people, and the urban centre of the Gogodala 
Rural LLG area (National Statistical Office 2014). Numerous small villages in the Gogodala 
Rural LLG area have a combined population of approximately 33,000 people (National 
Statistical Office 2014). There are very few roads outside of Balimo town, and travel is 
predominantly by foot, boat, or canoe (Figure 3.2). 
 
 
Figure 3.2: Aerial view of the southern region of Western Province. Travel in the region is 
primarily by air, boat, or foot, and there are very few roads. (Image credit: Tanya 
Diefenbach-Elstob) 
 
BDH is the primary health facility in the Middle Fly District capable of diagnosing TB and 
initiating treatment. As a district hospital, BDH is classified as a level four facility, based on 
the National Health Service Standards (Government of Papua New Guinea 2011a). This 
comprehensive guideline outlines minimum quality standards for patient care, leadership 
and management, human resources management, information systems, the environment, 
and improving performance (Government of Papua New Guinea 2011b). A number of 
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smaller health facilities in the Gogodala Rural LLG and Bamu Rural LLG areas are able to 
commence patients on TB treatment (see Appendix 2). However, these facilities can only 
diagnose TB clinically, and sputum or other clinical specimens should be sent to Balimo for 
laboratory confirmation. At BDH, TB diagnoses are primarily passive, based on symptomatic 
patients seeking care at the hospital through self-referral, or onwards referral from health 
workers at a peripheral health centre or aid post. 
 
3.2.2. Diagnostic and treatment outcome definitions 
BDH has not had the services of a resident medical officer since the 1990s. The only method 
available to confirm TB diagnoses is Ziehl-Neelsen (ZN)-stained smear microscopy, and X-ray 
was not available at the time of this study. As such, the majority of TB patients recorded in 
this study have received clinical diagnoses led by resident health extension officers (HEOs) 
trained in the management of drug-susceptible TB cases, and without laboratory 
confirmation of infection. In this region, the criteria for TB diagnoses and treatment 
outcomes are based on the PNG National TB Management Protocol and the WHO definitions 
(Department of Health 2011; World Health Organization 2013a). Based on these guidelines, 
all people for whom a health worker has decided to give a full course of TB treatment are 
recorded as a TB case (Department of Health 2011). This occurs regardless of laboratory 
confirmation of infection, or whether the diagnosis is pulmonary or extrapulmonary TB. A 
pulmonary TB diagnosis may be indicated by symptoms such as prolonged cough (more than 
2 – 3 weeks), fever, weight loss, and night sweats; or in extrapulmonary TB by signs and 
symptoms including lymphadenitis, loss of function in the lower limbs, headache, or mental 
confusion, according to the PNG National TB Management Protocol (Department of Health 
2011). 
Standardised TB treatment in the region is available only for drug-susceptible TB cases. Six 
months of treatment is provided using fixed dose combination (FDC) drugs (Figure 3.3). 
Category 1 treatment is used for new TB patients, and is comprised of a two-month intensive 
phase with RIF, isoniazid (INH), ethambutol (EMB), and pyrazinamide (PZA); followed by a 
four-month continuation phase with RIF and INH only (World Health Organization 2010). 
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Category 2 treatment is indicated for retreatment patients (those classified as relapse, 
treatment after default, treatment after failure, or other), and includes a three-month 
intensive phase followed by a five-month continuation phase (Department of Health 2011). 
This regimen includes daily streptomycin (STR) injections for the first 56 days, and EMB is 
included in the continuation phase (Department of Health 2011). In Balimo medications for 
DR-TB are not available, and patients who may have drug resistance must travel to Daru for 
diagnosis and treatment. 
 
 
Figure 3.3: A patient record book used for details of a patient's TB diagnosis and treatment in 
PNG. (Image credit: Tanya Diefenbach-Elstob) 
 
Treatment outcomes are defined in Table 3.1, based on the PNG National TB Management 
Protocol (Department of Health 2011). In addition, binary categorisation of treatment 
success and treatment failure has been used to define treatment outcomes in this study 
(Table 3.1). 
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Table 3.1: Definitions used for treatment outcomes, based on the PNG National TB 
Management Protocol (Department of Health 2011). 
Group (this study) Treatment outcome Definition 
Treatment success Cured Initially sputum smear-positive, but smear-
negative in last month of treatment, and on 
at least one previous follow-up occasion 
Treatment complete Completed treatment, but not classified as 
cure or treatment failure 
Treatment failure Treatment failure Smear positive at five months or later, or at 
two months if initially smear negative 
Died Death for any reason during treatment 
Default Treatment interruption for two or more 
consecutive months 
 
3.2.3. Data collection, transcription, and editing 
Patient data were primarily obtained from the TB patient register (hereafter called the TB 
register) held at BDH, including demographic, clinical, and laboratory details of all patients 
diagnosed with TB and commenced on treatment at the hospital during the period 26th April 
2013 to 25th February 2017. All pages of the register books available at the time of two study 
visits (April 2016 and February 2017) were transcribed into the TB study spreadsheet in 
Microsoft Excel. At the second study visit, the TB register was studied again, to update 
treatment outcomes added since the first visit. 
In addition to the TB register, patient data were obtained from a secondary source – the 
BDH TB laboratory database. This database is a register of all clinical samples investigated for 
TB at BDH using ZN-stained smear microscopy, and the results of those investigations.  
The TB register records were matched with patients recorded in the BDH TB laboratory 
database, based on name and demographic data, and any additional demographic or 
laboratory data were added to the TB study spreadsheet. For minor discrepancies (e.g. 
similar but not exact age), the TB register was assumed to be correct for demographic 
information. For any discrepancies in reported microscopy results, the laboratory database 
was assumed to be correct, as microscopy results are obtained directly from the laboratory 
database maintained by the BDH laboratory technician, Mr Daniel Pelowa (Figure 3.4). 
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Additional microscopy results included in the laboratory database, but not in the patient 
register, were added to the register data. This occurred due to some information in the 
patient register not always being up-to-date, especially in the case of follow-up microscopy 
results. However, the majority of patients (1294/1614, 80.2%) could not be matched to the 
laboratory database due to both a high proportion of clinical diagnoses and limited overlap 
of the data sources. 
 
 
Figure 3.4: Laboratory technician Mr Daniel Pelowa at the BDH laboratory. (Image credit: 
Jeffrey Warner) 
 
3.2.4. Data cleaning 
In this region, people are often uncertain of their age, and there was evident bias towards 
reporting of even-numbered ages (see Appendix 3). For this reason, age range categories 
were used, and where multiple different ages were recorded (e.g. in the TB register and the 
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laboratory database) people were placed in the age category that matched the average of 
the reported ages. 
Patient records frequently listed more than one town or village as the residential address. In 
these cases, the first location listed in the TB register was assumed to be the current 
residential address. The rationale for this assumption was that the recorded residential 
address is used to locate the patient if required. Subsequent towns or villages listed were 
assumed to be secondary residential addresses, such as the location of a person’s garden, or 
their home village. 
Some adjustments were made for the recording of primary residential addresses, as follows: 
- Localities within a town or village were adjusted to show the main village as the 
primary residential address. For example, Adiba Sub-Health Centre would be 
recorded as Adiba; while Page, which is a ward in Balimo town, would be recorded as 
Balimo. 
- There are two villages named Saweta. Based on advice from Sister Bisato Gula (a 
senior nurse at BDH, and the acting district TB coordinator), patients who listed both 
Waligi and Saweta were recorded as Waligi (a village close to Balimo), while patients 
who listed only Saweta were recorded as Saweta (a village near Awaba). 
Finally, where treatment commencement dates were missing, the treatment year and 
month were assumed to be the same as the patient registration date. 
 
3.2.5. Formulation of additional categories 
An additional category for language group was added to the data. This was based on the first 
village given in the address category. If Balimo was listed first, then the language group was 
instead based on the second address if one was given, as Balimo is an urban centre with a 
greater mix of people from the surrounding regions. For patients who listed a logging camp 
(Kamusie, Panakawa, or Sasareme) as their address, the language group was based on the 
second address if one was given. The justification for this decision was that logging camp 
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workers originate from a wide range of villages, and people from certain villages are more 
likely to work at one particular logging camp but not another. If no second address was 
given, the language group was recorded as ‘unknown’. Boundaries and included villages for 
the language groups were determined based on information available from the Summer 
Institute of Linguistics (2004) and Lewis (2009). It should be noted that the language group 
categorisations in this study do not necessarily reflect the language spoken by each patient 
with certainty, but rather are intended to indicate the diversity of language groups in the 
region from which patients in this study originate. 
 
3.2.6. Data analysis 
Statistical analyses were undertaken for 1518 of the 1614 patients recorded in the TB 
register. The 96 excluded patients were diagnosed through non-routine active case 
detection activities undertaken in the Bamu region, and were thus not considered to be 
representative of the usual patient cohort seen at BDH. These 96 patients are described 
separately in the results (see Section 3.3.6). Note that unless stated otherwise, any 
references to ‘all’ patients in the subsequent text of this chapter refer to all patients except 
the 96 excluded patients. 
Incidence of reported cases was estimated for the Gogodala region only, which consists of 
Balimo Urban LLG and Gogodala Rural LLG. Incidence was based on case numbers for new 
patients commenced on treatment in all full months and years of the study period. The total 
population for the two Gogodala LLG regions was used as the denominator, based on the 
2011 census data (National Statistical Office 2014). The most recent estimate of population 
growth in the province (2.5% per annum for the 2000 – 2011 period) was used to estimate 
population for all years subsequent to 2011 (National Statistical Office 2013), as shown in 
Table 3.2. The monthly trend of reported TB cases was based on the month of treatment 
commencement. 
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Table 3.2: Actual and calculated population figures for the combined Balimo Urban and 
Gogodala Rural LLGs in 2011 – 2017. 
Year Population Notes 
2011 37,427 Actual census figure 
2012 38,363 Calculated (2.5% population growth) 
2013 39,322 Calculated (2.5% population growth) 
2014 40,305 Calculated (2.5% population growth) 
2015 41,313 Calculated (2.5% population growth) 
2016 42,346 Calculated (2.5% population growth) 
2017 43,405 Calculated (2.5% population growth) 
 
Demographic and clinical categories were tabulated. Chi-square analyses were used to 
assess differences between patient groups based on TB presentation (pulmonary or 
extrapulmonary TB, with concurrent or unknown presentations excluded), and LLG area 
(combined Balimo Urban LLG and Gogodala Rural LLG, compared with Bamu Rural LLG, with 
any patients not from these regions excluded). In the analysis of LLG groups, the 96 
previously excluded patients were included in the Bamu Rural LLG group, as this analysis was 
intended to directly compare the demographic and infection characteristics of these 
patients. 
The monthly trend of TB patient diagnoses was assessed based on the month treatment was 
commenced. A bar chart was used to show the total number of cases per month, and the 
Chi-square goodness-of-fit test was used to analyse case numbers per month. Line graphs 
were used to show changes in the proportion of patients in the sex, incoming patient status, 
TB type, LLG area, and treatment outcome categories over time. 
Predictors of treatment failure were analysed using univariate and multivariate logistic 
regression, based on binary categorisation of treatment success (cured and treatment 
complete outcomes) or treatment failure (treatment default, death, and treatment failure 
outcomes). Excluded patients were those with a ‘transfer out’ status (n = 127) or unknown 
outcome (n = 293); as well as those patients commenced on treatment in the last six full 
months of the study period (August 2016 to February 2017) (n = 368), as insufficient time 
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had elapsed for these patients to have a treatment outcome recorded. All variables included 
in the univariate model were also included in the multivariate model. 
Tabulations, charts, and statistical analyses were performed using Stata/IC, version 14. 
Confidence intervals were calculated using the AusVet ‘Confidence limits for a proportion’ 
calculator (Sergeant 2017). Specific and direct standardised incidence rates were calculated 
using the Epi_Tools spreadsheet (LaMorte 2006). The pie chart and line graphs were created 
using GraphPad Prism 7. 
 
3.3. Results 
3.3.1. Incidence and distribution of the reported tuberculosis patients 
The TB patient numbers and the incidence of reported cases for patients commenced on 
treatment across the study period are shown in Figure 3.5. The average yearly reported 
incidence for the three complete years of the study period was 727 TB cases per 100,000 
people per year (Table 3.3). 
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Figure 3.5: Actual case frequencies, and incidence of reported new cases (per 100,000 
people) per month for TB across the study period. Cases in the Gogodala region include the 
Balimo Urban and Gogodala Rural LLG areas only. 
 
Table 3.3: Case numbers and incidence of reported cases per 100,000 people per year for 
new TB patients in the Gogodala region. 
Year n Calculated 
population 
Reported incidence 
(per 100,000) 
2014 310 40,305 769 
2015 197 41,313 477 
2016 396 42,346 935 
2014 – 2016  903  727 (average) 
n: number 
 
The distributions of patient demographic and clinical data are shown in Table 3.4. Of note 
are the large proportion of cases in children (25.0%, 95% CI 22.9 – 27.2), and that 77.1% 
(95% CI 75.0 – 79.2) of all TB patients had a diagnosis of extrapulmonary TB. The site of 
extrapulmonary infection was reported for 275 TB patients. The distribution of sites is shown 
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in Figure 3.6, with the majority localised to the glands or lymph nodes (n = 108, 37.6%, 95% 
CI 32.2 – 43.4); or the spine (n = 88, 30.7%, 95% CI 25.6 – 36.2). 
The 2014 – 2016 average specific and direct standardised rates per 100,000 people per year 
for sex are shown in Table 3.4, according to the national population proportion for PNG from 
the 2011 census (National Statistical Office 2015). Based on the standard population 
proportion, the number of cases in females was smaller than the reported incidence based 
on their proportion of the population, while the number of cases in males was higher than 
the reported incidence based on their proportion of the population. 
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Table 3.4: Patient demographic and clinical data for sex, age category, LLG area, TB type, and 
patient status. 
 Variable n % (95% CI) Specific and direct 
standardised 
incidence rates  
per 100,000 people 
(2014 - 2016 avg) 
Sex Female 722 47.6 (45.1 – 50.1) 709 (specific) 
Male 793 52.2 (49.7 – 54.7) 742 (specific) 
Unknown 3 0.2 (0.1 – 0.6) 726 (standardised) 
Age category 0 – 14 years 379 25.0 (22.9 – 27.2)  
15 – 24 years 254 16.7 (14.9 – 18.7)  
25 – 34 years 259 17.1 (15.3 – 19.0)  
35 – 44 years 211 13.9 (12.3 – 15.7)  
45 – 54 years 192 12.6 (11.1 – 14.4)  
55 – 64 years 138 9.1 (7.7 – 10.6)  
65+ years 31 2.0 (1.4 – 2.9)  
Unknown 54 3.6 (2.7 – 4.6)  
LLG area Balimo Urban 252 16.6 (14.8 – 18.6)  
Gogodala Rural 1010 66.5 (64.1 – 68.9)  
Bamu Rural 199 13.1 (11.5 – 14.9)  
Kiwai Rural 6 0.4 (0.2 – 0.9)  
Morehead Rural 4 0.3 (0.1 – 0.7)  
Nomad Rural 1 0.1 (0.1 – 0.4)  
Unknown 46 3.0 (2.3 – 4.0)  
TB type Pulmonary 321 21.1 (19.2 – 23.3)  
Extrapulmonary 1171 77.1 (75.0 – 79.2)  
Both 6 0.4 (0.2 – 0.9)  
Unknown 20 1.3 (0.9 – 2.0)  
Patient status New 1375 90.6 (89.0 – 91.9)  
Treatment after relapse 26 1.7 (1.2 – 2.5)  
Treatment after failure 11 0.7 (0.4 – 1.3)  
Treatment after default 77 5.1 (4.1 – 6.3)  
Transfer in 6 0.4 (0.2 – 0.9)  
Other 2 0.1 (0.0 – 0.5)  
Unknown 21 1.4 (0.9 – 2.1)  
Treatment 
category 
Category 1 1376 90.7 (89.1 – 92.0)  
Category 2 122 8.0 (6.8 – 9.5)  
Unknown 20 1.3 (0.9 – 2.0)  
avg: average; CI: confidence interval; LLG: local level government; n: number; TB: tuberculosis 
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Figure 3.6: Distribution of extrapulmonary TB site of infection. The site was known for 275 
TB patients, with a total of 287 sites recorded as some patients had more than one site 
recorded. 
 
The distribution of TB cases by age and sex is shown in Figure 3.7. In the age categories for 
25 years and over, the categories by sex contained similar numbers of cases. However, for 
cases aged up to 24, there were substantially more male cases in both the 0 – 14 and 15 – 24 
years age categories. 
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Figure 3.7: Distribution of TB cases by age and sex. Substantially more male cases were 
evident in the 0 – 14 and 15 – 24 years age groups. 
 
The residential address reported by patients included 103 towns and villages across five PNG 
provinces. The largest proportion of cases came from Balimo (n = 244), however other 
locations with substantial numbers of cases included Adiba (n = 59), Aketa (n = 47), Kimama 
(n = 162), Pisi (n = 73), and Widama (n = 48). The residential address was unknown for 33 
patients, due to insufficient information or no address being recorded. Patients came from 
19 different language group regions, with the majority from Gogodala region villages. 
However, substantial numbers of patients also came from villages in the Bamu (n = 213), 
Dibiyaso (n = 95), and Mubami (n = 35) language group regions. The association between 
geography and TB distribution will be explored further in Chapter 5. 
 
3.3.2. Smear microscopy results for tuberculosis patients 
Pre-treatment ZN smear microscopy results were recorded for 359 of the 1518 TB patients 
(23.6%, 95% CI 21.6 – 25.9), including 101/1171 (8.6%, 95% CI 7.2 – 10.4) patients diagnosed 
with extrapulmonary TB, 250/321 (77.9%, 95% CI 73.0 – 82.1) with pulmonary TB, 4/6 
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(66.7%, 95% CI 30.0 – 90.3) with concurrent infection, and 4/20 (20.0%, 95% CI 8.1 – 41.6) 
with unknown infection. Although the majority of smear results were obtained from sputum 
samples, a small proportion of extrapulmonary TB smear results were from other clinical 
specimens (e.g. discharge). For pulmonary TB patients, 65.7% (n = 211) were smear-positive, 
and 12.1% (n = 39) were smear-negative; no smear result was recorded for the remaining 
pulmonary TB patients. The microscopy results for each of the patient groups are shown in 
Table 3.5. Where more than one smear result was recorded, only the highest smear grade is 
shown here. 
 
Table 3.5: Pre-treatment ZN smear microscopy results for patients diagnosed with TB at 
BDH, based on the highest smear grade recorded for each patient. 
 Extrapulmonary, 
n (%) 
Pulmonary,  
n (%) 
Concurrent, 
n (%) 
Unknown,  
n (%) 
3+ 4 (0.3) 100 (31.2) 0 (0) 1 (5.0) 
2+ 2 (0.2) 58 (18.1) 1 (16.7) 0 (0) 
1+ 4 (0.3) 32 (10.0) 0 (0) 1 (5.0) 
Scanty 0 (0) 19 (5.9) 0 (0) 0 (0) 
Positive1 0 (0) 2 (0.6) 0 (0) 0 (0) 
NAFB 91 (7.8) 39 (12.1) 3 (50.0) 2 (10.0) 
Unsatisfactory 1 (0.1) 0 (0) 0 (0) 0 (0) 
Unknown 1 (0.1) 0 (0) 0 (0) 0 (0) 
No smear 1068 (91.2) 71 (22.1) 2 (33.3) 16 (80.0) 
Total 1171 (100.0) 321 (100.0) 6 (100.0) 20 (100.0) 
1Grade unknown; n: number; NAFB: no acid-fast bacilli (negative) 
 
3.3.3. Distribution of tuberculosis cases over time 
TB patient data for complete years were available for 2014, 2015, and 2016. Case numbers 
for all TB patients commenced on treatment in these years are shown in Table 3.6. Case 
numbers were similar in 2014 and 2016, but substantially lower in 2015. 
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Table 3.6: TB case numbers recorded in 2014, 2015, and 2016 for patients from all regions. 
Treatment year n % 
2014 460 38.7 
2015 260 21.9 
2016 470 39.5 
Total 1190 100.00 
n: number 
 
Variability in the TB patient numbers was evident over time (Figure 3.8). However, there was 
no pattern evident in the distribution of TB patients by month across the three complete 
years of the study. When grouped by month, November had the largest number of cases 
(Figure 3.9), although no significant difference was found in TB patient numbers among the 
calendar months (X2 = 13.01, p = 0.293). 
 
 
Figure 3.8: Distribution of all TB cases by month and year in the three complete years of the 
study period (2014 – 2016). 
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Figure 3.9: TB case numbers by month for all patients in the years 2014 – 2016. 
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The proportions of TB patients by sex are shown in Figure 3.10. Although distributions 
remained approximately equal over the full study period, substantially more male cases and 
fewer female cases were seen in the March 2015 – August 2015 period. 
 
 
Figure 3.10: Distribution of TB cases by sex over the May 2013 – January 2017 period. 
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The incoming patient status distribution is shown in Figure 3.11. In general, new cases 
gradually increased while retreatment cases gradually decreased, with the exception of in 
October 2015. 
 
 
Figure 3.11: Distribution of TB cases by incoming patient status over the May 2013 – January 
2017 period. 
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The distribution of TB patients by infection type is shown in Figure 3.12. The higher 
proportion of extrapulmonary TB patients seen in this study has been consistent across the 
full study period. However, it appears that pulmonary TB cases may have been higher earlier 
in the study period, while extrapulmonary cases appear higher more recently, although this 
observation requires further investigation. 
 
 
Figure 3.12: Distribution by TB patients by infection type over the May 2013 – January 2017 
period. 
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The proportions of TB patients by LLG area are shown in Figure 3.13. Increased proportions 
of patients from the Bamu region were seen in March – May 2014, and February 2015. 
Although fluctuating, there appears to be an upward trend in Balimo Urban LLG patients in 
the final year of the study period. 
 
 
Figure 3.13: Distribution of TB cases by LLG over the May 2013 – January 2017 study period. 
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Proportions for treatment outcomes are shown in Figure 3.14. The reason for the large 
number of unknown outcomes early in the study period is unknown. However, the 
increasing number of unknown outcomes in the final six months likely reflects the access 
challenges generally associated with TB management in this region, which may delay patient 
presentation at BDH for post-treatment evaluation.  
 
 
Figure 3.14: Distribution of treatment outcomes over the May 2013 – July 2016 study period. 
Note that this graph excludes the final six months of data shown in the other graphs, as 
insufficient time had elapsed for a treatment outcome to be known for these patients. 
 
3.3.4. Analysis of pulmonary and extrapulmonary tuberculosis patients 
The analysis comparing pulmonary and extrapulmonary patient groups (concurrent and 
unknown infection excluded) is shown in Table 3.7. There was a greater proportion of 
extrapulmonary TB patients in the 0 – 14 years age group (X2 = 117.45, p < 0.01) and ages 55 
years and over (X2 = 11.45, p < 0.01); and a greater proportion of pulmonary patients in the 
15 – 54 years age groups compared to both the 0 – 14 years and 55+ years age groups (Table 
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3.7). New patients were more likely to be diagnosed with extrapulmonary than pulmonary 
TB when compared to previously treated patients (X2 = 6.15, p = 0.01) (Table 3.7). 
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Table 3.7: Chi-square analysis comparing pulmonary and extrapulmonary TB patient groups 
by sex, age, incoming patient status, LLG area, and treatment outcome. 
Variable Number TB type 
Pulmonary Extrapulmonary 
Sex n n (%) n (%) 
Female 706 141 (20.0) 565 (80.0) 
Male 783 180 (23.0) 603 (77.0) 
Total 1489 321 1168 
Pearson X2 = 2.00, df = 1, p = 0.16 
Age category n n (%) n (%) 
0 – 14 years 376 11 (2.9) 365 (97.1) 
15 – 54 years 905 278 (30.7) 627 (69.3) 
Total 1281 289 992 
Pearson X2 = 117.45, df = 1, p < 0.01 
15 – 54 years 905 278 (30.7) 627 (69.3) 
55+ years 168 30 (17.9) 138 (82.1) 
Total 1073 308 765 
Pearson X2 = 11.45, df = 1, p < 0.01 
Patient status n n (%) n (%) 
New 1363 283 (20.8) 1080 (79.2) 
Previously treated 114 35 (30.7) 79 (69.3) 
Total 1477 318 1159 
Pearson X2 = 6.15, df = 1, p = 0.01 
Treatment outcome n n (%) n (%) 
Treatment success 605 169 (27.9) 436 (72.1) 
Treatment failure 119 25 (21.0) 94 (79.0) 
Total 724 194 530 
Pearson X2 = 2.43, df = 1, p = 0.12 
LLG area n n (%) n (%) 
Balimo Urban 249 43 (17.3) 206 (82.7) 
Gogodala Rural 995 223 (22.4) 772 (77.6) 
Bamu Rural 192 45 (23.4) 147 (76.6) 
Total 1436 311 1125 
Pearson X2 = 3.52, df = 2, p = 0.17 
df: degrees of freedom; LLG: local level government; n: number; TB: tuberculosis 
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3.3.5. Analysis of treatment outcomes 
Of the 1518 recorded TB patients, 368 who commenced treatment during the final six 
months of the study period were not under treatment long enough to have a known 
treatment outcome. Of the remaining 1150 patients registered early enough to have 
completed the full six-month treatment period, the treatment outcome was unknown for 
293 (25.5%, 95% CI 23.0 – 28.1). Treatment outcomes are shown in Table 3.8, for patient 
groups both including and excluding unknown treatment outcomes. Based on the overall 
treatment outcome categories for patients where the outcome was known, 611 patients 
(71.3%, 95% CI 68.2 – 74.2) had a treatment success outcome (cured or treatment 
complete), and 119 patients (13.9%, 95% CI 11.7 – 16.4) had a treatment failure outcome 
(default, failure, or died). A complete summary of all registered patients and treatment 
outcomes is shown in Figure 3.15. 
 
Table 3.8: TB treatment outcomes for all patients who had completed the six-month 
treatment period. The data on the left detail distributions where the treatment outcome 
was known, and the data on the right detail distributions with the inclusion of unknown 
treatment outcomes. 
Treatment outcome n % (95% CI) n % (95% CI) 
Cured 90 10.5 (8.6 – 12.7) 90 7.8 (6.4 – 9.5) 
Treatment complete 521 60.8 (57.5 – 64.0) 521 45.3 (42.5 – 48.2) 
Default 47 5.5 (4.1 – 7.2) 47 4.1 (3.1 – 5.4) 
Treatment failure 5 0.6 (0.3 – 1.4) 5 0.4 (0.2 – 1.0) 
Died 67 7.8 (6.2 – 9.8) 67 5.8 (4.6 – 7.3) 
Transfer out 127 14.8 (12.6 – 17.4) 127 11.0 (9.4 – 13.0) 
Unknown - - 293 25.5 (23.0 – 28.1) 
Total 857 100.0 1150 100.0 
CI: confidence interval; n: number
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Figure 3.15: Incoming patient status and treatment outcomes for all TB patients registered at BDH during the study period. All unknown 
treatment outcomes are included, regardless of whether the patient had been under treatment long enough to have completed their course of 
medication. 
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The logistic regression results for the analysis of treatment outcomes are shown in Table 3.9. 
In the univariate analysis, residence in the Bamu Rural LLG was a predictor of treatment 
failure (OR = 3.00, p = 0.01), while in the multivariate analysis, residence in either the 
Gogodala Rural LLG or Bamu Rural LLG was a predictor of treatment failure (Gogodala Rural, 
OR = 2.49, p = 0.02; Bamu Rural, OR = 4.11, p < 0.01). 
 
Table 3.9: Univariate and multivariate logistic regression examining predictors of treatment 
failure in all TB patients. A total of 680 complete observations were included in the 
multivariate model. 
 Univariate Multivariate 
Predictor variables n OR (95% CI) p OR (95% CI) p 
Sex Female 343 1.0  1.0  
Male 385 1.45 (0.97-2.16) 0.07 1.45 (0.94-2.22) 0.09 
Age 0 – 14 years 188 1.0  1.0  
15 – 24 years 140 0.62 (0.34-1.15) 0.13 0.81 (0.42-1.56) 0.53 
25 – 34 years 132 0.75 (0.41-1.37) 0.36 0.90 (0.46-1.73) 0.75 
35 – 44 years 102 0.62 (0.31-1.23) 0.17 0.67 (0.31-1.43) 0.30 
45 – 54 years 78 0.84 (0.42-1.70) 0.64 1.10 (0.52-2.37) 0.80 
55 – 64 years 64 1.18 (0.59-2.37) 0.64 1.63 (0.78-3.41) 0.20 
65+ years 12 1.41 (0.36-5.46) 0.62 1.65 (0.42-6.52) 0.48 
Patient status New 655 1.0  1.0  
Prev. treated 67 1.43 (0.77-2.68) 0.26 1.47 (0.77-2.79) 0.24 
TB type Pulmonary 194 1.0  1.0  
EP 530 1.46 (0.91-2.35) 0.12 1.47 (0.86-2.50) 0.16 
LLG area Balimo 110 1.0  1.0  
Gogodala 492 1.97 (0.99-3.93) 0.06 2.49 (1.15-5.40) 0.02 
Bamu 104 3.00 (1.36-6.64) 0.01 4.11 (1.70-9.96) <0.01 
CI: confidence interval; EP: extrapulmonary; LLG: local level government; n: number; OR: 
odds ratio; Prev: previously; TB: tuberculosis 
 
3.3.6. Description of tuberculosis patients diagnosed through non-routine case-
finding activities 
A total of 96 TB patients from eight Bamu-region villages were diagnosed through 
collaborative outreach activities between BDH and Youth with a Mission (YWAM). All of 
these diagnoses were made in the period 11th to 18th March 2016. The majority of patients 
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were female (n = 56, 58.3%, 95% CI 48.3 – 67.7). More than half of patients were aged 0 – 14 
years (n = 57, 59.4%, 95% CI 49.4 – 68.7) (Table 3.10). All patients were new TB diagnoses. 
Only two patients were diagnosed with pulmonary TB (2.1%, 95% CI 0.6 – 7.3). A treatment 
outcome was available for one patient, recorded as treatment complete.  
 
Table 3.10: Age distribution of Bamu Rural LLG area TB patients diagnosed through BDH and 
YWAM collaborative outreach activities. 
Age category n Percent 
0 – 14 years 57 59.4 
15 – 24 years 10 10.4 
25 – 34 years 12 12.5 
35 – 44 years 6 6.3 
45 – 54 years 7 7.3 
55 – 64 years 3 3.1 
65+ years 1 1.0 
Total 96 100.0 
n: number 
 
3.3.7. Comparison of demographic and diagnostic categories between Bamu- and 
Gogodala-region patients 
Of the 1557 TB patients who came from the Bamu or Gogodala regions only, 1262 (81.1%, 
95% CI 79.0 – 82.9) were from the Gogodala region (Balimo Urban LLG or Gogodala Rural 
LLG), while 295 (19.0%, 95% CI 17.1 – 21.0) were from the Bamu region (Bamu Rural LLG). 
For the Gogodala region, a slight majority of patients were male (n = 659, 52.3%, 95% CI 49.6 
– 55.1), while for the Bamu region, a slight majority were female (n = 151, 51.2%, 95% CI 
45.5 – 56.8). However, there was not a significant difference in sex between the two regions 
(X2 = 1.19, p = 0.28) (Table 3.11). Based on age categories, there was a significant difference 
between patients from the Bamu and Gogodala regions. In the Bamu region, patients were 
more likely to be aged 0 – 14 years, and less likely to be aged 55 years or older, when 
compared to the Gogodala region patients (Table 3.11). 
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When analysing the incoming patient status, there was no significant difference between the 
Gogodala and Bamu patient groups based on new or previously treated patient status (X2 = 
0.21, p = 0.65) (Table 3.11). There was a significant difference based on success or failure 
treatment outcomes between these two patient groups, with those from the Bamu region 
more likely to have a treatment failure outcome, and those from the Gogodala region more 
likely to have a treatment success outcome (X2 = 3.74, p = 0.05) (Table 3.11). The analysis of 
TB type between the two regions was suggestive of patients from the Gogodala region being 
more likely to be diagnosed with pulmonary TB, and patients from the Bamu region being 
more likely to be diagnosed with extrapulmonary TB (X2 = 3.69, p = 0.06) (Table 3.11). 
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Table 3.11: Chi-square analysis comparing TB patients from the Gogodala and Bamu regions 
by sex, age category, incoming patient status, TB type, and treatment outcome. 
  Residential region 
  Gogodala region Bamu region 
Sex n n (%) n (%) 
Female 751 600 (79.9) 151 (20.1) 
Male 803 659 (82.1) 144 (17.9) 
Total 1554 1259 295 
Pearson X2 = 1.19, df = 1, p = 0.28 
Age category n n (%) n (%) 
0 – 14 years 420 283 (67.4) 137 (32.6) 
15 – 54 years 914 774 (84.7) 140 (15.3) 
Total 1334 1057 277 
Pearson X2 = 52.36, df = 1, p < 0.01 
15 – 54 years 914 774 (84.7) 140 (15.3) 
55+ years 171 156 (91.2) 15 (8.8) 
Total 1085 930 155 
Pearson X2 = 5.04, df = 1, p = 0.03 
Patient status n n (%) n (%) 
New 1419 1150 (81.0) 269 (19.0) 
Previously treated 111 88 (79.3) 23 (20.7) 
Total 1530 1238 292 
Pearson X2 = 0.21, df = 1, p = 0.65 
TB type n n (%) n (%) 
Pulmonary 313 266 (85.0) 47 (15.0) 
Extrapulmonary 1219 978 (80.2) 241 (19.8) 
Total 1532 1244 288 
Pearson X2 = 3.69, df = 1, p = 0.06 
Treatment outcome n n (%) n (%) 
Treatment success 598 517 (86.5) 81 (13.6) 
Treatment failure 123 98 (79.7) 25 (20.3) 
Total 721 615 106 
Pearson X2 = 3.74, df = 1, p = 0.05 
df: degrees of freedom; n: number; TB: tuberculosis 
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3.3.8. Co-infection of HIV and tuberculosis 
Provider-initiated counselling and testing (PICT) for HIV is recommended for all TB patients 
and people being investigated for TB in PNG (Department of Health 2011). However, HIV 
testing was not routinely performed for TB patients at BDH at the time of this study. Of the 
1614 patients recorded in the TB register, 74 (4.6%, 95% CI 3.7 – 5.7) had a HIV test outcome 
recorded. Of these, four were positive (5.4%, 95% CI 2.1 – 13.1), one had no result recorded, 
and the remainder were negative. 
 
3.4. Discussion 
This study has described the high burden of TB in the Balimo region of PNG, and has 
particularly highlighted a very high proportion of clinically-diagnosed extrapulmonary TB 
patients, a high burden of childhood TB, and the increased likelihood of poor treatment 
outcomes for people from rural areas. 
 
3.4.1. The Gogodala region has a high burden of tuberculosis 
The overall incidence of reported new cases for TB in the Balimo Urban and Gogodala Rural 
LLG areas, estimated here to range from 477 – 935 cases per 100,000 people per year, is 
substantially higher than the PNG-wide WHO estimates. In 2016, the WHO reported that 
27,294 new TB cases were notified in an estimated population of 8.1 million people, 
equating to 337 case notifications per 100,000 people per year (World Health Organization 
2018a). By further comparison, the Western Pacific Region reported 1,305,408 new cases in 
an estimated population of 1.9 billion people, equating to 69 case notifications per 100,000 
people per year (World Health Organization 2018a). 
The extremely high number of TB diagnoses emphasises the heavy burden of disease that TB 
causes in this region. Our estimate for the Balimo region is higher than the previous Western 
Province region incidence estimate of 549 cases per 100,000 people per year (McBryde 
2012), as well as the more recent case notification rate of 674 cases per 100,000 people per 
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year (Aia et al. 2018). The South Fly District and the provincial capital of Daru have previously 
been noted for having a high burden of TB, and particularly DR-TB (Aia et al. 2016; Chandler 
2016; Furin & Cox 2016; Gilpin et al. 2008; Kase et al. 2016; McBryde 2012; Simpson et al. 
2011). A heavy burden of TB cases in the North Fly District has previously been observed, 
while more recent research described 18 cases of TB from Tabubil, with one of these 
identified as RIF-resistant (Aia et al. 2016; McBryde 2012). The data from the North Fly 
District, in combination with the Middle Fly District data described in our study, highlight the 
broad reach of TB across Western Province. Well-resourced health services across all three 
districts are essential to respond to TB across the province, and until that time, the burden 
on the urban capital Daru will continue. 
In this study of the Balimo region, extrapulmonary TB accounted for more than 75% of TB 
diagnoses. Globally, extrapulmonary TB usually accounts for about 15% of TB cases, although 
in the WHO Western Pacific Region, extrapulmonary TB cases are reported to be as low as 
8% (World Health Organization 2017a). The most recent nation-wide data for TB in PNG 
reported that 42.4% of cases were extrapulmonary, while 62.1% of notified cases in Western 
Province were extrapulmonary TB (Aia et al. 2018). The authors of one study from PNG have 
commented on the prevalence of extrapulmonary TB in the country, noting that both under-
diagnosis and over-diagnosis are possible outcomes in settings where diagnoses are 
predominantly symptom-based (Karki et al. 2017). The large proportion of extrapulmonary 
TB diagnoses in the Balimo region requires further investigation. Greater understanding of 
the epidemiology of extrapulmonary TB in this setting is particularly important given the 
presence of severe forms such as spinal TB and meningitis. 
The 1:1.1 ratio of female to male TB cases identified in this study differs from the PNG 
national, South-East Asia, and Western Pacific Region ratios, which in 2016 had estimated 
female:male incidence ratios of 1:1.7, 1:1.9, and 1:2.1 respectively (World Health 
Organization 2017a). Various factors have been suggested to contribute to the higher 
proportion of TB cases in men, including TB contacts, health-seeking behaviour, and smoking 
(Grandjean et al. 2011; Mason et al. 2016; Mason et al. 2017; Watkins & Plant 2006). In PNG, 
the prevalence of tobacco smoking in males is 37.3%, compared to only 14.5% in females 
(World Health Organization 2017c). As a result, it appears that smoking may not be a major 
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risk factor affecting the female:male ratio of TB patients in the Balimo setting, given the 
more equal proportion of TB cases. However, it should be noted that cooking fires are used 
extensively in this setting, which may affect more females and children. This observation is 
notable as the use of biomass stoves has been associated with TB in other settings, including 
India, Nepal, and Mexico (Kolappan & Subramani 2009; Pérez-Padilla et al. 2001; Pokhrel et 
al. 2010; Sehgal et al. 2014). 
The age distribution of TB cases in the Balimo region showed patients aged 0 – 14 years to 
be the largest group. In the analysis of pulmonary and extrapulmonary TB cases, the very 
low number of pulmonary cases in children aged up to 14 years is also of note. These results 
correspond with the general presentation of TB in children, which tends to be paucibacillary 
and have lymph node involvement (Marais 2014). However, from an epidemiological 
perspective high numbers of TB cases in children are concerning, as they tend to indicate 
recent MTB transmission, as well as ongoing transmission within the community (Marais et 
al. 2005). Furthermore, the distribution of childhood TB in Balimo suggests possible over-
diagnosis of extrapulmonary TB and under-diagnosis of pulmonary TB (Seddon et al. 2015). 
Further research would be necessary to understand TB transmission dynamics in this setting, 
particularly the risk of children acquiring TB and the disease presentation leading to TB 
childhood diagnoses. Understanding factors such as Bacille Calmette-Guérin (BCG) 
vaccination coverage would also be important, as this will likely play a role in the local 
epidemiology of childhood TB, and the forms of childhood extrapulmonary TB that may 
develop (Roy et al. 2014; Trunz et al. 2006). 
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Figure 3.16: Children in a rural village in the Gogodala region of PNG. (Image credit: David 
Plummer) 
 
Given that many of the TB cases reported in this study are clinically diagnosed without 
bacteriological confirmation, according to the PNG National TB Management Protocol 
(Department of Health 2011), there may be TB misdiagnosis among presenting patients. 
Factors such as case detection bias should also be considered, particularly in relation to high 
case numbers in children, and of extrapulmonary TB. However, treatment outcomes suggest 
that over-diagnosis is not a major concern. In this study, more than 70% of TB patients with a 
known treatment outcome were classified as ‘treatment success’, meaning that they were 
either cured or successfully completed treatment, in the absence of classification as 
treatment failure. This proportion is higher than the previously published data for Balimo, 
which showed treatment success of approximately 50% in 2011 TB cases at BDH (McBryde 
2012); and is moderately higher than the data for the southern region of PNG, which 
recorded a treatment success (combined treatment completion and cure) proportion of 
about 62% (Aia et al. 2018). Also of note is the substantially lower treatment default rate in 
this study, being approximately 5% compared to about 18% in the 2011 evaluation study 
(McBryde 2012). In a region where successful treatment is often the best supporting 
evidence for a TB diagnosis, this suggests that at BDH the recognition of non-laboratory 
confirmed cases of TB by clinicians is reasonable. Clinical diagnostic accuracy, particularly in 
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the context of extrapulmonary TB, will be investigated further in Chapter 7. It should also be 
noted that the use standard treatment approaches such as amoxicillin and aspirin or 
paracetamol have previously been described in the Balimo region (Diefenbach-Elstob et al. 
2017). This is a standard treatment approach to febrile illness throughout PNG (Saweri et al. 
2017), and there are a number of standard guidelines for the management of various 
disease presentations in PNG (National Department of Health 2012; Paediatric Society of 
Papua New Guinea 2016; Shann et al. 2003). However, whether such treatments are used 
concomitantly with TB treatment is unknown. The possibility of symptom resolution even if 
extrapulmonary TB has been incorrectly diagnosed should therefore be considered. 
However, regardless of the accuracy of TB diagnoses in this setting, misdiagnoses of TB may 
in fact place greater burdens on the health system, particularly if symptoms are not 
resolved. 
It is also of note that in this study a relatively high proportion of pulmonary TB cases had a 
positive smear result, being 65.8% compared to 31% of pulmonary TB cases with 
bacteriological confirmation across PNG (World Health Organization 2017a). The low 
proportion of smear-negative pulmonary TB cases may reflect additional challenges in 
pulmonary TB diagnosis, particularly in this setting where chest X-ray was not available at 
the time of the study. In addition, the low proportion of smear-negative pulmonary TB 
patients suggests under-diagnosis of this form of TB. This result supports earlier research 
undertaken by our group, where patient data was compared with molecular analysis of DNA 
extracted from TB sputum smear slides, and identified a substantial proportion of missed 
smear-negative pulmonary TB diagnoses (Guernier et al. 2018). 
The increased likelihood of new patients being diagnosed with extrapulmonary TB, while 
previously treated patients were more likely to be diagnosed with pulmonary TB, may have 
several possible explanations. The higher proportion of pulmonary TB diagnoses in 
previously treated cases may be influenced by emerging drug resistance in the region. DR-TB 
is known to occur in Balimo, and is likely to be more prevalent among pulmonary cases if 
these cases are more likely to truly be TB. An additional possibility for the increased 
likelihood of previous treatment among pulmonary cases is the status of the Balimo region 
as endemic for melioidosis (Diefenbach-Elstob et al. 2015; Warner et al. 2007; Warner et al. 
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2008). Melioidosis frequently presents with pulmonary symptoms, and may initially be 
misdiagnosed as TB (Bala Raghu Raji et al. 2018; Warner et al. 2010), thus increasing the 
possibility of a patient returning with ongoing symptoms, and potentially being retreated. 
Furthermore, limited diagnostic facilities in general result in challenges to infectious disease 
investigation and management in this region. 
In this study, approximately 90% of all TB cases were placed on Category 1 treatment, while 
8.0% were commenced on Category 2 treatment (Figure 3.17). However, the use of Category 
2 treatment in PNG is problematic due to high levels of generalised STR resistance, possibly 
as a result of extensive use of STR to treat TB, urinary tract infections, and Klebsiella 
infections in PNG in the past (Ley et al. 2014a; Maddocks et al. 1976; McBryde 2012; 
Simpson et al. 2011). 
 
 
Figure 3.17: The Category 1 standardised DOTS treatment packs used for TB in the Balimo 
region. The rear box shows the four-drug intensive phase treatment used for the first two 
months, while the front box shows the two-drug continuation phase treatment used in the 
last four months. (Image credit: Tanya Diefenbach-Elstob) 
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Treatment outcomes were unknown for just over 25% of TB patients who completed 
treatment at least six months before the end of the study period. This proportion may 
reflect the flexibility with which DOTS is often administered in the region, where patients 
may take their treatment packs back to their home village for the duration of treatment 
(Diefenbach-Elstob et al. 2017). In this study, the only factor found to be significantly 
associated with poorer treatment outcomes was the LLG area in which a patient resided, 
with poorer outcomes more likely in the rural LLGs. This finding may be linked to the 
challenges associated with obtaining healthcare for those patients who have a rural 
residence (Adamu et al. 2018; Gebrezgabiher et al. 2016). TB patients living in or around the 
Balimo Urban LLG area will face substantially lower travel and economic burdens in 
obtaining care initially, and continuing treatment once diagnosed. Furthermore, patients 
who have resolution of their symptoms may not return for post-treatment evaluation at the 
conclusion of treatment. Overall, unknown treatment outcomes are likely to result from a 
number of factors, including loss to follow-up, geographic and access challenges, and late 
updating or non-recording of outcomes in the TB register. 
 
3.4.2. Time trends of tuberculosis cases 
Although the reason for the fluctuation in TB cases over the three complete years of the 
study is uncertain, there are a number of potential influencing factors. These include staffing 
levels and practices; as well as the timing of TB awareness, education or outreach activities 
undertaken in Balimo and surrounds. It would be useful to evaluate community-level TB 
activities, and to investigate their impact on TB case detection. Although the difference in 
case numbers across the calendar months was not significant, there were higher case 
numbers overall in November. There are two factors that may influence patient numbers at 
this time. Ease of travel may be a factor, as November is the first month of the wet season. 
Travel in the region is easier when water levels are higher, which may result in a small influx 
of patients to the hospital in this month (Diefenbach-Elstob et al. 2017). Additionally, school 
holidays across the Christmas period will result in increased travel around the region. 
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Figure 3.18: Village houses in the Balimo region, with dugout canoes in the foreground. 
(Image credit: David Plummer) 
 
3.4.3. Comparison of Bamu- and Gogodala-region patients 
The majority of patients in this study originated from the Balimo Urban and Gogodala Rural 
LLG areas. However, with almost 20% of patients based in Bamu Rural LLG villages, people 
from the Bamu region also contribute substantially to TB patient presentations at BDH. 
In the analyses, Bamu-region patients were more likely to be children, and more likely to 
have a treatment failure outcome when compared with Gogodala-region patients. As 
already noted, the overall study found higher proportions of extrapulmonary cases in 
children, with this trend continuing in the comparison of the two patient groups. 
It is difficult to speculate on the reasons why these factors are more common in the Bamu 
region patients. However, the region is remote, and has been described as one of the 
‘poorest and least developed regions’ of the province (Jennifery 2012). Thus the extreme 
living conditions, combined with a lack of healthcare facilities capable of dealing with TB, 
may be contributors. 
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3.4.4. Limitations of the tuberculosis patient register analysis 
There are a number of limitations that may have influenced patient data analysis. Patient 
data is recorded in hand-written registers by a number of different health workers. As such, 
data entry mistakes may occur, and some patient data may go unrecorded. Record-keeping 
in this resource-limited region is undoubtedly difficult, especially given the lack of digital 
records. There are also inherent challenges resulting from the use of records in separate 
patient and laboratory registers, particularly in locating and updating historical records. 
Despite this, the TB register was assumed to be the most accurate record in the classification 
of patients, even if it was unclear how decisions were reached, given that the TB register 
represents the official TB record. For example, if a patient was classified as cured, but only 
one negative smear was recorded in the register, the cured classification was still used in this 
study. Furthermore, any missing treatment commencement dates were assumed to be the 
same as the patient registration date. As already noted in the methods (see Section 3.2.4), 
there are inherent problems with some data, including age inaccuracies and assumptions 
regarding patient residential locations. These problems are unavoidable in a data set such as 
that used in this study, but are mentioned here due to the need to interpret the results with 
caution. 
There was a substantial proportion (25.5%, 95% CI 23.1 – 28.1) of patients who had 
completed the six-month treatment period, but who did not have a treatment outcome 
recorded. In this setting where it is not unusual for patients to undertake TB treatment at 
home (Diefenbach-Elstob et al. 2017), it is possible that not returning for post-treatment 
evaluation could be linked with either successful or unsuccessful treatment. As a result, the 
potential influence of unknown treatment outcomes should be considered in the context of 
these results.  
Given the challenges of travel throughout the South Fly and Middle Fly Districts of the 
province, it is possible that some Gogodala- and Bamu-LLG area patients present directly at 
Daru or other peripheral health facilities instead of at Balimo. This may be particularly so for 
people located close to the Fly River, for whom water-based transport will be faster and 
easier than walking. Further research into travel patterns and seasonal factors would be 
required to quantify the number of Balimo-region TB patients who are not seen at BDH. Thus 
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the TB data presented here are not intended to be an exhaustive record of TB patients for 
the Balimo region, but a description of the TB cases presenting at BDH, the only hospital in 
this region of the Middle Fly District. 
 
 
Figure 3.19: Passengers preparing to travel by boat from Kawito. (Image credit: David 
Plummer) 
 
3.5. Conclusion 
The extremely high reported incidence of TB, and particularly the high proportion of 
extrapulmonary TB, demonstrates a heavy burden of TB disease in the Balimo region. 
Increased understanding of the epidemiology of TB in this setting provides important 
information in the context of TB control and elimination in Western Province and PNG more 
broadly. This is through insight into the distribution of the disease burden, and indicators of 
areas of particular concern. Although improved resources and facilities are an urgent need at 
BDH, this study has also demonstrated the substantial success of health care workers (HEOs, 
clinical nurses, and laboratory technicians) in diagnosing, treating, and managing TB in this 
non-doctor-led model of care setting, and the dedication of these staff to this task. The 
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burden of disease in this newly described TB-endemic region emphasises the need for the 
role of BDH to be considered in the broader Western Province TB control program. 
As described previously, TB in PNG may be diagnosed clinically based on the PNG National 
TB Management Protocol, and the WHO definitions (Department of Health 2011; World 
Health Organization 2013a). Misdiagnosis due to limited access to laboratory confirmation is 
possible, and indeed it is a feature of TB epidemics in these resource-limited settings. 
Therefore, this study also highlights the need to increase the capacity of laboratory and 
medical imaging-based diagnostics to aid in the accuracy of diagnosis, which will lead to 
more directed and evidence-based therapeutic interventions. 
The setting-specific data given in this chapter provides a broad epidemiological description 
of TB in the Balimo region, and the potential influence that these TB cases have on the 
control of TB in Western Province and PNG more broadly. This research provides a baseline 
for informing future research questions, as well as information that may support and 
enhance the existing Balimo TB control program. In addition, the focused epidemiological 
data may be combined with setting-specific social science research to provide local solutions 
to TB control. 
This thesis will continue to examine epidemiological aspects of TB in the Balimo region from 
a more focused perspective. The data presented in this chapter has described the incidence 
and distribution of TB, but noted that DR-TB should also be considered. Prior research from 
our group has identified genetic evidence of DR-TB in clinical samples from TB patients in the 
Balimo region (Diefenbach-Elstob and Moreau et al., unpublished data). Understanding the 
burden of DR-TB in the region is important as it will be linked to incidents of treatment 
failure in the context of either true DR-TB cases, or the possibility of misdiagnoses where 
other conditions such as melioidosis are also present. 
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MOLECULAR CHARACTERISATION OF 
MYCOBACTERIUM TUBERCULOSIS DRUG RESISTANCE 
IN THE BALIMO REGION 
 
4.1. Introduction 
In Chapter 3, tuberculosis (TB) in the Gogodala region of Papua New Guinea (PNG) was 
described, with characteristics of TB in the region being the large proportion of 
extrapulmonary TB, a large number of childhood cases, and the equal distribution of male 
and female patients. In addition, smear microscopy is the only laboratory-based method of 
diagnosis available at Balimo District Hospital (BDH). In such a setting TB diagnosis is 
complicated by the inability to differentiate other conditions that may present similarly to 
TB, such as melioidosis (Bala Raghu Raji et al. 2018; Warner et al. 2010), which is also 
endemic in the Balimo region (Diefenbach-Elstob et al. 2015; Warner et al. 2007; Warner et 
al. 2008). These diagnostic challenges mean that sometimes the only method of confirming a 
TB diagnosis is a positive response to treatment. In Chapter 3, for those patients where the 
treatment outcome was known, 13.9% had a treatment failure outcome (death, default, or 
treatment failure). Many factors may contribute to treatment failure, and rural residence 
was noted for its association with treatment failure. Another reason for treatment failure is 
the presence of drug-resistant TB (DR-TB). In this chapter, the extent of DR-TB in the Balimo 
region will be investigated. 
PNG is considered to have a high burden of both TB and DR-TB (World Health Organization 
2017a). In general, drug resistance is usually first identified in the form of rifampicin (RIF) 
mono-resistant TB (RR-TB), or multidrug-resistant TB (MDR-TB), which is resistance to both 
RIF and isoniazid (INH) (World Health Organization 2013a). In 2016, PNG had an estimated 
proportion of RR-TB and MDR-TB in 3.4% of newly diagnosed TB cases, and 26% of 
previously treated TB cases (World Health Organization 2017a). 
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In PNG, Western Province has been particularly noted for a high burden of DR-TB, although 
as Daru Hospital is the referral site for Xpert MTB/RIF testing in Western Province 
(Department of Health 2011), the proportion of DR-TB would be expected to be higher. A 
multi-site study that included Western Province found that 34.1% of new and previously 
treated cases at Daru Hospital in the provincial capital were MDR-TB, while proportions of 
MDR-TB ranged from 1.8 to 13.3% at sites in Madang, Morobe, and the National Capital 
District (Aia et al. 2016). Extensively drug-resistant TB (XDR-TB), which is MDR-TB with 
additional fluoroquinolone (FLQ) and second-line injectable antibiotic resistance, has also 
been described in Daru (Chandler 2016; Furin & Cox 2016; Kase et al. 2016) (Figure 4.1). 
There are also a number of studies describing Western Province-based TB patients who 
presented at Australian health clinics in the Torres Strait, which found MDR-TB in 25% of TB 
patients (Gilpin et al. 2008; Simpson et al. 2011). These studies provide evidence of the 
substantial burden of DR-TB in PNG, and particularly Western Province. 
 
 
Figure 4.1: A partial aerial view of Daru, the capital of Western Province, located on an island 
to the south of mainland PNG. (Image credit: David Plummer) 
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Phenotypic drug susceptibility testing (DST) of Mycobacterium tuberculosis (MTB) bacilli 
isolated and cultured from patient clinical samples (usually sputum) serves as a reference 
standard for the diagnosis of DR-TB (World Health Organization 2018d). However, this 
method is laborious and time-consuming, taking as long as 8 – 12 weeks to obtain a result 
(Migliori et al. 2008). Furthermore, culture and DST are high risk activities, requiring 
biosafety cabinets and appropriate physical containment facilities, thus limiting their use to 
centralised well-equipped laboratories (World Health Organization 2012, 2015b). The 
growing demand for rapid identification of drug resistance has resulted in molecular 
techniques being increasingly utilised, based on the identification of mutations in numerous 
genes in the MTB genome that have been associated with a drug-resistant phenotype 
(Ramaswamy & Musser 1998). These mutations occur as single base changes in the MTB 
genome, and are known as single nucleotide polymorphisms (SNP). 
The molecular basis of RIF resistance has been well-characterised, with 96% of this 
resistance associated with mutations in an 81-base pair RIF-resistance determining region 
(RRDR) located in the centre of the rpoB gene (Ramaswamy & Musser 1998). Resistance to 
INH has been frequently associated with mutations in the katG and inhA genes (Ramaswamy 
& Musser 1998). Because a large proportion of RIF-resistant strains have concomitant INH 
resistance, the molecular detection of RIF resistance in MTB isolates is often used as an early 
indicator of MDR-TB before phenotypic susceptibilities are available, or in countries where 
DST is not routinely available (Traore et al. 2000). The Xpert MTB/RIF assay (Cepheid, USA) 
that operates on the GeneXpert platform has been recommended by the World Health 
Organization (WHO) for the detection of RIF resistance in all people suspected of having 
MDR-TB (World Health Organization 2013c). The test is based on the molecular detection of 
rpoB mutations (Helb et al. 2010; Ioannidis et al. 2011; World Health Organization 2013c). 
However, the Xpert MTB/RIF does not detect INH resistance. As such, in the absence of 
phenotypic DST the Xpert MTB/RIF and other molecular drug resistance detection 
techniques that focus on rpoB may overestimate MDR-TB, especially if the prevalence of RR-
TB locally is unknown (Traore et al. 2000). An approach that can identify both rpoB and katG 
mutations is more likely to differentiate RR-TB, MDR-TB, and strains in which MDR-TB is 
likely to develop (Manson et al. 2017). 
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The presence of DR-TB in the Middle Fly District of Western Province, including the Balimo 
region, has already been noted (see Section 3.5). Given the challenges of diagnosis and the 
presence of DR-TB in this region of PNG, the aim of this study is to provide information 
about the molecular patterns and frequency of DR-TB in the Balimo region. The approach is 
based on genetic drug resistance characterisation of the rpoB and katG genes in MTB DNA 
extracted from sputum samples collected from TB patients and people undergoing TB 
investigations at BDH. This investigation will further understanding of the burden of DR-TB in 
the Balimo region of Western Province, as well as provide insights into the impact of DR-TB 
on TB diagnostics and treatment outcomes. 
 
4.2. Materials and Methods 
4.2.1. Study setting and patient characteristics 
The Balimo setting and description of TB case-finding activities have been previously 
described in Chapter 3. However, the data presented in this chapter is focused on 
presumptive pulmonary TB patients only, and includes analysis of samples collected from 
people undergoing investigation for TB, newly diagnosed TB patients, and follow-up samples 
collected from people who had previously been commenced on TB treatment. Sputum 
samples were obtained through routine collection from presumptive TB patients who 
presented at BDH for either new or follow-up TB investigations. 
 
4.2.2. Initial collection and preparation of samples 
Sputum samples were collected during the period April 2016 to June 2017, with a total of 
240 samples provided on a convenience sampling basis for this study. These samples 
represented approximately 37% of those collected and processed at the BDH laboratory 
during the corresponding time period. These included decontaminated and concentrated (n 
= 213) and fresh (n = 27) sputum samples. Processed sputum was prepared at the BDH 
laboratory, with decontamination and concentration procedures according to the modified 
Petroff’s method (Kent & Kubica 1985; Petroff 1915). Following processing, sputum was 
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smeared onto microscope slides, and examined using Ziehl-Neelsen (ZN) staining for the 
presence of acid-fast bacilli. Fresh sputum samples were decontaminated and concentrated 
at James Cook University (JCU), Townsville, following the same procedure used at BDH. 
 
4.2.3. Preparation of DNA template 
DNA extraction procedures were undertaken in biosafety level three laboratories. 
Approximately 100 – 150 µL of each decontaminated sputum was transferred to a 2 mL tube 
and heat inactivated at 80oC in a thermal block for 1 hour. The sputum was then centrifuged 
at 3,000 g for 15 minutes, and the supernatant removed. A volume of 1 mL of a 4M 
guanidine isothiocyanate (GIT) solution was added to each tube, and incubated overnight at 
37oC. The samples were then centrifuged at 13,000 rpm for 10 minutes, and the supernatant 
removed. 
Following inactivation, DNA was extracted using the High Pure PCR Template Preparation Kit 
(Roche Diagnostics, Germany). Initially, the spun pellets were resuspended in 200 µL of 
tissue lysis buffer and 40 µL of proteinase K solution, and incubated overnight at 55oC, or 
until all sediment was dissolved. Subsequent steps were performed according to the 
manufacturer’s instructions. Extracted DNA was stored at minus-80oC until use. 
 
4.2.4. Confirmation of Mycobacterium tuberculosis infection 
Two TaqMan real-time PCR (qPCR) assays were used to confirm M. tuberculosis complex 
(MTBC) infection in the DNA extracts, according to protocols published by Broccolo et al. 
(2003). The first assay (IS6110) targeted a 122-base pair sequence located within the central 
region of the IS6110 multicopy element, allowing detection of the Mycobacterium species. 
The second assay (senX3-regX3) targeted a 146-base pair sequence in the senX3-regX3 
intergenic region, which is present only in strains of the MTBC. Primer and probe sequences 
for the assays are shown in Table 4.1. The IS6110 assay targets a multi-copy element, and as 
such has an increased ability to detect MTB DNA, even if the original DNA quantity is low. By 
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comparison, the senX3-regX3 assay is more specific but less sensitive as it targets a single 
copy gene, and may thus have a reduced chance of reactivity when there is a low copy 
number of the DNA in the extraction product. 
 
Table 4.1: Primer and probe sequences of the TaqMan qPCR assay targeting the IS6110 
multicopy element and the senX3-regX3 intergenic region. (Source: Broccolo et al. 2003) 
Name Primer 
direction 
Sequence 
IS6110 multicopy element (Mycobacterium species) 
TAQM3 Forward 5’-AGG CGA ACC CTG CCC AG-3’ 
TAQM4 Reverse 5’-GAT CGC TGA TCC GGC CA-3’ 
n/a Probe 5’-TGT GGG TAG CAG ACC TCA CCT ATG TGT CGA-3’ 
senX3-regX3 intergenic region (M. tuberculosis complex) 
TAQregT2 Forward 5’-GTA GCG ATG AGG AGG AGT GG-3’ 
TAQreg2L Reverse 5’-ACT CGG CGA GAG CTG CC-3’ 
 Probe 5’-ACG AGG AGT CGC TGG CCG ATC C-3’ 
 
Each qPCR reaction (20 µL) contained 1X GoTaq Probe qPCR Master Mix (Promega, Madison 
WI, USA), 0.8 µM each of forward and reverse primer, 0.1 µM of probe, and 2 µL of DNA 
template. The real-time PCR protocol consisted of an initial denaturation step of 95oC for 2 
minutes, followed by 45 cycles of denaturation at 95oC for 5 seconds, and 
annealing/elongation at 60oC for 15 seconds. The positive control used genomic DNA from 
the MTB H37Rv reference strain (NC_000962.3). The qPCR assays were carried out on a 
Rotor-Gene Q6000 (QIAGEN, Hilden, Germany). 
The IS6110 qPCR assay was undertaken in duplicate, with a triplicate run for samples with 
discordant results. The senX3-regX3 qPCR assay was undertaken once on all samples. A DNA 
extract was considered to be reactive if the cycle threshold (Cq) was less than 40 cycles. 
Samples that were reactive in both the IS6110 and senX3-regX3 assays were considered 
MTB-positive. In this setting, non-tuberculous mycobacteria (NTM) are considered to be 
rare, and the IS6110 assay has been used previously for the detection of MTBC in PNG 
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(Guernier et al. 2018). Accordingly, for this study samples with duplicate reactivity of the 
IS6110 assay but no reactivity of the senX3-regX3 assay were classified as ‘MTBC or NTM’. 
 
4.2.5. Targeted PCR amplification and mutation analysis of the rpoB and katG genes 
Of the 240 sputum samples that were initially assessed, 102 classified as either MTB (n = 62) 
or ‘MTBC or NTM’ (n = 25) were further tested using both the rpoB and katG targeted primer 
sets. A further 15 samples reactive for early runs of the IS6110 assay, but ultimately 
classified as negative, were also included. 
Targeted PCR was used to assess the DNA extracts for mutations in the resistance-associated 
regions of the rpoB and katG genes. The primer sets have been described elsewhere (Ballif et 
al. 2012b), and details are shown in Table 4.2. 
 
Table 4.2: Targeted sequencing primers and PCR conditions used to identify drug resistance-
associated markers in the rpoB and katG genes. The primer sets have been previously 
described in Ballif et al. 2010. 
Gene Primer 
direction 
Sequence Amplicon 
size (bp) 
 
rpoB 
(Rv0667) 
Forward 5’- TCG GCG AGC TGA TCC AAA ACC A -3’ 601 
 
 
Reverse 5’- ACG TCC ATG TAG TCC ACC TCA G -3’ 
katG 
(Rv1908c) 
Forward 5’- CCA GCG GCC CAA GGT ATC -3’ 850 
 
 
Reverse 5’- GCT GTG GCC GGT CAA GAA GAA GTA -3’ 
bp: base pairs; PCR: polymerase chain reaction 
 
Each PCR reaction (25 µL) contained 1X GoTaq G2 Green Master Mix (Promega, Madison WI, 
USA), 0.5 (rpoB) or 0.8 (katG) µM each of forward and reverse primer, and 2 µL of DNA 
template. The positive control consisted of genomic DNA from the MTB H37Rv reference 
strain (NC_000962.3). 
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The optimised rpoB PCR protocol consisted of an activation step of 94oC for 2 minutes; 
followed by 35 cycles of denaturation at 94oC for 30 seconds, annealing at 58oC for 30 
seconds, and extension at 72oC for 40 seconds; and a final extension step of 72oC for 5 
minutes. The optimised katG protocol consisted of an activation step of 94oC for 2 minutes; 
followed by 40 cycles of denaturation at 94oC for 30 seconds, annealing at 60oC for 30 
seconds, and extension at 72oC for 60 seconds; and a final extension step of 72oC for 5 
minutes. The PCR assays were undertaken on the BIOER GeneTouch and Kyratec SuperCycler 
Trinity conventional PCR machines. Amplicons were analysed by agarose gel electrophoresis 
using a 1% agarose gel. Where clear bands of the correct size were visible, the remaining 
aliquot was dispatched to Macrogen Korea for sequencing of the amplicons in both 
directions to ensure accurate results. Chromatograms were analysed using Geneious R10 
(Biomatters Limited, Auckland, New Zealand). The consensus sequences of each sample 
were compared to the wild-type (WT) MTB rpoB (GeneID 888164) and katG (GeneID 885638) 
gene sequences of the H37Rv reference strain (NC_000962), downloaded from the National 
Center for Biotechnology Information (NCBI) in order to identify the mutations. 
Throughout the results and discussion, the nomenclature used to describe identified SNPs is 
as follows: 
- Nucleotide mutations: #NN (where # refers to the nucleotide number, and N refers 
to the WT and mutated nucleotides respectively) 
- Codon mutations: A#A (where # refers to the codon number, and A refers to the WT 
and mutated amino acids respectively) 
 
4.2.6. Samples excluded from the analyses 
Three samples were excluded from the analyses, being duplicates from three patients. One 
patient returned identical lab results for the two duplicate samples, so the second sample 
was excluded. The two other patients returned identical microscopy results, but discrepant 
qPCR results, i.e. negative / ‘MTBC or NTM’ for one patient, and MTB / ‘MTBC or NTM’ for 
the other. In the first case, only the ‘MTBC or NTM’ sample was retained, while in the second 
case, only the MTB sample was retained. 
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4.3. Results 
4.3.1. Demographic information and detection of Mycobacterium tuberculosis 
infection 
Of the 240 sputum samples tested in this study, the analysis included samples collected from 
237 people based on the exclusion criteria described previously (see Section 4.2.6). The 
analysis included 125 (52.7%) females, 111 (46.8%) males, and one person for whom sex was 
not recorded. Age at the time of collection was recorded for 133 participants. These people 
ranged in age from 3 – 75 years, including 16 children (aged up to 17 years), and 117 adults. 
The remainder of participants included 103 adults (age unknown), and one unknown. Of the 
237 sputum samples that were analysed, 212 (89.5%) were new samples collected for TB 
investigation, 21 (8.9%) were follow-up samples collected after the patient had been 
commenced on TB treatment, and four (1.7%) had an unknown sample status. Of the 212 
new sputum samples, 32 (15.1%) had a positive smear status, 177 (83.5%) were smear-
negative, and three (1.4%) were unknown. The complete sputum smear microscopy results, 
stratified by sample status, are shown in Table 4.3. Where more than one smear result was 
recorded for a single sample, only the highest smear grade is shown here. 
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Table 4.3: Balimo sputum smear microscopy results stratified by sample status. 
Sample status ZN microscopy n (%) 
New NAFB 177 (74.7) 
 Scanty 1 (0.4) 
 1+ 11 (4.6) 
 2+ 6 (2.5) 
 3+ 14 (5.9) 
 Unknown 3 (1.3) 
Follow-up NAFB 16 (6.8) 
 1+ 1 (0.4) 
 2+ 2 (0.8) 
 3+ 2 (0.8) 
Unknown NAFB 1 (0.4) 
 Unknown 3 (1.1) 
Total  237 
n: number; NAFB: no acid-fast bacilli; ZN: Ziehl-Neelsen 
 
Based on the classification criteria for molecular detection of MTB, 62/237 (26.2%, 95% CI 
21.0 – 32.1) samples were classified as MTB, and 24/237 (10.1%, 95% CI 6.9 – 14.6) were 
classified as ‘MTBC or NTM’. The remainder (151/237, 63.7%, 95% CI 57.4 – 69.6) of the 
samples were classified as negative for MTB. 
 
4.3.2. Prevalence and characteristics of single nucleotide polymorphisms in Balimo-
region tuberculosis patients 
Adequate amplicons for sequencing were obtained from 50 samples using the rpoB primer 
set, and 48 samples using the katG primer set (Figure 4.2). Five of the samples that returned 
rpoB amplicons did not return adequate katG amplicons, while three samples that returned 
katG amplicons did not return adequate rpoB amplicons, resulting in a total of 53 amplicons 
that were suitable for sequencing. One ‘MTBC or NTM’ sample returned good rpoB 
sequences, while all other sequences were obtained from samples classified as MTB. One 
sample found to be MTB by qPCR returned a clean sequence in both directions for the rpoB 
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target region, but the BLAST results revealed that the closest matches were the 
Corynebacterium species (100% query cover out of 589 nucleotides and 92% identity). 
Sequencing results are shown in Table 4.4. A total of 34 of the 53 sequenced samples 
(64.2%) had no mutations identified and were classified as WT. A further six samples were 
WT for either rpoB or katG only, as the other gene sequencing was unsuccessful. 
 
 
Figure 4.2: A gel image showing PCR products obtained from amplification of DNA extracted 
from decontaminated sputum samples using the rpoB primer set. PCR products from extract 
numbers 650, 652, 657, 665, 671, and 672 were considered adequate for sequencing. 
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Table 4.4: Summary of sequencing results and codon mutations for amplicons that were 
successfully sequenced. 
rpoB conclusion katG conclusion Combined n 
WT WT WT 34 
WT n/a rpoB WT 
katG unknown 
5 
S450L* WT RIF DR 
katG WT 
4 
S450L* and I480V WT RIF DR 
katG WT 
1 
WT or F548L WT rpoB uncertain 
katG WT 
1 
n/a WT rpoB unknown 
katG WT 
1 
n/a P219L^ rpoB unknown 
katG mutated 
1 
n/a A361V^ 
P365S^ 
S383L^ 
R396C^ 
D419D^ 
rpoB unknown 
katG mutated 
1 
WT WT or E261K^ rpoB WT 
katG uncertain 
1 
WT WT or G279R^ rpoB WT 
katG uncertain 
3 
Other species n/a Other species 1 
Total   53 
n: number; n/a: not available (amplification or sequencing failed); RIF DR: rifampicin drug 
resistance; WT: wild-type 
*Codon mutation located within the RRDR of the rpoB gene 
^katG mutations with uncertain association with drug resistance 
 
The S450L (1349CT) mutation in the rpoB gene was identified in five of the sequenced 
extracts. One of these extracts also carried an additional I480V (1438AG) mutation in the 
same gene. When considering all samples that were classified as either MTB or ‘MTBC or 
NTM’ (n = 86), but excluding the follow-up samples for those participants who also had a 
new sample included (n = 3), 6.0% (5/83, 95% CI 2.6 – 13.3) of tested samples were 
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considered to be RIF-resistant. When those samples with a ‘MTBC or NTM’ classification 
were excluded, the proportion considered to be RIF-resistant was 8.1% (5/62, 95% CI 3.5 – 
17.5). 
A number of katG mutations were identified in two extracts that were WT for the rpoB gene 
target. The katG P219L (656CT) mutation was identified in one sample, while five katG 
mutations, namely A361V (1082CT), P365S (1093CT), S383L (1148CT), R396C 
(1186CT), and the silent mutation D419D (1257CT) were identified in a second sample. 
In five samples, there were unconfirmed mutations based on the identification of a mutation 
in one sequence direction, but a WT nucleotide in the other sequence direction (Figure 4.3). 
These were rpoB WT or F548L (1644CA) in one extract, katG WT or E261K (781GA) in 
one extract, and katG WT or G279R (835GC) in three extracts. These mutations were not 
investigated further as they are not known to be associated with any drug resistance. 
 
 
Figure 4.3: Sequencing chromatogram showing an uncertain katG mutation, due to a SNP in 
one direction, but a WT genotype in the other direction. 
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4.3.3. Repeat testing of new and follow-up samples 
Both new and follow-up samples were available for three patients. All three patients were 
sputum smear-positive on their initial sample collection, with smear grades of 2+ or 3+; and 
classified as MTB and WT based on the molecular and sequencing assays. The follow-up 
samples collected from these patients were obtained at different time-points, ranging from 
two to four months following treatment commencement. The follow-up samples were all 
sputum smear-negative, although interestingly, two samples were classified as MTB based 
on the molecular assays, while the third sample was classified as ‘MTBC or NTM’. The MTB 
samples were WT for rpoB and katG based on the sequencing results. The ‘MTBC or NTM’ 
sample was WT for rpoB, although a suitable amplicon was not available for katG 
sequencing. This later sample reacted twice with the IS6110 assay but had very late 
reactivity (40 < Cq < 45) with the senX3-regX3 assay. Comparing each new sample with its 
paired follow-up, the average Cq values of the IS6110 assays had increased for all three 
samples; very slightly for one sample (Cq 18.5 to 19.5), and substantially for the other two 
samples (Cq 14.5 to 23, and Cq 20 to 33.5). 
 
4.4. Discussion 
This study was undertaken on sputum samples collected in the rural Balimo region of PNG 
from patients suspected or confirmed to have TB. Molecular diagnostic techniques were 
able to identify MTB in 26 – 36% of the tested presumptive TB samples (depending on 
chosen positivity criteria), and RIF resistance-associated SNPs were identified in 6.0% (n = 5) 
of the tested samples with MTB and ‘MTBC or NTM’ classifications. 
 
4.4.1. Drug resistance-associated single nucleotide polymorphisms identified in the 
Balimo region 
The rpoB S450L (1349CT) codon mutation identified in five extracts in this study is 
arguably the most frequently identified RIF resistance-associated mutation in the rpoB gene 
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(Brandis & Hughes 2013; Heep et al. 2001). This codon mutation has been described 
previously in three studies examining genetic drug resistance in samples from PNG, including 
in Western Province (Bainomugisa et al. 2018; Ballif et al. 2012b; Ley et al. 2014a). The I480V 
(1438AG) codon mutation, identified in one extract in this study, is much less common, 
and was first described in a study from Mexico where it appeared as a double mutation 
alongside S450L as in our sample (Ramaswamy et al. 2004). Interestingly, the same double 
mutation has recently been identified in a single clinical sample investigated at Daru General 
Hospital in Western Province, PNG (Bainomugisa et al. 2018). However, the origin of the 
patient sample was not stated. Given that Daru is the provincial hospital, as well as the 
referral hospital for presumptive DR-TB patients from Balimo and across Western Province, 
clinical samples collected there cannot be assumed to be from people who are also Daru 
residents. 
 
 
Figure 4.4: Researchers and health workers at the hospital in Newtown (Balimo), including 
from left (1) Sister Keyanato Siwaeya, (3) Prof David Plummer, (4) Sister Bisato Gula, (5) 
myself, and (9) Mr Daniel Pelowa. (Image credit: Jeffrey Warner) 
 
There is less certainty regarding the drug resistance association of the mutations identified 
in the katG gene. In this study S315T, the most common INH resistance-associated katG 
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mutation, was not identified. As a result, neither genotypic INH mono-resistance nor MDR-
TB were identified. Despite this finding, genotypic INH resistance should continue to be 
monitored, especially as the katG S315T mutation has been identified in other studies from 
PNG, including in Western Province (Bainomugisa et al. 2018; Ballif et al. 2012b; Ley et al. 
2014a). Furthermore, several hundred different katG mutations have been documented in 
INH-resistant TB samples (Sandgren et al. 2009; Seifert et al. 2015; Vilchèze & Jacobs Jr 
2014), and descriptions of new mutations conferring INH resistance are likely to occur in the 
future. 
Only one of the katG mutations identified in the Balimo collection has been previously 
described. This was the P365S codon mutation, which has been identified in a single INH-
susceptible sample from Korea (Yoon et al. 2012). One other similar mutation has been 
identified, although the nucleotide substitution was different and coded for another amino 
acid, i.e. S383L in Balimo versus S383P in Japan (Ando et al. 2010). In the Balimo study, the 
mutation at codon 419 was silent. However, this codon is a site where a number of INH-
resistant mutations have been described, including D419A, D419Y, D419E, and D419H 
(Brossier et al. 2006; Cardoso et al. 2004; Huang et al. 2009). Based on currently available 
data (Sandgren et al. 2009; Vilchèze & Jacobs Jr 2014), the other katG mutations identified in 
Balimo (P219L, A361V, and R396C) appear to be not previously reported. However, given the 
uncertain drug resistance association of the katG mutations described in this study, the 
related samples would need to be confirmed as phenotypically resistant using DST. 
 
4.4.2. Comparison of Mycobacterium tuberculosis drug resistance to global and Papua 
New Guinea data 
This study found that 6.0% (95% CI 2.6 – 13.3) of the 83 MTB and ‘MTBC or NTM’ samples 
collected at BDH are RIF-resistant, based on the presence of drug resistance-associated 
mutations in the rpoB gene. These results demonstrate that DR-TB is already an established 
concern in the Middle Fly District. The proportion of drug resistance is comparable to the 
global, regional (Western Pacific) and PNG national estimates for RR-TB and MDR-TB, which 
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are 4.1% (95% CI 2.8 – 5.3), 5.3% (95% CI 2.9 – 7.8), and 3.4% (95% CI 1.7 – 5.0) respectively 
(World Health Organization 2017a). 
However, regional estimates from site-specific studies undertaken in PNG have been 
variable. In Gulf Province (Figure 4.5), 3/48 (6.3%) sputum samples from TB patients tested 
with Xpert MTB/RIF were found to be positive for RIF resistance (Cross et al. 2014). In 
Madang Province, drug resistance was identified based on DST results in 8.7% of a collection 
of 69 isolates from new and previously treated TB patients (Luke et al. 2008; 
Phuanukoonnon et al. 2008). Another study from Madang Province identified RR-TB and/or 
MDR-TB in 5.8% (10/172) of samples that underwent DST (Ballif et al. 2012a). Two multi-site 
studies have been undertaken, with results based on DST. A study of patient samples from 
Eastern Highlands, Milne Bay, and Madang Provinces found 4.2% (9/212) of samples to have 
RR-TB and/or MDR-TB (Ley et al. 2014a). A larger study undertaken in Madang, Morobe, 
National Capital District (NCD), and Western Provinces found MDR-TB in 44/1145 (3.8%) new 
and previously treated TB patients, with site-specific distributions for MDR-TB ranging from 
1.8% at Kilakila and Port Moresby General Hospital in the NCD, to 34.1% at Daru Hospital in 
Western Province (Aia et al. 2016). 
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Figure 4.5: A populated area near Kerema, the capital of Gulf Province, PNG. (Image credit: 
Tanya Diefenbach-Elstob) 
 
There are also a number of studies focused on TB patients in Australia that have described 
drug resistance in patients from PNG. During the 1998 – 2012 period, 244 MDR-TB cases 
were notified in Australia, and 72 (29.5%) of these were from PNG (Francis et al. 2018). In 
Queensland, 96 MDR-TB patients were diagnosed during the 2000 – 2014 period, with 73 
(76.0%) of these patients from PNG (Baird et al. 2018). Two studies focused on Western 
Province-based TB patients who presented at Australian health clinics in the Torres Strait 
found MDR-TB in 25% of these patients, based on culture and DST results (Gilpin et al. 2008; 
Simpson et al. 2011). This evidence confirms the substantial burden of DR-TB in PNG, and 
particularly in Western Province. 
As described earlier, the proportion of DR-TB cases identified in Western Province is higher 
than the PNG national proportion, based on research undertaken in Daru and from 
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Australian studies reporting data from Western Province-based TB patients (Aia et al. 2016; 
Gilpin et al. 2008; Simpson et al. 2011; World Health Organization 2017a). However, clinical 
samples tested at the hospital in Daru will be collected from local residents as well as 
patients from across Western Province, as Daru is the referral hospital for presumptive DR-
TB patients from Balimo, the Middle Fly District, and across the province (Department of 
Health 2011). In order to investigate possible heterogeneity between different areas of the 
province, it would be important to investigate the geographic origins of samples collected 
and analysed at Daru. This knowledge is essential to the implementation of strategic efforts 
aimed at control of DR-TB across Western Province. 
Currently in Balimo, TB patients with presumptive DR-TB must provide a sputum sample 
which is sent to the provincial capital of Daru for Xpert MTB/RIF testing (Department of 
Health 2011). If positive, the patient must then travel to Daru to be commenced on DR-TB 
treatment, which is to be completed under the supervision of an appropriately trained 
health worker (Department of Health 2011). There are a number of potential patient and 
provider challenges that are associated with the absence of a rapid diagnostic for DR-TB in 
Balimo. These include (i) delays in initiation of adequate treatment, (ii) active transmission of 
DR-TB to others, (iii) loss-to-follow-up while waiting for diagnostic results, and (iv) access 
challenges due to the long travel time to reach Daru (approximately eight hours in a 
motorised dinghy). Our earlier work from the Balimo region has described the difficulties 
associated with treatment adherence if people do not have a support network (Diefenbach-
Elstob et al. 2017), which will be a challenge further amplified for patients from the Balimo 
region undergoing treatment in Daru (Figure 4.6). 
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Figure 4.6: Undertaking an interview about TB treatment adherence during earlier research 
in the Balimo region. (Image credit: Jeffrey Warner) 
 
The identification of RIF resistance in Balimo demonstrates a need for rapid identification of 
drug-resistant strains, as well as the resources, facilities, and training necessary to treat DR-
TB patients at BDH. As such, implementation of a method such as the WHO-recommended 
Xpert MTB/RIF, which is capable of MTB diagnosis as well as detection of RIF resistance, 
should be considered. In addition, training of health workers already experienced in the 
management of TB to deliver and manage second-line treatment for DR-TB patients would 
be necessary, concurrent with ongoing supply of the required medications. In Western 
Province, a decentralised approach with improvement of resources and facilities at BDH 
could play a role in reducing the strain placed on Daru Hospital in the management of DR-TB 
patients, especially in this region where geographic and economic challenges are particularly 
relevant for TB patients. 
 
4.4.3. Detection of Mycobacterium tuberculosis in follow-up samples 
Detectable MTB DNA was present in all three of the follow-up sputum samples found to be 
smear-negative. Even though there was a reduction in detectable DNA between the initial 
‘new’ sample and the follow-up sample from the same patient, the qPCR positivity of the 
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follow-up samples is of concern as these patients had been under treatment for two to four 
months at the time of the follow-up collection. It has been suggested that TB patients are 
non-infectious after two weeks of treatment, although this belief has been disputed (Ahmad 
& Morgan 2000; Schwartzman & Menzies 2000). Furthermore, smear-negative TB patients 
are often considered to be less infectious, although studies have demonstrated that they are 
still able to transmit TB, and indeed there is evidence of TB transmission from patients who 
are nucleic acid amplification test-negative (Behr et al. 1999; Hernández-Garduño et al. 
2004; Tostmann et al. 2008; Xie et al. 2018). The presence of smear-negative/qPCR-positive 
samples supports results from previous research in the Balimo region, and demonstrates the 
inherent challenges of TB diagnosis in this setting where limited laboratory-based methods 
are available (Guernier et al. 2018). 
 
4.4.4. Limitations 
Laboratory registration of ‘new’ samples did not include information on whether a patient 
had previously been treated for TB. As a result, there may have been a higher risk of DR-TB 
for some patients. However, given only 7.5% of TB patients identified in Chapter 3 of this 
study had an incoming relapse, failure, or default status (see Table 3.4), the proportion of 
retreatment patients in this sample of TB investigation patients is likely to be small. 
This was a small study, undertaken on samples collected on a passive case detection basis at 
BDH. Although the sample size was small, confidence intervals have been calculated to 
provide context for the proportion of DR-TB. However, a larger study would be necessary to 
provide greater understanding of the burden of DR-TB in the Balimo region. 
In this study, samples were diagnosed with MTB based only on sputum smear microscopy 
and molecular assays, with no confirmation using culture-based assays. As a result, culture 
and subsequent DST would be necessary to confirm RIF resistance in samples where rpoB 
resistance-associated SNPs were identified. 
Our investigation of possible INH resistance included only one of the several genes 
associated with INH resistance, with gene targets such as inhA and ahpC not investigated. As 
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such, there may have been INH-resistant samples in our study that were not identified. 
Further investigation including these other genes would be necessary to develop a complete 
picture of the burden of genotypic DR-TB in the Balimo region. 
In the majority of samples, sequencing was performed only once, and in some samples only 
one sequence direction was able to be read. This approach is not problematic for SNPs 
identified at nucleotide and codon sites that have previously been described and associated 
with drug resistance. However, for the katG SNPs that have been described in this study, 
repeat sequencing would be necessary to confirm the results. In addition, DST would be 
required to determine drug resistance status. 
 
4.5. Conclusion 
This study has demonstrated the presence of RIF-resistant MTB strains in the Balimo region, 
based on the identification of resistance-associated mutations in the RRDR of the rpoB gene. 
Although katG mutations known to be associated with INH resistance were not identified in 
the study, the inhA and ahpC genes were not investigated, and thus MDR-TB cannot be ruled 
out. The results emphasise the need for an efficient method of diagnosing DR-TB patients 
and commencing them on treatment at BDH, without the potential delays caused by 
resistance identification being conducted only in the provincial capital of Daru, and the 
necessity of travel for DR-TB treatment and management. Furthermore, the presence of RIF 
resistance in this region distant from Daru emphasises the importance of understanding the 
burden and possible heterogeneity of DR-TB across Western Province. 
Given the presence of DR-TB patients in the Balimo region, it is possible that DR-TB may be 
associated with factors such as particular villages or distance from a health facility. In 
addition, the presence of DR-TB in the Balimo region raises the question of whether some 
treatment failure TB cases are linked with drug resistance – a possibility which would require 
further investigation. Understanding the spatial distribution of TB in the Balimo region may 
provide insights into setting-specific factors that influence the development of DR-TB. 
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THE SPATIAL DISTRIBUTION OF TUBERCULOSIS 
IN THE BALIMO REGION OF PAPUA NEW GUINEA 
 
5.1. Introduction 
In Chapter 3, the descriptive epidemiological analysis of tuberculosis (TB) patients diagnosed 
at Balimo District Hospital (BDH) showed that patients present from an extensive region of 
the Middle Fly District of Western Province, although primarily within the Balimo Urban, 
Gogodala Rural, and Bamu Rural local level government (LLG) areas. This vast region, 
situated on the Aramia, Fly, and Gama River floodplains, is geographically isolated due to a 
lack of roads, with transport predominantly by boat or foot (Figure 5.1). The majority of 
people in the region have subsistence-based livelihoods, and monetary income is limited. 
These factors can make travel over long distances prohibitively expensive, laborious, and 
time-consuming. In addition to the data from Chapter 3, Chapter 4 described the extent of 
DR-TB in a cohort of people investigated for TB at BDH. This analysis highlighted the 
potential link of DR-TB with treatment failure, but noted that poor access to health services 
may also play a role in treatment failure. 
 
 
Figure 5.1: Floodplain region in the south of Western Province, PNG. (Image credit: David 
Plummer) 
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Health facilities in the Balimo region are limited. BDH is the only hospital in the Middle Fly 
District, and is the primary facility providing TB diagnosis and DOTS-based TB treatment in 
the region. Other smaller peripheral health facilities, including health clinics and aid posts, 
provide limited TB services (see Appendix 2 for details of peripheral health facilities known 
to be operating at the time of this study). The services provided include clinical 
extrapulmonary TB diagnosis and treatment, and pulmonary TB services only where a 
sputum sample is not able to be transferred to Balimo. All of these facilities are supplied 
with TB resources and medications by BDH. Although the TB services provided by peripheral 
health facilities have limited scope, the presence of these facilities in close proximity to 
villages is likely to increase TB case detection in that area, and to decrease the numbers of 
patients seen at BDH from those villages. 
Previous research in the Balimo region has highlighted the extensive reach of TB, and local 
health workers have attested to the presence of TB cases in every village in the district 
(Diefenbach-Elstob, unpublished interview data). If this belief is indeed the case, 
understanding the geographic distribution of TB cases in relation to population distribution 
will provide insights into hotspots of TB infection. Villages with a lack of identified TB cases 
may be indicative of a need for active case-finding investigations in those areas, particularly 
as our earlier research has identified ease of travel and proximity to health services as 
important factors in accessing TB care (Diefenbach-Elstob et al. 2017). 
This study aims to investigate the intersection between location and TB in the Balimo region. 
The objectives are: 
1. To define the catchment region of BDH, based on the locations in Western Province 
from where TB patients seek and access services. 
2. To describe the distribution of TB patients and determine if there is non-random 
clustering of TB in the BDH catchment region. 
3. To describe the locations of DR-TB patients, and identify any clustering. 
Investigation of these objectives will provide insight into the previously undescribed 
influence of geography, access, and proximity to health services on TB and DR-TB 
distribution in the Balimo region. 
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5.2. Materials and Methods 
5.2.1. Study setting and patient cohort 
The analysis of TB patients is based on the Balimo TB patient register data previously 
described in Chapter 3 (see Section 3.2.3). For analyses in this chapter, residence is defined 
as the first residential address provided by a TB patient, based on the assumption that the 
first address provided was more likely to reflect the patient’s most recent place of residence. 
All patients included in the data presented in Chapter 3 were also included in the spatial and 
clustering analyses, with the exception of those from outside Western Province, and where a 
residential address was not able to be determined, as shown in Figure 5.2. The boundaries of 
the LLG areas of the Middle Fly District are shown in Figure 5.3. The cluster analyses focused 
only on TB patients from the Gogodala (Balimo Urban and Gogodala Rural LLGs) and Bamu 
(Bamu Rural LLG) regions, and thus a further eleven TB patients were excluded from these 
analyses, as described in Figure 5.2. 
 
 
Figure 5.2: Flow diagram detailing TB patients excluded from the spatial and cluster analyses. 
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Figure 5.3: Map of towns, villages, and LLG areas in Western Province, PNG. (Map sources: 
Esri, HERE, Garmin, Intermap, increment P Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, 
IGN, Kadaster NL, Ordnance Survey, Esri japan, METI, Esri China (Hong Kong), swisstopo, © 
OpenStreetMap contributors, and the GIS User Community) 
 
Kiunga Urban 
Balimo Urban 
Daru Urban 
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5.2.2. Identification of drug-resistant tuberculosis patients 
Drug-resistant TB patients were identified from the JCU laboratory database, which records 
results for all samples received and analysed at JCU Townsville. All patients who provided a 
clinical sample that was found to have genetic evidence of any drug resistance-associated 
mutation were considered to be DR-TB patients for the mapping analysis. This dataset 
included those patients described previously in Chapter 4, as well as DR-TB patients 
identified in earlier genetic analyses undertaken by our group (Diefenbach-Elstob and 
Moreau et al., unpublished data), which included samples collected from April 2012 to June 
2017. 
 
5.2.3. Geographic and population data 
 
PNG has 22 regional electorates, which includes 20 provinces, plus the Autonomous Region 
of Bougainville, and the National Capital District (NCD). Each province or region is sub-
divided into one or more districts, with these districts further sub-divided into one or more 
LLG areas. For voting and census purposes, the LLG areas are sub-divided into rural wards or 
urban areas. These wards and urban areas are further sub-divided into census units, which 
approximately correlate to villages, or areas within larger towns (Figure 5.4). 
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Figure 5.4: Flowchart detailing the structure of electoral and census divisions used in PNG. 
 
 
In this chapter, ward-level population data were used for all analyses, as current population 
data for census units were not available. Electoral wards were added to the TB patient 
register data for each patient, based on the first residential address recorded. This was 
performed by matching the first recorded residential address to a census unit, and from 
there to an electoral ward, based on PNG census data. Villages not matched based on this 
population data were matched to an electoral ward based on data obtained from the 2012 
and 2017 PNG government election polling schedules (Papua New Guinea Electoral 
Commission 2012, 2017). 
Population data for electoral wards were obtained from the final census figures released by 
the National Statistical Office (2014). These data are based on population figures from the 
2011 national census. Current population numbers were calculated based on the most 
recent estimate of population growth, as described previously (see Section 3.2.6). 
 
Province
(Example: Western)
District
(Example: Middle Fly)
LLG
(Example: Gogodala Rural)
Rural ward / Urban area
(Example: Isago)
Census unit
(Example: Isago No. 1)
125 
 
A number of localities in the Balimo catchment region are known by alternate names or 
alternate spellings, with the census unit and/or ward name being different to the village 
name used locally and in the patient data. Potential village name discrepancies that were 
identified were checked and confirmed locally. Alternate names are shown in Table 5.1. 
 
Table 5.1: BDH catchment region wards and census units known by alternate names. 
Location name Location type(s) Alternate name 
Bamustu / Bamutsa Census unit / Ward Aba 
Dadi Census unit / Ward Widama 
Dewara Census unit / Ward Dewala 
Dogona Census unit / Ward Dogono 
Gagori Census unit / Ward Gagoro-Matakaia 
Ike Census unit / Ward Togowa 
Kamusi Ward Kamusie 
Kawiapo Census unit / Ward Kawiyapo 
Kenewa Census unit / Ward Kaenewa 
Sisiam Ward Sisiami 
Uric Census unit / Ward Urio 
Wasapea Census unit / Ward Wasapeya 
 
 
Latitude and longitude coordinates were obtained from census-level population data. Where 
a census ward included more than one census unit, the average ward coordinates were 
calculated from the latitude and longitude coordinates of all included census units. Average 
coordinates were calculated using the Geographic Midpoint Calculator available at 
http://www.geomidpoint.com/. 
In a few cases, latitude and longitude data were not able to be obtained from the supplied 
population data. For these locations, Google was used to search for latitude and longitude 
data from alternate sources, as shown in Appendix 5. 
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The use of alternate coordinate sources meant that it was occasionally necessary to convert 
between the latitude-longitude and degrees-minutes-seconds (DMS) coordinate systems. All 
conversions were performed using the conversion calculator available at 
http://www.latlong.net/lat-long-dms.html. 
Coordinate systems used for the data included in this analysis were based on the following 
systems: 
- Projected Coordinate System: WGS_1984_Web_Mercator_Auxiliary_Sphere 
- Geographic Coordinate System: GCS_WGS_1984 
- Datum: D_WGS_1984 
 
5.2.4. Sources for maps 
The basemap layer was the ‘World Topographic Map’ provided within the Esri ArcGIS Online 
package. The data sources for this map include the following: Esri, HERE, DeLorme, 
Intermap, increment P Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, IGN, Kadaster NL, 
Ordnance Survey, Esri Japan, METI, Esri China (Hong Kong), swisstopo, MapmyIndia, © 
OpenStreetMap contributors, and the GIS User Community. Provincial, district, and LLG 
boundary data, and coordinates for populated places within Western Province, were 
sourced from the PNG National Statistical Office. 
 
5.2.5. Data analysis 
All data layers and maps were created and manipulated using ArcGIS – ArcMap 10.4.1 (Esri, 
Redlands, California, USA). 
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Specific case notification rates and standardised incidence ratios were calculated for new TB 
patients in wards in the Balimo Urban and Gogodala Rural LLG areas. This included only new 
TB patients diagnosed during the three full years of the study period (2014 – 2016) (i.e. 
retreatment, transfer in, other, and unknown patients were excluded). Case numbers for the 
three full years were totalled, and then divided by three to determine an average number of 
cases per year. Population for each ward was calculated for the midpoint of the time period 
(i.e. 2015), using the 2011 census data (National Statistical Office 2014), and based on the 
method and growth rate described previously (see Section 3.2.6). Specific case notification 
rates for each ward were calculated using the average case number as the numerator, and 
the calculated population as the denominator, per 100,000 people. Standardised incidence 
ratios were calculated based on the expected rate of TB from the overall calculated 
incidence of 727 TB cases per 100,000 people per year (see Section 3.3.1). Calculations were 
undertaken using the ‘Epidemiology/Biostatistics Tools’ worksheets (LaMorte 2006). 
  
 
All TB patients registered at BDH from 26th April 2013 to 25th February 2017 were mapped, 
with the exception of the excluded cases described previously (see Section 5.2.1). The map 
depicting the locations of TB patients was based on census unit-level coordinates. However, 
patients from a number of localities were mapped based on the average coordinates for a 
number of census units within the town/village, as the precise census unit was rarely known 
for these patients (Figure 5.5). Localities where average coordinates were used are described 
in Table 5.2. All other epidemiological maps depicting descriptive and spatial statistics were 
based on ward-level coordinates. 
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Figure 5.5: Weekend football match in the town of Balimo. The Balimo Urban ward is 
comprised of six census units, however these individual census units are rarely recorded in 
the TB patient register. (Image credit: David Plummer) 
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Table 5.2: Localities where multiple census units were used to derive average ward-level 
coordinates. 
Location Census units Average latitude Average longitude 
Adiba Ago 
Alibi 
Lubi 
Sanabase 
-8.058689 142.87474 
Awaba Awaba Community School 
Awaba Health Centre 
Awaba High School 
Awaba Mission 
-8.009253 142.752998 
Balimo Balimo 01 
Balimo 02 
Balimo 03 
Balimo 04 
Balimo Village (1) 
Balimo Village (2) 
-8.037795 142.957082 
Bina Bina No. 1 
Bina No. 2  
-8.103306 143.679974 
Isago Isago Community School 
Isago No. 1 
Isago No. 2 
-8.0097 142.687083 
Pirupiru Pirupiru No. 1 
Pirupiru No. 2 
-8.037183 143.721821 
Sisiami Sisiami No. 1 
Sisiami No. 2 
-8.094085 143.560867 
 
 
Case, population, and coordinate data was tabulated in Microsoft Excel, and imported into 
SaTScanTM. The spatial scan statistic was then calculated using SaTScanTM (versions 9.4.4 and 
9.6), which is a trademark of Martin Kulldorff. The SaTScanTM software was developed under 
the joint auspices of (i) Martin Kulldorff, (ii) the National Cancer Institute, and (iii) Farzad 
Mostashari of the New York City Department of Health and Mental Hygiene (Kulldorff & 
Information Management Services 2009). 
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A discrete Poisson probability model was used because occurrence of the disease is rare 
(Kulldorff 1997). The data was scanned for areas with either high- or low-rate clusters. A 
circular spatial window was used, and the maximum spatial cluster size was set at the 
default size of 50% of the population at risk. The analysis was run with 999 replications, and 
statistical significance was set at p < 0.05. Secondary clusters that were significant were Gini 
clusters. These non-overlapping clusters are selected to maximise the Gini index, which is a 
measure of statistical dispersion, to ensure that there is a large difference between the 
cluster and non-cluster areas (Boscoe et al. 2003; Han et al. 2016; Kulldorff 2015). Shapefiles 
describing the cluster areas were generated as part of the SaTScanTM analyses, and overlaid 
on maps of the Gogodala and Bamu regions using ArcGIS – ArcMap 10.4.1 (Esri, Redlands, 
California, USA). 
 
5.3. Results 
Of the 1614 TB patients registered at BDH from 26th April 2013 to 25th February 2017, a total 
of 1568 were mapped following exclusion of the patients described previously (see Section 
5.2.1). 
 
5.3.1. The catchment area of Balimo District Hospital 
The locations of towns and villages where TB patients were identified in this study are shown 
in Figure 5.6. As shown by the LLG boundaries on the map, Balimo Urban LLG and Gogodala 
Rural LLG are the primary catchment regions of BDH. However, the locations of some 
identified TB patients demonstrate that patients originate from across the region more 
broadly, particularly including a large part of the Bamu LLG, and to a limited extent areas to 
the north (Nomad Rural LLG), west (Morehead Rural LLG), and south (Kiwai Rural LLG) of the 
Gogodala region. 
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Figure 5.6: Map of Western Province showing all localities with TB patients identified in this 
study, differentiated by LLG area. (Map sources: Esri, HERE, Garmin, Intermap, increment P 
Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, IGN, Kadaster NL, Ordnance Survey, Esri 
Japan, METI, Esri China (Hong Kong), swisstopo, © OpenStreetMap contributors, and the GIS 
User Community) 
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5.3.2. Density of tuberculosis cases 
The specific case notification rates and standardised incidence ratios (SIR) for ward are 
shown in Table 5.3. These case notification rates reflect the average number of new TB cases 
in the Gogodala region over the complete 2014 – 2016 period. Some wards were found to 
have extremely high rates of TB based on the standardised incidence rates. For example, the 
SIR of Kimama ward was 514% higher than that of the Gogodala region overall. 
The density of TB cases was mapped in the Balimo region, depicting the number of TB cases 
in relation to ward-level population size (Figure 5.7). Overall, this map demonstrates lower 
case density in the peripheral regions, and higher case density in the area immediately 
surrounding Balimo, particularly along the river. 
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Table 5.3: Average case numbers, specific CNR (per 100,000 people), and SIR by ward for 
new TB patients in the Gogodala region over the 2014 – 2016 period. SIR calculations are 
based on the average incidence of 727 TB cases per 100,000 people per year. 
Ward Average 
cases (n) 
Population Specific CNR  
(per 100,000) 
SIR (95% CI) 
Adiba 15.7 1893 829 114 (65 – 186) 
Aduru 0 800 0 0 
Aketa 12.3 935 1316 181 (94 – 314) 
Ali 7.7 1814 424 58 (25 – 117) 
Awaba 1.7 1816 94 13 (1 – 51) 
Balimo 63.7 4850 1313 181 (139 – 231) 
Bamustu 9.3 380 2446 337 (156 – 633) 
Baramula 0 899 0 0 
Dadi 11.7 928 1261 173 (89 – 305) 
Dede 1 1376 73 10 (0 – 56) 
Dewara 0 952 0 0 
Dogono 4 835 479 66 (18 – 169) 
Duaba 0 744 0 0 
Ike 8.3 665 1248 172 (75 – 334) 
Isago 13.7 1154 1187 163 (89 – 276) 
Kawiapo 5.7 1314 434 60 (21 – 132) 
Kawito Station 0 166 0 0 
Kenewa 5 760 658 90 (29 – 211) 
Kewa 7 904 774 107 (43 – 219) 
Kimama 34.7 778 4460 614 (427 – 854) 
Kini 5.3 468 1131 156 (52 – 355) 
Konedobu 0 355 0 0 
Kotale 9.7 983 987 136 (64 – 252) 
Kubu 1.7 130 1306 180 (15 – 713) 
Lewada 0.3 1511 20 3 (0 – 39) 
Makapa 9 2047 440 60 (28 – 115) 
Pagona 1.3 962 135 19 (0 – 87) 
Pikiwa 5 1040 481 66 (21 – 154) 
Pisi 16.3 1235 1320 182 (104 – 294) 
Semabo 1.3 513 254 35 (1 – 163) 
Sialoa 0 716 0 0 
Tai 9 504 1785 246 (112 – 466) 
Tapila 0.3 562 53 7 (-1 – 105) 
Ugu 12.3 1550 794 109 (57 – 189) 
Uladu 7 492 1423 196 (78 – 403) 
Urio 0.7 1609 43 6 (0 – 43) 
Waligi 7.3 852 857 118 (48 – 239) 
Wasapeya 4 344 1161 160 (43 – 409) 
Waya 4 762 525 69 (19 – 178) 
Yau 5 713 701 96 (31 – 225) 
Total 301 41311 729 100 (89 – 112) 
CI: confidence interval; CNR: case notification rate; n: number; SIR: standardised 
incidence ratio; TB: tuberculosis 
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Figure 5.7: Case density map based on ward-level population data for TB cases identified in the Balimo region during the study period. Circle 
sizes reflect the population size of the villages, with the colour representing the number of TB cases. (Map sources: Esri, HERE, Garmin, 
Intermap, Increment IP Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, IGN, Kadaster NL, Ordnance Survey, Esri Japan, METI, Esri China 
(Hong Kong), swisstopo, © OpenStreetMap contributors, and the GIS User community)
Low case 
numbers 
High case 
numbers 
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5.3.3. Cluster analyses 
TB patients in the Bamu (n = 295) and Gogodala (n = 1262) regions were analysed separately 
to investigate for TB case clusters. Clusters identified in the Gogodala region are described in 
Table 5.4 and depicted in Figure 5.8. The optimal Gini coefficient was found at 20%, so only 
clusters with less than 20% of the population at risk were reported. In general, high-rate 
clusters (more cases observed than expected given the population density) were identified 
close to Balimo, while low-rate clusters (less cases observed than expected given the 
population density) were seen on the outskirts of the region. However, a low-rate cluster 
was identified at Awaba ward, and high-rate clusters were identified in the individual wards 
of Kimama and Pisi. 
Clusters identified in the Bamu region are described in Table 5.4. These are depicted in 
Figure 5.9, although only clusters that were statistically significant are shown. The optimal 
Gini coefficient was found at 12%, so only clusters with less than 12% of the population at 
risk were reported. Three high-rate clusters were identified in the lower regions of the Bamu 
and Gama Rivers; while low-rate clusters were identified further along the Gama River, and 
in the far north of the Bamu Rural LLG.
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Table 5.4: High- and low-rate TB clusters identified in the Gogodala and Bamu regions using the spatial scan statistic. 
No. Locations in cluster Gini cluster Population Observed 
cases 
Expected 
cases 
RR p 
Gogodala region 
1 Kimama Yes 704 162 23.74 7.68 <0.01 
2 Lewada, Dede, Konedobu, Tapila, Dewala, Pagona, Duaba Yes 5854 20 197.39 0.09 <0.01 
3 Bamustu, Uladu, Kewa, Kotale, Tai, Balimo Urban Yes 7351 429 247.87 2.11 <0.01 
4 Urio, Kenewa, Waya, Ugu, Kawiapo, Aduru, Baramula Yes 6970 116 235.02 0.44 <0.01 
5 Awaba Yes 1646 6 55.50 0.10 <0.01 
6 Ali, Makapa, Sialoa Yes 4147 68 139.83 0.46 <0.01 
7 Pisi Yes 1119 73 37.73 1.99 <0.01 
8 Ike, Yau, Aketa, Adiba, Kawito Station, Dadi Yes 4801 212 161.88 1.37 0.01 
Bamu region 
1 Sisiami Yes 331 37 7.27 5.68 <0.01 
2 Bamio Yes 741 54 16.27 3.84 <0.01 
3 Samakopa Yes 1292 2 28.38 0.06 <0.01 
4 Kawalasi Yes 654 2 14.36 0.13 <0.01 
5 Nemeti Yes 229 15 5.03 3.09 0.02 
6 Ukusi Yes 293 0 6.44 0.00 0.03 
7 Garu No 549 3 12.06 0.24 0.09 
8 Ibuo No 385 2 8.46 0.23 0.27 
9 Gagoro No 184 8 4.04 2.01 0.92 
10 Miruwo No 789 22 17.33 1.29 1.00 
RR: relative risk; TB: tuberculosis
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Figure 5.8: Geographic distribution of high- and low-rate TB clusters identified in the Gogodala region. (Map sources: Esri, HERE, Garmin, 
Intermap, increment P Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, IGN, Kadaster NL, Ordnance Survey, Esri Japan, METI, Esri China (Hong 
Kong), swisstopo, © OpenStreetMap contributors, and the GIS User Community)
Low case cluster (observed < expected) 
High case cluster (observed > expected) 
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Figure 5.9: Geographic distribution of high- and low-rate TB clusters identified in the Bamu region. Only clusters that were statistically 
significant are shown. (Map sources: Esri, HERE, Garmin, Intermap, increment P Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, IGN, 
Kadaster NL, Ordnance Survey, Esri Japan, METI, Esri China (Hong Kong), swisstopo, © OpenStreetMap contributors, and the GIS User 
Community)
Low case cluster (observed < expected) 
High case cluster (observed > expected) 
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5.3.4. Cluster analyses of demographic variables 
Comparative cluster analyses are shown for sex (Figure 5.10), age (Figure 5.11), and TB type 
(Figure 5.12). These analyses are consistent with the broader cluster analyses, and show that 
across the demographic variables there are consistently higher rates of TB in the Balimo 
region and immediate surrounds, while lower rates of TB are seen in the outlying areas. 
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Figure 5.10: Cluster analyses for (a) all TB patients, (b) male TB patients, and (c) female TB 
patients in the Gogodala region. (Map sources: Esri, HERE, Garmin, Intermap, increment P 
Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, IGN, Kadaster NL, Ordnance Survey, Esri 
Japan, METI, Esri China (Hong Kong), swisstopo, © OpenStreetMap contributors, and the GIS 
User Community) 
(a) 
(b) 
(c) 
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Figure 5.11: Cluster analyses for (a) all TB patients, (b) adult TB patients, and (c) child TB 
patients in the Gogodala region. (Map sources: Esri, HERE, Garmin, Intermap, increment P 
Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, IGN, Kadaster NL, Ordnance Survey, Esri 
Japan, METI, Esri China (Hong Kong), swisstopo, © OpenStreetMap contributors, and the GIS 
User Community) 
(a) 
(b) 
(c) 
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Figure 5.12: Cluster analyses for (a) all TB patients, (b) pulmonary TB patients, and (c) 
extrapulmonary TB patients in the Gogodala region. (Map sources: Esri, HERE, Garmin, 
Intermap, increment P Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, IGN, Kadaster NL, 
Ordnance Survey, Esri Japan, METI, Esri China (Hong Kong), swisstopo, © OpenStreetMap 
contributors, and the GIS User Community) 
(a) 
(b) 
(c) 
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5.3.5. Drug-resistant tuberculosis in the Balimo region 
The distribution of DR-TB is depicted based on the locations of 12 patients who had genetic 
evidence of TB drug resistance in any of the gene targets investigated (Figure 5.13). The 
ward-level locations of DR-TB patients were Adiba, Balimo, Bamustu, Bibisa, Dadi, Isago, 
Kawiyapo, Kewa, and Ugu. The majority of DR-TB cases were located along the river. The 
proportion of childhood TB and clustering results for these locations are shown in Table 5.5. 
There was no obvious association of DR-TB patients with overall high- or low-rate cluster 
locations, as patients were located in wards identified as low-rate, high-rate, and non-
clustered. However, three DR-TB patients were located in Balimo, and two were located at 
the logging site of Panakawa in the Bibisa ward.
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Figure 5.13: Locations where DR-TB patients were identified based on molecular characterisation of drug resistance-associated genes. (Map 
sources: Esri, HERE, Garmin, Intermap, increment P Corp., GEBCO, USGS, FAO, NPS, NRCAN, GeoBase, IGN, Kadaster NL, Ordnance Survey, Esri 
Japan, METI, Esri China (Hong Kong), swisstopo, © OpenStreetMap contributors, and the GIS User Community)
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Table 5.5: Proportions of childhood TB and clustering (Gogodala region only) for ward-level 
locations that had DR-TB cases. 
Location No. DR-TB cases Child TB % Clustering 
Adiba 1 13.8 H Overall 
H Adult 
H Pulmonary 
Balimo 3 17.3 H Overall 
H Adult 
H Extrapulmonary 
H Pulmonary 
H Female 
H Male 
Bamustu 1 38.9 H Overall 
H Child 
H Adult 
H Extrapulmonary 
H Pulmonary 
H Female 
H Male 
Bibisa 2 28.0 n/a 
Dadi 1 23.4 H Overall 
H Adult 
Isago 1 10.7 H Adult 
Kawiyapo 1 27.3 L Overall 
L Extrapulmonary 
L Female 
L Male 
Kewa 1 28.6 H Overall 
H Adult 
H Extrapulmonary 
H Pulmonary 
H Female 
H Male 
Ugu 1 42.9 L Overall 
H Child 
L Extrapulmonary 
L Female 
DR-TB: drug-resistant tuberculosis; H: included in high-rate cluster area; 
L: included in low-rate cluster area; No.: number; TB: tuberculosis 
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5.4. Discussion 
The results of this analysis describe the broad region of Western Province from which 
patients present at BDH. High-rate TB clusters were consistently seen closer to Balimo, while 
low-rate TB clusters occurred in the more remote areas. 
 
5.4.1. The locations of tuberculosis patients demonstrate the broad Balimo District 
Hospital catchment region 
Mapping of TB patients diagnosed at BDH demonstrates the broad catchment region served 
by the hospital. Although the majority of cases originate from the Gogodala region, a large 
number also present from the Bamu region to the north-east of Balimo. Understanding the 
reach of the BDH catchment region is important in the context of the broader Western 
Province TB control program, as the large number of TB patients presenting at BDH from 
outside the Gogodala region emphasises the importance of the hospital to the Middle Fly 
District more broadly. The broad catchment region also illustrates the considerable distances 
that people may need to travel to seek care for TB symptoms. 
In the Gogodala region, most villages had TB cases identified during the study period, and 
villages where TB patients were not identified were predominantly located in the south of 
the region, along the Fly River. Villages within the Gogodala region where no TB was 
identified should be noted for future investigation. It would be necessary to identify if there 
are people symptomatic for TB in these locations, and if so, to determine if people with TB 
symptoms in these locations travel elsewhere for investigation (for example, to Daru in the 
south, which may particularly be the case for people located near the Fly River). Geographic 
challenges may be particularly important for people from the Fly River region, as travel to 
either Balimo or Daru will be lengthy, and as such TB cases may remain undiagnosed. 
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5.4.2. Higher tuberculosis case densities closer to Balimo may reflect access 
challenges and health-seeking behaviour 
The challenges associated with travel in PNG, particularly in the context of TB care, have 
been described previously. Ongugo et al. (2011) noted this issue, stating that only 35% of the 
PNG population live within 10 kilometres of a major road, and 17% have no access to roads 
at all. This situation is indeed the case in the Gogodala and Bamu regions, where roads are 
limited to the Balimo town area, and in proximity to the logging camps (Figure 5.14). Travel 
in the region is primarily by foot or boat. Air travel is prohibitively expensive for most 
people, and limited to smaller prop-driven aircraft capable of landing on short, grass airstrips 
(Figure 5.15). Additionally, the airport at Balimo has been closed since 2013 (Orere 2017). 
This closure necessitates a journey of 30 to 60 minutes by motorised boat upstream to the 
closest airport at Kawito, which has scheduled flights limited to once or twice per week. 
 
 
Figure 5.14: Logging road near Sasareme logging camp in Western Province, PNG. (Image 
credit: Tanya Diefenbach-Elstob) 
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Figure 5.15: A DHC-6 Twin Otter used for air travel from Port Moresby to Kawito Station, 
upstream of Balimo in Western Province, PNG. (Image credit: Tanya Diefenbach-Elstob) 
 
The presence of high-rate clusters and higher densities of TB patients in the area 
immediately surrounding Balimo is not surprising, as access to care will be easier for people 
living closer to Balimo, and in villages adjacent to the Balimo lagoon and Aramia River (Figure 
8.5). Such influences have also been described in Ethiopia, with studies finding higher TB 
density in regions with closer proximity to urbanised areas (Dangisso et al. 2015a), a greater 
risk of mortality in children under five living further away from a regional health facility 
(Okwaraji et al. 2012), and delayed treatment-seeking in people who had to travel to a 
health facility by foot (Robel et al. 2017). In addition, urbanisation is associated with higher 
rates of TB, as a result of factors such as overcrowding and increased TB transmission risk 
(Antunes & Waldman 2001; Oppong et al. 2015; Wanyeki et al. 2006). 
Smaller villages with high TB patient numbers, particularly those within the immediate 
Gogodala area, should be noted for further investigation to identify the underlying causes of 
the high TB burden. In this context, both Kimama and Pisi were identified in this analysis. 
Neither of these villages had DR-TB patients identified in the analysis, and both had 
proportions of childhood TB comparable to the average proportion (17.6% and 26.4% 
respectively). Furthermore, villages with a low density of TB, particularly those with easier 
access to health services, should also be identified. Such villages may have their own locally-
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implemented public health measures for management of TB that could provide useful 
approaches applicable in high-burden villages. 
Other possible reasons for high case density in particular villages include the presence of an 
actively staffed aid post or health clinic that regularly refers presumptive TB patients to 
Balimo, or increased case-finding or awareness activities (by either health workers or 
community members) (Figure 5.16). Proximity to a health facility, health worker training, 
and local TB awareness activities are all factors that have been associated with increased TB 
notifications in other settings (Dangisso et al. 2015b; Datiko et al. 2017; Parija et al. 2014; 
Yassin et al. 2013). Furthermore, a study from South Africa has described a large proportion 
of people with TB symptoms being overlooked for further investigation, highlighting the 
importance of health worker awareness and education in the identification and diagnosis of 
TB (Chihota et al. 2015), which may play a role in the number of patients who are 
subsequently diagnosed with TB. Interestingly, neither Kimama nor Pisi were sites with 
active peripheral health facilities at the time of this study. If these villages reflect accurate 
rates of TB diagnosis, rather than comparatively high rates of disease, villages with low case 
densities may indicate TB under-diagnosis, and thus sites where active TB investigations 
should be undertaken. 
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Figure 5.16: Sister Bisato Gula providing TB awareness and education during a health worker 
patrol to a Gogodala-region village. (Image credit: Tanya Diefenbach-Elstob) 
 
Lower TB patient density in the regions further from Balimo are likely to occur for two 
reasons. The greater distance from Balimo will result in access challenges for people who 
must travel further to access care (Diefenbach-Elstob et al. 2017). Indeed, distance and 
easier access as a factor in TB diagnostic delay and illness duration have been described in 
other resource-limited settings (Babatunde et al. 2015; Demissie et al. 2002; Lawn et al. 
1998). The second reason likely to influence the locations of TB patients in the Balimo region 
is that people with TB symptoms who are located in villages in the south of the Gogodala 
Rural LLG, particularly along the Fly River, may be more likely to travel to Daru to seek care, 
rather than to Balimo. However, the presence of Fly River-region patients at Balimo indicates 
that choosing to walk to Balimo rather than travel by boat to Daru (a long and potentially 
rough journey) is still a preferred option for some people. 
The low-rate cluster identified in Awaba will be a reflection of TB patient recording. Awaba is 
a larger village with a population of more than 1600 people. It has one of the few high 
schools in the region, and is the site of the largest health centre in the Gogodala region 
outside of Balimo. This low-rate cluster will reflect the separate registration of TB patients 
diagnosed and commenced on TB treatment at Awaba Health Centre. The Awaba TB register 
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was not available for this study, although TB incidence at the centre was estimated to be 381 
cases per 100,000 people per year in the 2011 Western Province TB evaluation study 
(McBryde 2012). It would be interesting to investigate the Awaba TB register in the future to 
provide further understanding of the burden of TB disease present in the Gogodala region. 
The reasons for high- and low-rate TB clustering in the Bamu region were not always 
obvious, as this region does not have an urban centre. However, the high-rate clusters 
located at Nemeti and Sisiami will be the result of non-routine active case-finding activities 
undertaken in March 2016. Another high-rate cluster was located at Bamio, which is the 
location of a peripheral health clinic (see Appendix 2), which may suggest an increased 
likelihood of symptomatic people being referred to Balimo from this health centre. The low-
rate clusters in other areas of the Bamu Rural LLG (Samakopa, Kawalasi, and Ukusi) likely 
reflect a combination of access challenges, and travel to health centres other than Balimo 
for TB care, as these were the most geographically distant of the identified cluster locations. 
 
 
Figure 5.17: People travelling by motorised dugout canoe in the Gogodala region. (Image 
credit: David Plummer) 
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There was no apparent clustering in the spatial distribution of DR-TB patients. However, the 
majority of DR-TB patients were located in river- or lagoon-based villages, which will have 
easier access to BDH. Given the limited amount of available data about DR-TB patients from 
the region, caution must be used in drawing interpretations. The presence of three DR-TB 
patients in Balimo likely reflects both ease of access and the high proportion of TB patients 
overall in Balimo. Notably, urbanisation has been associated with DR-TB elsewhere (Alene et 
al. 2017). Two DR-TB patients were located at the logging site of Panakawa, which is 
frequently referred to as a TB hotspot by health workers in the Balimo region (Diefenbach-
Elstob et al, unpublished interview data). Overall, the presence of DR-TB in the area is 
worrying due to the potential for transmission of DR-TB strains across a broad geographic 
region. 
The presence of low-rate clusters should also be considered in the context of the burden of 
TB across the Gogodala and Bamu regions. If high-rate clusters are actually representative of 
the true TB burden in the regions where they occur, then low-rate clusters may be indicative 
of TB under-diagnosis. 
 
5.4.3. Non-routine case-finding may reflect the true tuberculosis burden 
There are some issues of note with the 57 excluded patients (see Section 5.2.1). The 11 
patients from within Western Province, but outside the Gogodala and Bamu regions, may be 
important when considering importation of TB into the Gogodala region. Seven of the 11 
patients had alternative addresses recorded within the Gogodala and Bamu regions, 
including two at logging camps, and one at Awaba High School. These alternative addresses 
suggest mobility of people in the region, particularly in the context of education and 
employment. Such mobility is important when considering TB transmission, as movement of 
people will increase the number of contacts that TB patients have. 
There were 96 TB patients diagnosed as a result of non-routine active case-finding activities 
(see Section 3.3.6), and it was noted in Section 5.4.2 that two of the Bamu-region high-rate 
clusters were likely to be associated with this activity. However, these patients also 
demonstrate the potentially even higher burden of TB in this region. During the active case-
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finding activity, patients from eight villages (located in the Nemeti, Magiwe, Sisiami, Oropai, 
Bunigi, Torobina, Upati, and Bina wards) were diagnosed with TB (2 with pulmonary TB and 
94 with extrapulmonary TB) in an eight-day period. By comparison, there were only 31 
patients diagnosed from these eight villages over the remainder of the study period. 
Although the majority of these patients were extrapulmonary TB, this difference suggests a 
substantial proportion of people with TB living in remote and difficult-to-reach locations who 
may not otherwise be diagnosed with TB. In the case of pulmonary TB, this situation 
increases the likelihood of transmission to others, and in all cases, reflects diminished quality 
of life for these people due to potentially long-term morbidity from TB symptoms. 
 
5.4.4. Limitations of the geographic analysis 
There are some limitations to the spatial data that has been presented in this chapter. As 
noted in the methods, it can occasionally be difficult to determine the ‘correct’ residential 
address to use for a patient. People frequently have more than one address recorded in the 
TB register. However, in this analysis only the first address recorded was used, as it was 
assumed that this address was where the patient was most likely to be living at the time, and 
thus reflected their most recent residence. However, people with more than one address 
may be more mobile, particularly if travelling between their residential village and home 
village (i.e. their place of birth or family village), and if they work at a logging site. 
Earlier in this thesis it was noted that there are a number of smaller health facilities in the 
region where TB patients may be registered and commenced on treatment (see Appendix 2). 
These are small facilities, but there will be an unknown proportion of TB patients who would 
influence these analyses to an extent that is difficult to determine. The overall cluster 
analyses attempt to account for this by showing the locations of the peripheral health 
facilities. However, peripheral facilities were located in regions of both high- and low-rate 
density, implying that these facilities do not have a substantial impact on the overall 
distribution of TB patients in the region. 
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5.5. Conclusion 
This analysis has provided insight into the influence of geography on TB distribution in the 
BDH catchment region. The results include baseline data about TB distribution across the 
region, as well as targeted information that points to the need for village- and ward-specific 
TB investigations. The provision of TB services to people outside of the immediate Gogodala 
region highlights the importance of BDH in TB control in the Middle Fly District of Western 
Province, and emphasises the importance of investment in resources and facilities at the 
hospital. 
In this region, TB clustering likely reflects the ease with which people are able to travel and 
seek treatment, demonstrating the importance of being able to access health services. Easier 
access to health services, through targeted case-finding activities, may reveal an 
undiagnosed TB burden in the region. 
The lack of any clear association of DR-TB patients with particular factors such as childhood 
TB or case density raises the question of whether DR-TB in the region is less likely to be due 
to transmission, and more likely the result of de novo mutagenesis or acquired resistance as 
a result of insufficient treatment. For those patients where access is difficult and treatment-
seeking is delayed, the time taken to be diagnosed and commenced on treatment will also 
play a role in the development of drug resistance. Further research is necessary to develop a 
better understanding of the epidemiology of DR-TB in this area, and research undertaken 
using techniques such as whole genome sequencing would be useful to demonstrate links 
between DR-TB strains. However, the wide distribution of DR-TB across the Balimo region is 
of particular concern due to the risk of transmission of these strains across an extensive 
geographic region. The management of geographically dispersed DR-TB patients will be 
challenging, from both a patient and provider viewpoint, due to the need for travel to Daru 
for diagnosis and treatment.  
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VALIDATION OF SMEAR MICROSCOPY IN THE DIAGNOSIS OF 
TUBERCULOSIS IN A RESOURCE-LIMITED SETTING 
 
6.1. Introduction 
The results presented in this thesis have described a heavy burden of tuberculosis (TB), 
particularly extrapulmonary TB, as well as the presence of drug-resistant TB (DR-TB) in the 
Gogodala region. In Chapter 3 the proportion of bacteriologically-confirmed pulmonary TB 
diagnosed at Balimo District Hospital (BDH) was described, with 77.9% (250/321) of 
pulmonary TB patients having a smear result recorded, and 65.8% (211/321) being smear-
positive. However, smear microscopy is a diagnostic method known to have low and variable 
sensitivity, which systematic reviews have found to range from 31 – 98%, depending on the 
smear processing method used (Steingart et al. 2006a; Steingart et al. 2006b). The 
proportion of bacteriologically-confirmed pulmonary TB seen at BDH is high in comparison 
to the Papua New Guinea (PNG) national average, where 25.9% of pulmonary TB cases were 
bacteriologically confirmed (Aia et al. 2018). The known variable sensitivity of smear 
microscopy combined with the high proportion of smear-positive pulmonary TB in the 
Balimo setting indicates the possibility of missed pulmonary TB cases, including smear-
negative results considered not to be TB that are indeed smear-negative pulmonary TB. This 
background signals a need for better understanding of the utility of smear microscopy for TB 
diagnoses at BDH. This chapter will examine smear microscopy results obtained from BDH, 
and validate these results based on comparison to culture and molecular methods. 
The difficulties associated with bacteriological confirmation of Mycobacterium tuberculosis 
(MTB) infection are reflected in the World Health Organization (WHO) definitions of a TB 
case, which include patients with either bacteriological confirmation or a clinical diagnosis 
(World Health Organization 2013a). Bacteriologically confirmed TB cases must have provided 
a clinical specimen, which is then found positive for the presence of MTB using smear 
microscopy, culture, or a WHO-approved rapid diagnostic such as the Xpert MTB/RIF or 
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Xpert MTB/RIF Ultra (World Health Organization 2013a, 2017d). A clinically diagnosed TB 
case is a patient who does not meet the criteria for bacteriological confirmation, but for 
whom a qualified practitioner has diagnosed active TB and decided to commence a full 
course of TB treatment (World Health Organization 2013a). These guidelines mean that 
where a diagnostic specimen is unavailable, the lack of bacteriological confirmation does not 
preclude the diagnosis of active TB. In practice, bacteriological confirmation of TB is often 
easily achieved only for pulmonary TB cases, as has been demonstrated in the BDH TB 
patient cohort where 77.9% of pulmonary TB patients had a smear result recorded, 
compared to only 8.8% of extrapulmonary TB patients. 
 
 
Figure 6.1: Labelling sputum pots and collecting clinical information during a TB patrol to a 
rural village in the Balimo region. (Image credit: Mauri Amadu) 
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Other diagnostic methods used for the identification of pulmonary TB also rely on the 
examination of a sputum sample. Historically, culture has been considered the gold standard 
in the detection of MTB (Public Health Laboratory Network 2006). However liquid culture, 
often using mycobacteria growth indicator tubes (MGIT), has an increased chance of 
detecting a variety of other mycobacterial species, and thus requires differentiation of the 
MTBC from other mycobacterial growth, which can include a variety of non-tuberculous 
mycobacteria (NTM) (Chihota et al. 2010; Public Health Laboratory Network 2006). Both 
solid and liquid culture are time-consuming, with results taking about two weeks for liquid 
culture, and up to eight weeks for solid culture (Chihota et al. 2010). More recently, 
molecular methods are increasingly being used, and the Xpert MTB/RIF or MTB/RIF Ultra are 
both WHO-approved rapid diagnostics for active TB (World Health Organization 2017d). 
Molecular methods such as the Xpert platforms have advantages for both patients and 
health providers, requiring a single on-the-spot sputum sample, results available within two 
hours, and detection of drug resistance (World Health Organization 2013c). 
The variety of methods available for TB diagnosis mean that in specific settings one or more 
techniques may be used depending on the available resources and facilities. Although 
microscopy is the only method available at BDH, clinical samples used for smear microscopy 
have also been analysed by our group at James Cook University (JCU) using culture and 
molecular techniques. The aim of this study is to support the BDH laboratory by validating 
the smear microscopy technique, through comparison of BDH smear microscopy results with 
JCU laboratory results from culture and molecular testing methods undertaken on clinical 
samples collected from people being investigated for TB. This will provide insight into the 
potential misdiagnosis and/or under-diagnosis of TB at BDH. The specific objectives are: 
1. To describe microscopy, culture, and molecular diagnostic results in samples from 
patients being investigated for TB 
2. To determine the diagnostic utility of smear microscopy at BDH, based on culture and 
real-time PCR (qPCR) as gold standards. 
3. To compare diagnostic outcomes where two or more methods were used on the 
same sample. 
 
158 
6.2. Materials and Methods 
6.2.1. Diagnostic methods 
This study analysed the results of diagnostic tests undertaken on samples collected at BDH 
from people being investigated for TB. For each sample, one or more of three different 
laboratory-based methods were used to identify MTB – microscopy, culture, and a molecular 
TaqMan qPCR assay. 
Microscopy was undertaken at BDH using techniques described previously (see Section 
4.2.2). Smear slides were examined at BDH, and smear grades were provided for each slide. 
Culture was undertaken in the PC3 laboratory at James Cook University, Townsville. 
Decontaminated sputum samples were inoculated into PANTA-supplemented MGITs 
(Becton, Dickinson, Australia), and incubated at 37oC for up to seven weeks. 
The qPCR assay results were the outcome of analyses undertaken on genomic DNA extracted 
from smeared sputum slides, culture supernatant, and direct from decontaminated sputum. 
For the sputum smear slides, the DNA extraction procedure was a modified version of a 
Chelex DNA extraction method (Guernier et al. 2018; Van Der Zanden et al. 2003). For 
culture, DNA was extracted from positive MGIT cultures using the High Pure PCR Template 
Preparation Kit (Roche, Germany). The method undertaken for DNA extracted directly from 
decontaminated sputum has been described in Section 4.2. All molecular results have been 
grouped together for the analyses in this chapter, regardless of the origin of the extracted 
DNA (microscope slide, culture supernatant, or sputum). 
 
6.2.2. Sources of diagnostic data 
This analysis focused only on ‘new’ samples, i.e. only samples collected from people 
undergoing initial investigations for TB. Follow-up samples were excluded as these were 
collected from people who had been commenced on or had completed TB treatment, and 
were thus being investigated to exclude rather than identify the MTB organism. Smear 
microscopy data were primarily obtained from the BDH laboratory database. For cases that 
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were able to be matched to the TB patient register, any additional smear results that were 
recorded were also included. The results of the culture and molecular methods were 
obtained from the JCU laboratory database. 
Laboratory test results were categorised depending on the test used and the result reported. 
For microscopy, if multiple smears were produced and read, only the highest smear result 
was retained for the analysis. For example, a sputum sample with microscopy results of 3+ 
and 2+ was categorised as 3+, while a sputum sample with reads of 1+ and no acid-fast 
bacilli (NAFB) was categorised as 1+. Positivity in the molecular assay was based on analysis 
of the IS6110 assay, which was considered reactive when the cycle threshold (Cq) was less 
than or equal to 40 cycles. Samples considered to be ‘MTBC or NTM’ were classified as 
positive for this analysis, as described previously in Section 4.2.4. 
In cases where more than one sputum sample was collected from an individual, either on 
the same day or within four days of each either, only one sample was retained for the 
analysis, with this being the positive result if the results were discrepant. The diagnostic 
results were combined for one sample that had been split for processing. 
 
6.2.3. Data analysis 
Diagnostic methods were statistically analysed using 2x2 tables constructed as shown in 
Table 6.1. 
 
Table 6.1: Format of 2x2 tables for calculation of diagnostic statistics. 
  Gold standard  
  Positive Negative Total 
Diagnostic 
method 
Positive a c a + c 
Negative b d b + d 
 Total a + b c + d a + b + c + d 
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Based on the 2x2 tables, diagnostic statistics were calculated using MedCalc’s diagnostic test 
evaluation calculator, according to the following formulae (MedCalc Software 2018): 
 
𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑎
𝑎 + 𝑏
 
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =
𝑑
𝑐 + 𝑑
 
𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑣𝑒 𝑣𝑎𝑙𝑢𝑒 (𝑃𝑃𝑉) =
𝑎
𝑎 + 𝑐
 
𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑣𝑒 𝑣𝑎𝑙𝑢𝑒 (𝑁𝑃𝑉) =
𝑑
𝑏 + 𝑑
 
𝑝𝑟𝑒 − 𝑡𝑒𝑠𝑡 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 =
𝑎 + 𝑏
𝑎 + 𝑏 + 𝑐 + 𝑑
 
𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑟𝑎𝑡𝑖𝑜 =
𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
1 − 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
 
𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑟𝑎𝑡𝑖𝑜 =
1 − 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
 
 
Likelihood ratio nomograms showing the pre- and post-test probabilities of disease were 
calculated and constructed using an online diagnostic test calculator (Schwartz 2006). For 
these calculations, the pre-test probability (prevalence) was set at 10%. The kappa index was 
calculated using GraphPad QuickCalcs (GraphPad Software 2018). 
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6.3. Results 
6.3.1. Overall sputum sample testing results 
A total of 804 sputum samples were transferred to JCU during the period April 2012 to June 
2017. Of these, 655 were retained as ‘new’ samples for this analysis. Results for microscopy, 
culture, and qPCR are shown in Table 6.2. 
 
Table 6.2: Diagnostic results for sputum samples tested with smear microscopy, liquid 
culture, and qPCR. The ‘% of known’ column shows the proportions of positive and negative 
results in each group with the unknown proportions excluded. 
Method Overall result n (%) % of known 
Microscopy Positive 142 (21.7) 142 (23.1) 
 Negative 472 (72.1) 472 (76.9) 
 Unknown 41 (6.3)  
 Total 655 (100.0) 614 (100.0) 
Liquid culture Positive 127 (19.4) 127 (29.1) 
 Negative 310 (47.3) 310 (70.9) 
 Unknown 218 (33.3)  
 Total 655 (100.0) 437 (100.0) 
qPCR Positive 232 (35.4) 232 (47.3) 
 Negative 258 (39.4) 258 (52.7) 
 Unknown 165 (25.2)  
 Total 655 (100.0) 490 (100.0) 
n: number; qPCR: real-time polymerase chain reaction 
 
6.3.2. Comparative results in samples tested with more than one diagnostic method 
Comparative results were tabulated for sputum samples where two results were known. 
These comparisons included smear microscopy and liquid culture (n = 400) (Table 6.3); 
smear microscopy and qPCR (n = 457) (Table 6.4); and liquid culture and qPCR (n = 272) 
(Table 6.5). There was poor agreement between the diagnostic techniques when comparing 
smear microscopy with liquid culture (kappa = 0.02, 95% CI -0.08 – 0.12), and when 
comparing liquid culture with qPCR (kappa = -0.12, 95% CI -0.23 – 0.00); while there was 
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moderate agreement between the methods when comparing smear microscopy with qPCR 
(kappa = 0.50, 95% CI 0.43 – 0.57). 
 
Table 6.3: Comparative results for sputum smear microscopy and liquid culture for sputum 
samples where both results were known. 
  Liquid culture  
  Positive Negative Total 
Smear 
microscopy 
Positive 32 (8.0) 76 (19.0) 108 
Negative 81 (20.3) 211 (52.7) 292 
 Total 113 287 400 
 
Table 6.4: Comparative results for sputum smear microscopy and qPCR for sputum samples 
where both results were known. 
  qPCR  
  Positive Negative Total 
Smear 
microscopy 
Positive 109 (23.9) 2 (0.4) 111 
Negative 109 (23.9) 237 (51.9) 346 
 Total 218 239 457 
qPCR: real-time polymerase chain reaction 
 
Table 6.5: Comparative results for liquid culture and qPCR for sputum samples where both 
results were known. 
  qPCR  
  Positive Negative Total 
Liquid culture Positive 62 (22.8) 57 (21.0) 119 
Negative 98 (36.0) 55 (20.2) 153 
 Total 160 112 272 
qPCR: real-time polymerase chain reaction 
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Based on the above results, the sensitivity, specificity, PPV, and NPV for each of the 
compared techniques are shown in Table 6.6, while disease prevalence and likelihood ratios 
are shown in Table 6.7. Based on the prevalence and likelihood ratios, nomograms of post-
test probability of disease are shown for each of the compared techniques in Figure 6.2.
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Table 6.6: Sensitivity, specificity, positive predictive value, and negative predictive value for the smear microscopy and liquid culture diagnostic 
techniques. 
Technique Gold standard Sensitivity %  
(95% CI) 
Specificity %  
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
Microscopy Liquid culture 28.3 (20.2 – 37.6) 73.5 (68.0 – 78.5) 29.6 (22. – 37.4) 72.3 (69.5 – 74.9) 
Microscopy qPCR 50.0 (43.2 – 56.8) 99.2 (97.0 – 99.9) 98.2 (93.2 – 99.5) 68.5 (65.6 – 71.3) 
Liquid culture qPCR 38.8 (31.2 – 46.8) 49.1 (39.5 – 58.7) 52.1 (45.5 – 58.7) 36.0 (30.9 – 41.3) 
CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value; qPCR: real-time polymerase 
chain reaction 
 
Table 6.7: Prevalence and likelihood ratios for the smear microscopy and liquid culture diagnostic techniques. 
Technique Gold standard Pre-test proportion* 
 % (95% CI) 
+LR (95% CI) -LR (95% CI) 
Microscopy Liquid culture 28.3 (23.9 – 32.9) 1.1 (0.8 – 1.5) 1.0 (0.9 – 1.1) 
Microscopy qPCR 47.7 (43.0 – 52.4) 59.8 (14.9 – 239.1) 0.5 (0.4 – 0.6) 
Liquid culture qPCR 58.8 (52.7 – 64.7) 0.8 (0.6 – 1.0) 1.3 (1.0 – 1.6) 
+LR: positive likelihood ratio; -LR: negative likelihood ratio; CI: confidence interval; qPCR: real-time 
polymerase chain reaction 
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Figure 6.2: (a) Post-test probability of TB based on smear microscopy with liquid culture as the gold standard, indicating that culture was not 
useful as a gold standard in analysing sputum samples from this setting; (b) Post-test probability of TB based on smear microscopy with qPCR as 
the gold standard, indicating that a positive smear microscopy result had a high probability of indicating TB, while a negative smear microscopy 
result indicated only a moderate probability of the absence of TB; (c) Post-test probability of TB based on liquid culture with qPCR as the gold 
standard, indicating that culture results had little effect on either increasing or decreasing the probability of TB.
(a) (c) (b) 
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6.3.3. Diagnostic results in culture-negative samples 
There were 153 sputum samples that were culture-negative, and that were also tested with 
both smear microscopy and qPCR. In these culture-negative samples, 89 (58.2%, 95% CI 50.3 
– 65.7) samples were also smear-negative, and of these 43 (48.3%, 95% CI 38.2 – 58.6) were 
qPCR-negative while 46 (51.7%, 95% CI 41.5 – 61.8) were qPCR-positive (Figure 6.3). A total 
of 47 samples were culture-negative but both smear- and qPCR-positive. The remaining 17 
culture-negative samples had been tested with all three methods, with 12 found to be qPCR-
negative and five qPCR-positive, but the smear microscopy results were unknown. Overall 
98/153 (64.1%, 95% CI 56.2 – 71.2) of the culture-negative samples tested with microscopy 
and qPCR were qPCR-positive. 
 
 
Figure 6.3: Smear microscopy and qPCR results in sputum samples that were culture-
negative. 
 
6.4. Discussion 
This analysis focused on the utility of three laboratory-based techniques used in the 
diagnosis of TB, using sputum samples collected from people undergoing investigation for 
TB. The smear microscopy and sputum processing were undertaken in a resource-limited 
Samples with negative culture
ZN unknown
ZN positive
ZN-neg 
(n = 89, 
58.2%) 
qPCR-pos 
(n = 46, 
 51.7%) qPCR-neg 
(n = 43, 
48.3%) 
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laboratory in Balimo, while the liquid culture and TaqMan qPCR were undertaken in a well-
resourced laboratory at JCU Townsville, using the same sputum samples that were originally 
processed on-site in Balimo. The comparative overall positive and negative proportions show 
that there is considerable variation between the three diagnostic methods, with microscopy 
detecting the lowest proportion of MTB and qPCR detecting the highest. Samples that were 
negative for all three methods will be partially explained by the unknown number of people 
who were tested but who did not actually have TB, although some samples may have 
returned false-negative results for all three methods. 
In studies from many settings, culture results are considered the gold standard for 
comparison to microscopy and molecular assays (Afsar et al. 2018; Darban-Sarokhalil et al. 
2013; Pinyopornpanish et al. 2015; Sharma et al. 2015). However in this study, the large 
proportion of negative culture results, and the poor agreement of culture with the other 
techniques, highlight the considerable challenges associated with the culture of samples 
collected and stored in resource-limited settings. In addition, the poor culture results limit 
the usefulness of comparisons to culture-based results in other settings. As a result, for this 
study the molecular technique was considered a more appropriate gold standard due to its 
increased ability to detect MTBC. 
 
6.4.1. Diagnostic performance of smear microscopy at Balimo District Hospital 
When considering the molecular method as the gold standard, microscopy undertaken at 
the BDH laboratory had limited sensitivity, but specificity was very high. These results 
emphasise the known variable sensitivity of smear microscopy as a diagnostic method for TB 
(Steingart et al. 2006b). Similarly for the likelihood ratios and nomograms, a positive smear 
indicated a high probability of TB, while a negative smear indicated only a moderate 
probability of the absence of TB. In this setting, smear microscopy is useful as a rule-in test 
for TB, but not as a rule-out test. 
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6.4.2. Diagnostic performance compared to previous analysis 
In the analyses focused on direct comparison of two diagnostic methods on a single sample, 
the qPCR technique continued to detect the highest proportion of MTB. Earlier research 
from our group described qPCR and smear microscopy results in 309 samples from the 
Balimo region (Guernier et al. 2018), and that sub-set of samples was also incorporated in 
the sample set described here. In the more comprehensive analysis described here, the 
smear-negative/qPCR-negative group continued to contain the largest proportion of samples 
(51.9% compared to 38.5% previously). The increase in smear-negative/qPCR-negative 
results may have been due to the DNA extraction process used on more recently analysed 
samples, as spoligotyping analysis of these DNA extracts was also unsuccessful in 
comparison to the smear microscopy DNA (Guernier et al., unpublished data). Overall, the 
high proportion of smear-negative/qPCR-positive samples confirms that molecular methods 
have improved sensitivity over smear microscopy, as seen in other studies (Boehme et al. 
2011; Ngabonziza et al. 2016; Opota et al. 2016; Theron et al. 2014).  
Compared to the earlier study (Guernier et al. 2018), there was a smaller proportion of 
samples in the smear-positive/qPCR-positive group (23.9% compared to 31.7% previously), 
and in the smear-negative/qPCR-positive group (23.9% compared to 29.1% previously). 
Although the proportions of both of these groups decreased, it is of note that the 
proportions of the groups within each study remained similar to each other. The higher 
proportion of smear-positive/qPCR-positive samples in the earlier study may have been due 
to the inclusion of both new and follow-up samples, meaning that a higher proportion of 
samples from TB patients (rather than TB investigations) were included. Sampling bias may 
also have occurred, particularly if patients with certain clinical symptoms were more or less 
likely to have sputum samples collected and stored at certain times, thus affecting between-
study results. The lower proportion of smear-negative/qPCR-negative samples in the earlier 
study may have been an outcome of sample collection, as trips were undertaken to Balimo 
more frequently from 2014 to 2017, meaning that the larger sample set may have included a 
broader selection of samples, and thus potentially less focus on TB patients or those 
suspected of DR-TB. 
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Figure 6.4: A Stop TB Kit used for treatment of drug-susceptible TB. (Image credit: Tanya 
Diefenbach-Elstob) 
 
The comparison of diagnostic results between smear microscopy and qPCR identified two 
samples that were smear-positive but qPCR-negative. This very low proportion, as described 
previously, may have been due to a false-negative result with the qPCR assay due to poor 
quality of the DNA extraction, the presence of inhibitors in the sputum sample, or a low copy 
number of the IS6110 target (Guernier et al. 2018; Lira et al. 2013). It is also possible that the 
two microscopy smear results were false-positives. This may be due to the presence of NTM, 
which have been seen in smear-positive samples in other settings (Buijtels et al. 2010; 
Desikan et al. 2017; Koh et al. 2003). The diagnostic primer sets used on these two samples 
(described previously in Chapter 4) have been tested against eight different mycobacterial 
species that are not part of the MTBC, and have demonstrated reactivity for seven of these 
species using the IS6110 primer set, but no reactivity using the senX3-regX3 primer set 
(Broccolo et al. 2003). Thus the detection of other NTM that have not been tested is 
possible. However, only a small number of NTM have been detected in PNG thus far (Aia et 
al. 2016; Ley et al. 2015), so their presence in these two samples is considered unlikely, 
although research is warranted. The presence of the Nocardia species, which were not 
170 
tested with these primer sets, may also result in false-positive microscopy results. The 
Nocardia species have a similar appearance to MTB when examined with sputum smear 
microscopy, and can present similarly to TB (Desikan et al. 2017; Muricy et al. 2014; 
Thirouvengadame et al. 2017). Further research would be necessary to determine the cause 
of smear-positive/qPCR-negative results. 
 
6.4.3. Challenges associated with sample processing and transport 
When considering sputum sample processing and storage in Balimo, the results obtained for 
each of the diagnostic methods are not surprising. In this setting, there are power outages 
daily, meaning that samples are subject to multiple freeze-thaw cycles prior to analysis at 
JCU. This has been shown to result in DNA of lesser quality in other organisms and sample 
types (Hasan et al. 2012; Ingersoll et al. 2008). Although smear microscopy is undertaken 
promptly on sputum samples in Balimo, the low proportion of positive results using this 
technique, based on the TaqMan qPCR assay as the gold standard, reflects the previously 
mentioned poor and variable sensitivity of smear microscopy as a diagnostic method 
(Steingart et al. 2006a; Steingart et al. 2006b). 
The poor liquid culture results and comparatively better qPCR results will also be influenced 
by storage issues. As liquid culture requires growth of the MTB organism, if the organism is 
no longer viable due to unsatisfactory storage this growth will not be possible. The negative 
impact of storage and transport on MTB sputum culture yield and contamination has been 
described in other settings (Banda et al. 2000; Maharjan et al. 2016; Paramasivan et al. 1983; 
Šula et al. 1960). By contrast, the qPCR method that detects only DNA will have a greater 
chance of success even if organisms are undetectable or no longer viable, as seen in studies 
showing improved detection of MTB using molecular methods when compared to culture 
(Omar et al. 2016; Traore et al. 2006). Other research has demonstrated the challenges 
inherent in culturing MTB from sputum samples, with contamination due to other bacterial 
organisms known to be a problem in liquid culture even when decontamination of the 
sputum has been undertaken (Ahmad et al. 2017; Chang et al. 2002; Cornfield et al. 1997). In 
Balimo, for samples where both the collection and transport dates were known, the longest 
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storage time of a sample prior to transfer from Balimo to JCU Townsville was approximately 
11 months. In addition, once samples are collected, the transit time is lengthy and may 
involve substantial temperature fluctuations, thus contributing to the discordant results 
seen in this study (Figure 6.5). 
 
 
Figure 6.5: Itinerary of a trip undertaken from Balimo to Townsville in November 2017 
(airport locations are approximate). (Image source: Google; Map data: ©2018 GBRMPA, 
Google) 
 
Although molecular diagnostic methods are valuable, particularly in settings where sample 
storage is challenging and culture is not feasible, the successful culture of TB is important in 
the confirmation of DR-TB through drug susceptibility testing (DST) (World Health 
Organization 2018f). This method relies on the direct testing of the organism, rather than 
inferring drug resistance from genetic mutations, and is the gold standard in identifying DR-
TB (World Health Organization 2018d). However, a culture-based approach is problematic 
when considering the testing of samples that have been stored in sub-optimal conditions, 
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and that may no longer contain viable organisms. In these cases, detection and testing of the 
organism may no longer be possible, and cases of both drug-susceptible and DR-TB may be 
missed. 
The utility of various diagnostic techniques is particularly important in the Balimo setting 
when considering DR-TB. The Balimo region has been established as endemic for DR-TB, 
based on evidence of resistance-associated MTB gene mutations described earlier in this 
thesis (see Chapter 4), and discussions with health workers at BDH, who have identified DR-
TB patients based on treatment response and subsequent confirmation at the provincial 
hospital in Daru. Given the presence of DR-TB in the Balimo region, the results described in 
this chapter emphasise the importance of the implementation of a rapid and achievable 
diagnostic method for TB in Balimo that is capable of both MTB disease and drug resistance 
detection. Such methods, particularly the WHO-endorsed Xpert MTB/RIF, are increasingly 
being implemented in resource-limited settings (Muyoyeta et al. 2015; Nakiyingi et al. 2013). 
Such methods also hold future promise in the identification of a broader range of drug 
resistance, with the ongoing development of molecular techniques and whole genome 
sequencing. 
Molecular methods such as the Xpert MTB/RIF are also increasingly useful in the detection 
and confirmation of extrapulmonary TB. Published research has described confirmation of 
MTB infection based on Xpert MTB/RIF analysis of non-sputum bodily fluids, including urine, 
stool, cerebrospinal fluid, and tissue samples (Denkinger et al. 2014; Hillemann et al. 2011; 
Marouane et al. 2016; Maynard-Smith et al. 2014; Suzana et al. 2016; Zeka et al. 2011). 
Although extrapulmonary TB detection in Balimo would still be limited by the challenges 
associated with obtaining a clinical sample, a rapid method with improved sensitivity will still 
increase the number of bacteriologically confirmed cases, thus contributing to improved 
accuracy in extrapulmonary TB diagnoses in this setting. 
 
6.4.4. Limitations 
The molecular method used for the results presented in this study was undertaken according 
to a published protocol for identifying the Mycobacterium species and MTBC, as described in 
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Chapter 4. However, this method is different to the technique employed by Xpert MTB/RIF, 
and thus there may have been some differences in results if testing had been undertaken 
using Xpert MTB/RIF. 
Diagnostic test results were not linked with TB patient register data, which could have 
provided further insight into discordant results, and the impact of smear-negative 
microscopy results on health worker decisions to commence empirical TB treatment. 
HIV infection is known to negatively influence the sensitivity of smear microscopy for TB 
(Cattamanchi et al. 2009; Elliott et al. 1993), thus increasing the possibility of false-negative 
smear results. However, there is limited evidence suggesting a high burden of HIV in the 
Balimo region, and this factor is unlikely to influence a large proportion of samples. 
 
6.5. Conclusion 
This chapter has described the validation of smear microscopy used to detect MTB in 
sputum samples collected and processed at BDH, based on comparison to culture and 
molecular methods. Almost 35% of smear-negative samples were culture- and/or qPCR-
positive. The results presented in this chapter did not include comparison to the TB patient 
register. However, the substantial proportion of smear-negative but culture- and/or qPCR-
positive results, in combination with the low proportion of smear-negative pulmonary TB 
described earlier (see Table 3.5), continues to support the possibility that smear-negative 
pulmonary TB is under-diagnosed or misdiagnosed in Balimo (Guernier et al. 2018). This 
finding is particularly important because smear-negative results may complicate diagnostic 
protocols, especially in a setting where melioidosis and DR-TB are also endemic. In a setting 
such as Balimo, clinical response to treatment in the absence of bacteriological confirmation 
of MTB infection is often the only method of confirming a TB diagnosis. In cases of 
melioidosis and DR-TB there will not be positive response to treatment, although for DR-TB 
the diagnosis of TB will actually have been correct. Thus, a reliance on clinical outcomes is 
not sufficient to differentiate TB and other infections. 
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Overall, the qPCR molecular method had the greatest sensitivity in detecting MTB, while 
microscopy missed half of the qPCR-positive samples. However, microscopy was shown to 
be very useful as a rule-in test for TB. The high rate of qPCR-positive/smear-negative 
samples in a setting known to be endemic for DR-TB emphasises the benefit that would be 
gained from the implementation at the BDH laboratory of a rapid molecular MTB diagnostic 
with additional drug resistance detection abilities. In this resource-limited setting, the 
challenges associated with the diagnosis of pulmonary TB are amplified for presumptive 
extrapulmonary TB patients, where no clinical sample may be available. As a result, further 
investigation of extrapulmonary TB diagnoses in the Balimo region will provide greater 
insight into TB diagnoses at BDH. 
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INVESTIGATION OF EXTRAPULMONARY AND 
LATENT TUBERCULOSIS IN THE BALIMO REGION 
 
7.1. Introduction 
The research previously presented in this thesis has described the very high burden of 
extrapulmonary tuberculosis (TB) in the Balimo region, occurring in more than 75% of all TB 
cases (see Chapter 3). This is a setting where diagnosis of TB is primarily clinical (based on 
the Papua New Guinea (PNG) guidelines), and where smear microscopy has a positive 
predictive value (PPV) of 98.2% and a negative predictive value (NPV) of 68.5% (based on a 
molecular method as the gold standard) (see Chapter 6). Extrapulmonary TB is known to 
present diagnostic challenges for clinicians for a number of reasons, including paucibacillary 
presentation, the large number of possible differential diagnoses, and the difficulties 
involved in obtaining suitable diagnostic specimens to achieve laboratory confirmation of 
infection (Purohit & Mustafa 2015). Furthermore, latent TB in a population represents a 
potential reservoir of infection that may reactivate into clinical disease, some of which will 
have pulmonary presentation and thus contribute to ongoing transmission of TB (Rangaka et 
al. 2015; Uplekar et al. 2015). 
Symptomatic extrapulmonary TB patients may present similarly to those with pulmonary TB, 
with symptoms such as fever, night sweats, and weight loss, but with additional symptoms 
localised to the site of infection (Peirse & Houston 2017). Examples of localised symptoms 
include lymphadenitis (lymph node TB); bone and joint pain or swelling (bone or joint TB); 
and fatigue and headache (tuberculous meningitis) (Peirse & Houston 2017; Thwaites 2017). 
However, difficulty in reaching a diagnosis of extrapulmonary TB is not uncommon, and 
diagnostic delay may be lengthy. For example, one study describes a man from Guatemala 
with extrapulmonary TB presenting as masses in his neck, who was not diagnosed with TB 
until 10 months after he first presented at a healthcare provider (Shah et al. 2017). It should 
also be noted that even in a setting with a high level of resources, diagnosis can still be 
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challenging. This situation is demonstrated in a study of 117 extrapulmonary TB patients in 
Australia, where microbiological confirmation was achieved for only 58.1% of patients, 
56.4% had histopathological confirmation, and 78.6% overall had microbiological or 
histopathological confirmation (Pollett et al. 2016). 
These diagnostic challenges mean that diagnoses of extrapulmonary TB are frequently 
clinical, based solely on presenting signs and symptoms. Indeed, the World Health 
Organization (WHO) diagnostic guidelines include the classification of a TB case based solely 
on the decision of a clinician to commence a patient on TB treatment, without 
bacteriological confirmation of infection (World Health Organization 2013a). 
Diagnostic challenges, and particularly the limited resources available to achieve laboratory 
confirmation of Mycobacterium tuberculosis (MTB) infection, are evident at Balimo District 
Hospital (BDH) (see Chapter 6). In this hospital setting, diagnoses of TB, and particularly 
extrapulmonary TB, are predominantly clinical. This situation was described earlier in this 
thesis, with sputum smear microscopy results recorded in 77.9% of pulmonary TB cases, 
while 91.2% of extrapulmonary TB patients did not have a smear result recorded (see 
Section 3.3.2). The high proportion of clinical diagnoses that occur in Balimo are primarily 
due to two reasons: 
1. Laboratory facilities for TB diagnosis are limited to microscopy, which has been 
demonstrated in this study to have sensitivity of only 50% (based on a molecular 
method as the gold standard) (see Section 6.3.2). 
2. More than 75% of TB cases are extrapulmonary, with a clinical sample frequently not 
able to be obtained. 
The combination of these two factors results in a situation where positive response to 
treatment is often the only means of supporting or confirming a TB diagnosis. However, a 
positive response to treatment cannot be relied upon as proof of extrapulmonary TB 
infection (Colebunders & Bastian 2000). Extrapulmonary TB is frequently difficult to diagnose 
due to its non-specific presentation. Therefore, it is possible that some clinically diagnosed 
cases of extrapulmonary TB are actually misdiagnoses, and in some cases may have been 
self-limiting conditions which would have resolved regardless of the initiation of TB 
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treatment. In addition, the antibiotics contained within the four-drug combination used to 
treat TB may be effective against other infections, particularly in the case of rifampicin (RIF), 
which has broad antibacterial activity (McCabe & Lorian 1968; Thornsberry et al. 1983); 
again implying that resolution of symptoms does not provide proof of TB (Figure 7.1). 
 
 
Figure 7.1: The four-drug combination tablets, including RIF, that are used in the two-month 
intensive phase of TB treatment. (Image credit: Tanya Diefenbach-Elstob) 
 
In a setting where a lack of diagnostic facilities means that confirmation of extrapulmonary 
TB infection frequently relies on assessing the response to treatment, there are a number of 
potential problems: 
- There is a reliance on patients being available for ongoing monitoring and 
assessment, which may be challenging due to factors such as limited access to a 
health facility. This situation may lead to delays in patient management and loss to 
follow-up. 
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- Non-response to treatment cannot be relied on as an indicator that a TB diagnosis 
was incorrect if the patient’s region of origin is endemic for drug-resistant TB (DR-
TB). 
- For patients who do not have TB, there will be substantial delay in the provision of a 
correct diagnosis and treatment, and thus possible worsening of their condition. 
For these reasons, it is important to attempt to confirm clinically-diagnosed TB cases, as well 
as to understand the clinical decision-making processes that are involved in making these TB 
diagnoses. 
The laboratory confirmation of extrapulmonary TB relies on techniques such as microscopy, 
histology, culture, and molecular tests (Purohit & Mustafa 2015). However, all of these 
techniques are limited by the need for a diagnostic specimen on which to undertake the 
MTB-specific analysis. 
Other methods can provide underlying evidence for TB infection by demonstrating immune 
reactivity. While not supported as a means of diagnosing active TB at an individual level, the 
tuberculin skin test (TST) and the interferon (IFN)-ɣ release assay (IGRA) can give valuable 
insight into the proportion of TB infection at a community level, and hence the rates of 
misclassification of TB in the setting described. Advantages of the IGRA over TST include the 
need for a single visit to a health facility for collection of a whole blood sample, and the 
ability to provide evidence of M. tuberculosis (MTBC) exposure without false-positive results 
due to prior Bacille Calmette-Guérin (BCG) vaccination (Division of Tuberculosis Elimination 
2016; Katsenos et al. 2010). 
In a setting where symptoms are the primary method of extrapulmonary TB diagnosis, 
immunological tests such as IGRAs may be able to provide evidence to support a TB 
diagnosis (Feng et al. 2012; Shin et al. 2015). The IGRA provides evidence of previous MTBC 
exposure through the detection and measurement of IFN-ɣ released by lymphocytes that 
have been exposed to MTBC-derived antigens including ESAT-6 and CFP-10 (Division of 
Tuberculosis Elimination 2016; QIAGEN 2016). 
The IGRA is based on the collection of whole blood into four blood collection tubes. The nil 
(negative control) and mitogen (positive control) tubes validate the assay in two ways. 
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Measurement of IFN-ɣ in sample wells derived from the nil tube allows adjustment for any 
background IFN-ɣ that is produced but not associated with cellular responses to the assay’s 
peptide antigens (QIAGEN 2016). The mitogen tube determines that there is an adequate 
immune response, as it contains a non-specific T-cell stimulator, thus demonstrating the 
ability of lymphocytes to generate IFN-ɣ (QIAGEN 2016; Quest DiagnosticsTM 2014). The TB1 
and TB2 tubes are the MTBC-specific tubes of the assay. The TB1 tubes are designed to elicit 
cell-mediated immune responses from CD4+ T-helper lymphocytes, while the TB2 tubes 
additionally target the CD8+ cytotoxic T lymphocytes (QIAGEN 2016). Furthermore, the CD8+ 
T lymphocytes that are specific for ESAT-6 and CFP-10 may be associated with active TB, or 
more recent exposure to MTB (Day et al. 2011; Nikolova et al. 2013; QIAGEN 2016; Rozot et 
al. 2013). 
The IGRA assay is not able to differentiate active from latent TB, and is thus not a diagnostic 
for active TB (Division of Tuberculosis Elimination 2016). This limitation is because the assay 
detects an immune response that reflects prior T-cell exposure to the MTBC (QIAGEN 2016), 
and thus the assay may be positive in cases of both latent and active infection. However, on 
a population level, comparison of IGRA-positive and -negative proportions in patient and 
non-patient groups may provide insight into the accuracy of TB diagnoses in a setting where 
diagnoses are predominantly clinical. However, it is important to understand the burden of 
IGRA-positivity in the underlying general population, as this proportion will reflect the 
baseline positive proportion that should be expected regardless of active TB infection status 
in the patient group. 
The aim of this chapter is to provide evidence to test the accuracy of clinical diagnoses of TB 
at BDH, with a particular focus on extrapulmonary TB, through the use of an IGRA. The 
specific objectives are: 
1. To assess the burden of MTBC infection (latent TB) in the BDH catchment population, 
based on the IGRA; with comparison across community, health worker, and TB 
patient groups. 
2. To inform the accuracy of clinical extrapulmonary TB diagnoses, based on the 
comparison of IGRA results in non-patient and extrapulmonary TB patient groups, 
with reference to the burden of latent TB. 
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7.2. Materials and Methods 
7.2.1. Study setting and participant recruitment 
The Balimo region has been previously described in Chapter 3. For this study, participant 
recruitment was undertaken in the immediate Balimo area. Participants were classified into 
five groups, as follows: general population, health worker, TB patients, TB investigation, and 
other. 
People in the TB patient, TB investigation, and ‘other’ groups were inpatients at BDH, 
present at hospital clinics at the time of the study, or identified by health workers from BDH. 
Health workers were employees at BDH who volunteered to participate in the study. General 
population participants were community members who volunteered to participate following 
communication of the study by BDH staff. The groups will be described in greater detail in 
Section 7.2.4. 
 
7.2.2. Collection of participant data and diagnostic specimens 
Participants were recruited during three study visits, and identified and approached in 
collaboration with local health workers. A total of 220 participants were recruited across 
three study visits, as shown in Table 7.1. Recollections occurred for five participants – three 
at the request of the participants, and two due to borderline results (TB2 tube concentration 
within 0.15 IU/mL of the 0.35 IU/mL threshold) in an earlier run of the assay (initial 
collection occurring in the second visit). 
 
Table 7.1: Timing of hospital visits and participant numbers across the study period. 
Visit Date Participants Recollections Total 
collections 
1 February 2017 25 0 25 
2 June 2017 99 0 99 
3 November 2017 96 5 101 
Total  220 5 225 
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Demographic and clinical data were collected for each participant, including age, sex, clinical 
signs and symptoms (if relevant), and current and past TB diagnosis and treatment details. 
The TB patient register (previously described in Chapter 3) was searched to identify diagnosis 
and treatment information for current patients and people who indicated a past history of 
TB. 
 
 
A volume of 1 mL of whole blood was collected from each participant into the four labelled 
QuantiFERON® blood collection tubes (1 mL into each tube), in accordance with the package 
directions. Immediately following blood collection, the tubes were gently shaken to coat the 
inner surface of the tubes with blood. Tubes were then placed upright in a 37oC incubator or 
water bath (Figure 7.2). Following incubation, tubes were refrigerated, and plasma was 
harvested. To do this, tubes were centrifuged at 2000 – 3000 g to separate the cells from the 
plasma, and plasma was harvested into cryotubes using a micropipette. Harvested plasma 
was stored at minus-20oC in Balimo, and at minus-80oC following transfer to JCU Townsville. 
 
 
Figure 7.2: Incubating blood collection tubes in a water bath at the BDH laboratory. (Image 
credit: Tanya Diefenbach-Elstob) 
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7.2.3. Technical details of the interferon-ɣ release assay analysis 
The QuantiFERON®-TB Gold Plus (QFT®-Plus) ELISA (QIAGEN, Hilden, Germany) was 
undertaken according to the manufacturer instructions (QIAGEN 2016). The optical density 
(OD) of each well was measured using a microplate reader fitted with a 450 nm filter and a 
620 nm reference filter. Plates processed at JCU Townsville (sample numbers 1 – 125) were 
read using a SPECTROstar Nano (BMG LABTECH, Ortenberg, Germany), while plates 
processed at the BDH laboratory (sample numbers 126 – 225) were read using an EZ Read 
400 (Biochrom Ltd., Cambridge, United Kingdom). 
The ODs were measured, IFN-ɣ concentrations were calculated, and IGRA results were 
interpreted using the QuantiFERON-TB Gold Plus Analysis Software (version 2.71) (QIAGEN, 
Hilden, Germany). The measured ODs from the IGRAs were interpreted according to the 
package insert (QIAGEN 2016). For reference, the criteria for interpretation are shown in 
Table 7.2. 
 
Table 7.2: Criteria for interpretation of QFT-Plus® results. (Source: QIAGEN 2016) 
Nil 
(IU/mL) 
TB1 minus Nil 
(IU/mL) 
TB2 minus Nil 
(IU/mL) 
Mitogen 
minus Nil 
(IU/mL) 
QFT-Plus 
result 
Interpretation 
≤8.0 
≥0.35 and 
≥25% of Nil 
value 
Any 
Any Positive 
MTB infection 
likely 
Any 
≥0.35 and 
≥25% of Nil 
value 
<0.35 or ≥0.35 
and <25% of 
Nil value 
<0.35 or ≥0.35 
and <25% of 
Nil value 
≥0.5 Negative 
MTB infection 
not likely 
<0.35 or ≥0.35 
and <25% of 
Nil value 
<0.35 or ≥0.35 
and <25% of 
Nil value 
<0.5 
Indeterminate 
Likelihood of 
MTB infection 
cannot be 
determined >8.0 Any 
IU/mL: international units per millilitre; MTB: Mycobacterium tuberculosis 
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7.2.4. Allocation of participant groups 
Participants were allocated into five primary groups based on their status at the time of 
sample collection, as described previously: general population, health worker, TB patient, TB 
investigation, and other. If a participant had a history of TB diagnosis and treatment they 
were also given a secondary allocation to the TB patient group. Allocation to the ‘other’ 
group was the result of being unwell but having symptoms not suspected to be TB by the 
recording health worker (backache, asthma), being a guardian of a patient admitted to the 
hospital ward, undertaking non-TB treatment, or not having a status recorded (i.e. 
unknown). Due to the very small number of these participants (n = 8), the ‘other’ group was 
excluded in the comparison of all patient groups. In the analyses, any person who had ever 
received TB treatment was classified as a TB patient, while any person who was undergoing 
investigation for TB was classified as TB investigation. In the comparison of the non-patient 
and extrapulmonary TB patient groups, the non-patient group included general population, 
health workers with no history of TB, and others; while the extrapulmonary TB patient group 
included all current and past extrapulmonary TB patients. By definition, this comparative 
analysis excluded all people being investigated for TB, and any TB patients with non-
extrapulmonary TB diagnoses (pulmonary, concurrent, or unknown). 
Five participants had two sets of IGRA results due to recollections, and were classified as 
follows: 
- Two participants were IGRA-positive at both collections, and one participant was 
IGRA-negative at both collections. The IFN-ɣ concentrations from the most recent 
collections were analysed. 
- One participant was initially IGRA-negative, but then IGRA-positive at recollection. 
The results from the IGRA-positive collection were analysed, as this participant also 
returned a positive molecular result in sputum testing undertaken external to this 
study. 
- One participant was initially IGRA-positive, but then IGRA-negative at recollection. 
The results from the IGRA-negative collection were analysed, as the initial IGRA-
positive concentration was very close to the assay threshold; the likelihood of 
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discordant results in borderline IGRA results have been described previously based 
on an earlier version of the QuantiFERON assay (Banaei et al. 2016). 
In some analyses it was necessary to exclude results that were unable to be categorised. 
These are described below: 
- When comparing IFN-ɣ concentrations across all participant groups: 
o One participant with discordant IGRA results (reversion) could not be 
classified – this was a TB investigation participant. 
- When comparing non-patient and extrapulmonary TB patient groups: 
o In the non-patient group, one general population participant was included in 
the IFN-ɣ concentration analysis, but not the IGRA interpretation analysis, 
because they had a borderline IGRA result; while one ‘other’ participant was 
excluded from both analyses because they had an uncertain IGRA result due 
to IGRA reversion. 
o In the extrapulmonary TB patient group one patient was included in the IFN-ɣ 
concentration analysis, but not the IGRA interpretation analysis, because they 
had an indeterminate IGRA result (based on the criteria described in Table 
7.2). 
 
7.2.5. Statistical analyses 
The IGRA interpretations and IFN-ɣ concentrations were analysed using GraphPad Prism 
version 7.03 and 7.04 (GraphPad Software, Inc., La Jolla (CA), USA). All test wells with an OD 
greater than 4.000 (i.e. an IFN-ɣ concentration greater than 10.0 IU/mL) were assigned an 
IFN-ɣ concentration of 10.0 IU/mL for the analyses, as with other published studies 
(Petruccioli et al. 2017; Xia et al. 2015). Fisher’s exact test was used to test for differences 
between patient and non-patient groups. The Kruskal-Wallis test was used to examine IFN-ɣ 
concentrations between the four main participant groups (general population, health 
worker, TB investigation, and TB patient), with Dunn’s multiple comparisons test used for 
pairwise comparisons. The Mann-Whitney test was used to analyse differences in IFN-ɣ 
concentrations between the non-patient and extrapulmonary TB patient groups. The 
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Wilcoxon matched-pairs signed rank test was used to test for differences between the TB1 
and TB2 tubes, based on subtracting the TB1-Nil value from the TB2-Nil value. The threshold 
for statistical significance was set at p ≤ 0.05 for all analyses. In the graphs, statistical 
significance was depicted as follows: **** (p-values < 0.0001); *** (p-values < 0.001); ** (p-
values < 0.01); and * (p-values 0.01 to 0.05). 
 
 
Figure 7.3: A meeting with local health authorities and health workers at BDH to discuss 
research in the region. (Image credit: David Plummer) 
 
7.3. Results 
7.3.1. Demographic characteristics of participant groups 
Based on the categorisation of any patient with a history of TB treatment as a TB patient, 
participants were classified as follows: 
- General population (n = 114) 
- Health workers (n = 24) 
- TB patients (n = 59) 
- TB investigation (n = 15) 
- Other (n = 8) 
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The TB patient group included 13 health workers, while the TB investigation group included 
two health workers. The age and sex distributions of each of the participant groups are 
shown in Table 7.3. 
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Table 7.3: Age and sex distributions of the participant groups. 
 General 
population 
Health 
worker 
TB patient TB 
investigation 
Other Total 
Sex 
Male 53 11 19 9 3 95 
Female 60 13 40 6 5 124 
Unknown 1 0 0 0 0 1 
Total 114 24 59 15 8 220 
Age 
0 – 14 years 42 0 4 3 1 50 
15 – 24 years 20 1 10 0 0 31 
25 – 34 years 18 7 10 2 0 37 
35 – 44 years 10 4 12 3 2 31 
45 – 54 years 13 6 12 2 1 34 
55 – 64 years 5 3 8 1 3 20 
65+ years 3 0 1 0 0 4 
Adult 3 3 1 3 1 11 
Unknown 0 0 1 1 0 2 
Total 114 24 59 15 8 220 
TB: tuberculosis 
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7.3.2. Interferon-ɣ release assay interpretations by group 
In the general population group, 24 participants (21.1%, 95% CI 14.6 – 29.4) were IGRA-
positive. Health workers who had no history of TB had a higher proportion of IGRA-positive 
results than the general population (n = 12, 50%, 95% CI 31.4 – 68.6). In the TB patient 
group, 32 participants (54.2%, 95% CI 41.7 – 66.3) had an IGRA-positive result. Overall, three 
participants had uncertain IGRA results. These were due to a borderline result (IFN-ɣ 
concentration of 0.01 IU/mL above the threshold) in one general population participant, and 
reversions (IGRA-positive to IGRA-negative) in one TB investigation participant and one 
‘other’ participant. There were also three indeterminate outcomes – two in TB patients and 
one in a TB investigation participant. A summary of IGRA results is shown in Table 7.4. 
Among the TB patients, there were 33 participants with a current diagnosis of TB, of whom 
16 were IGRA-positive and 17 were IGRA-negative; and there were 24 participants with a 
past history of TB, of whom 16 were IGRA-positive and 8 were IGRA-negative. There was no 
significant difference in the odds of having a positive or negative IGRA result between the 
current and past TB patient groups (OR = 0.5, 95% CI 0.2 – 1.4). 
 
Table 7.4: Interpretations of the IGRA analysis for all study participants by group. 
 Negative,  
n (%) 
Positive,  
n (%) 
Uncertain, 
n (%) 
Indeterminate, 
n (%) 
Total 
General population 89 (78.1) 24 (21.1) 1 (0.8) 0 (0.0) 114 
Health worker 12 (50.0) 12 (50.0) 0 (0.0) 0 (0.0) 24 
TB patient 25 (42.4) 32 (54.2) 0 (0.0) 2 (3.4) 59 
TB investigation 5 (33.3) 8 (53.3) 1 (6.7) 1 (6.7) 15 
Other 2 (25.0) 5 (62.5) 1 (12.5) 0 (0.0) 8 
Total 133 81 3 3 220 
n: number; TB: tuberculosis 
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7.3.3. Interferon-ɣ concentrations in participant groups 
The distribution of IFN-ɣ concentrations across the participant groups are shown in Figure 
7.4. There were no significant differences between the groups for the nil tubes (H = 4.89, p = 
0.18). However, there was a significant difference between the groups for the mitogen tubes 
(H = 13.86, p < 0.01), with a significantly lower IFN-ɣ concentration in the TB investigation 
group compared to the general population group (Dunn’s multiple comparisons test: p < 
0.01). There was also a significant difference between the groups in the analysis of the TB1 
(H = 17.18, p < 0.001) and TB2 tubes (H = 15.34, p < 0.01), with the IFN-ɣ concentration 
higher for the TB patient group when compared to the general population (Dunn’s multiple 
comparisons test: TB1, p < 0.001; TB2, p < 0.01). 
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Figure 7.4: IFN-ɣ concentrations for the participant groups, as measured in the (a) Nil, (b) 
Mitogen-Nil, (c) TB1-Nil, and (d) TB2-Nil tubes. The plot lines indicate the median and 
interquartile ranges. The dotted lines on graphs (c) and (d) indicate the assay cut-off value of 
0.35 IU/mL. 
  
(a) 
(d) (c) 
(b) 
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7.3.4. Comparison of the non-patient and extrapulmonary tuberculosis patient 
groups 
The positive and negative IGRA results for the non-patient and extrapulmonary TB patient 
groups are shown in Table 7.5. There was a significant difference between these two 
participant groups (Fisher’s exact test, p < 0.01). The extrapulmonary TB patient group had 
increased odds of a positive IGRA result (OR = 2.8, 95% CI 1.4 – 5.6) in comparison to the 
non-patient group. 
 
Table 7.5: Distribution of positive and negative IGRA results in non-patients and 
extrapulmonary TB patients. 
 Positive, n (%) Negative, n (%) Total 
Extrapulmonary TB 22 (52.4) 20 (47.6) 42 
Non-patient 41 (28.5) 103 (71.5) 144 
Total 63 123 186 
n: number; TB: tuberculosis 
 
In the comparison of the non-patient and extrapulmonary TB patient groups, there was no 
difference between the groups for the nil and mitogen tubes. However, there was a 
significant difference between the two groups in both the TB1 (U = 2306, p < 0.01) and TB2 
(U = 2378, p = 0.02) tubes. The IFN-ɣ concentration distributions are shown for the four tube 
sets in Figure 7.5. 
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Figure 7.5: IFN-ɣ concentrations for the non-patient and extrapulmonary TB patient groups, 
for the (a) Nil, (b) Mitogen-Nil, (c) TB1-Nil, and (d) TB2-Nil tubes. The plot lines indicate the 
median and interquartile ranges. The dotted lines on graphs (c) and (d) indicate the assay 
cut-off value of 0.35 IU/mL. 
 
The IFN-ɣ concentrations measured in the TB1 and TB2 tubes were also investigated within 
the non-patient and extrapulmonary TB groups. In the analysis of the paired tubes, there 
was a significant difference in the non-patient group (p < 0.01), but not the extrapulmonary 
(a) 
(d) (c) 
(b) 
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TB patient group (p = 0.68). The graphs of differences between the tubes for the two 
participant groups are shown in Figure 7.6. 
 
 
Figure 7.6: Differences in IFN-ɣ concentrations for the TB1-Nil and TB2-Nil tubes in the (a) 
non-patient and (b) extrapulmonary TB patient groups. The data points show the TB1-Nil 
tubes subtracted from the TB2-Nil tubes. 
 
7.4. Discussion 
This study examined the T-cell response to TB peptides, based on the QFT®-Plus IGRA, in 
samples collected from various participant groups in the TB-endemic Balimo region. In the 
general population, 21.1% (95% CI 14.6 – 29.4) of participants were IGRA-positive, compared 
to 54.2% (95% CI 41.7 – 66.3) of TB patient participants who were either being treated or 
had been treated previously. When comparing non-patients with people with a history of 
extrapulmonary TB, the patient group were significantly more likely to be IGRA-positive, and 
to have increased IFN-ɣ concentrations based on analysis of the TB1 and TB2 tubes. 
 
7.4.1. Low proportion of latent tuberculosis in the general population 
Historically, it has often been suggested that approximately one-third of the world’s 
population has latent TB infection, based on data that was estimated in 1997 (Dye et al. 
(a) (b) 
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1999; Houben & White 2015). However, the global burden of latent TB has more recently 
been estimated to be lower, and is now suggested to be 23.0% globally and 27.9% in the 
Western Pacific region (Houben & Dodd 2016). 
Due to the lack of a gold standard test for latent TB, studies investigating the sensitivity and 
specificity of assays such as the QFT®-Plus have focused on people with active TB (Pieterman 
et al. 2018). In such studies, sensitivity has been estimated to range from 83 – 99% 
(Hoffmann et al. 2016; Horne et al. 2018; Petruccioli et al. 2017; Takasaki et al. 2018; 
Telisinghe et al. 2017; Yi et al. 2016). Based on an approximate sensitivity of 90%, the 21.1% 
positivity identified in this study equates to a rate of IGRA positivity of approximately 23% 
(21.1% / 0.9 = 23.4%). Therefore, given the estimated global proportions of latent TB, and 
the high reported incidence of TB in the Balimo region, at approximately 23% the general 
population group in this study had an unexpectedly low proportion of IGRA-positivity. 
There are some possible explanations for the relatively low proportion of latent TB in the 
general population. Potential over-diagnosis of TB in the Balimo setting has been discussed 
in previous chapters, which would support a lower than expected proportion of IGRA-
positivity in the general population. The demographics of participants in this aim of the study 
may also be relevant, as participants were predominantly resident in the urban Balimo area. 
Although results are variable by region, studies in some settings have demonstrated that 
people resident in urban settings may have decreased diagnostic delay (Godfrey-Faussett et 
al. 2002; Mesfin et al. 2009). In Balimo, this possibility is supported by the results presented 
in Chapter 3 (see Section 3.3.5), which described a higher likelihood of treatment failure 
outcomes in people from rural areas. Our earlier research in the Balimo region has described 
the challenges faced in TB treatment adherence, including the costs and difficulties of travel 
(Diefenbach-Elstob et al. 2017). These factors will particularly influence people from rural 
and remote areas, and will impact all facets of TB management, including time to diagnosis, 
treatment adherence, and ongoing patient follow-up. The high incidence of extrapulmonary 
TB seen in this study of the Balimo region combined with the relatively low proportion of 
latent TB seen in the general population of the Balimo urban area raises the possibility that 
there is high awareness of TB in this region. This would reflect the lower level of latent TB 
seen in this predominantly urban population if TB symptoms are rapidly recognised and 
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treated. It would be necessary to undertake comparative investigation of latent TB in the 
rural and remote areas surrounding Balimo to determine if there is truly a difference 
between the urban and rural populations. Another possible explanation for the relatively 
low proportion of latent TB is the substantial proportion of younger people who were in the 
general population group. As the proportion of individuals with latent TB infection has been 
shown to increase with age (Ncayiyana et al. 2016; Wood et al. 2010), the younger general 
population age group in our study may partially explain the lower overall proportion of 
latent TB. 
 
7.4.2. High proportion of interferon-ɣ release assay positivity in health workers 
This study identified a high proportion of latent TB in health workers, even when only health 
workers without a history of TB diagnosis or treatment were investigated (Figure 7.7). Health 
workers are a group known to have a higher risk of MTB exposure and latent TB, as 
described in numerous published studies and reviews (Adams et al. 2015; Agaya et al. 2015; 
Alele et al. 2018; El-Sokkary et al. 2015; Malotle et al. 2017). Although not unexpected given 
their risk of TB exposure, the high proportion of latent TB in this group in the Balimo region 
has important implications for infection control and management of health facilities. 
 
 
Figure 7.7: Health workers at BDH on International Day of the Tropics in 2016. (Image credit: 
Bisato Gula) 
196 
7.4.3. Interferon-ɣ release assay interpretations and concentrations in tuberculosis 
patients 
The analysis of the IGRA interpretations and IFN-ɣ concentrations indicate that a substantial 
proportion of clinically-diagnosed extrapulmonary TB patients in the Balimo setting have 
evidence of MTBC infection. This conclusion is based on both the IGRA interpretations and 
the IFN-ɣ concentrations, with a higher proportion of IGRA-positive participants and 
significantly higher IFN-ɣ concentrations in the TB patient group. This trend continued when 
considering extrapulmonary TB patients in comparison to the non-patient group, with 
increased odds of an IGRA-positive result and significantly increased IFN-ɣ concentrations in 
the extrapulmonary TB patients. The greater likelihood of detectable TB1 and TB2 responses 
in the extrapulmonary TB patients provides evidence of the TB patient group being more 
likely to have had T-cell recognition of MTB, despite the substantial proportion of TB patients 
who had an IGRA-negative result. 
There are a number of possible reasons for the large proportion of IGRA-negative results in 
the TB patient group, including false-negative results. The form of extrapulmonary TB may 
be linked with the likelihood of a positive or negative IGRA result. For example, studies of 
extrapulmonary TB patients have found proportions of IGRA-positive results of 81 – 93% in 
patients with tuberculous lymphadenitis (Kim et al. 2011; Shin et al. 2015; Song et al. 2009). 
However, other forms of extrapulmonary TB can have lower proportions of IGRA-positive 
results, including only 45% in patients with skeletal involvement, and 38.5% in pleural TB 
(Shin et al. 2015; Song et al. 2009). In a recent study from Indonesia, among 57 
extrapulmonary TB patients with confirmed MTB infection (based on histopathology or 
smear microscopy), seven were IGRA-negative (Rumende et al. 2018). Although results vary 
across settings and studies, false-negative and indeterminate IGRA results in TB patients 
have been linked with factors including older age, being underweight or overweight, long 
diagnostic delay, bilateral disease, use of immunosuppressive drugs, lymphocytopenia, 
elevated C-reactive protein, and HIV co-infection (Azghay et al. 2016; de Visser et al. 2015; 
Hang et al. 2011; Kim et al. 2014; Kobashi et al. 2012; Kwon et al. 2015; Pan et al. 2015). 
False-negative IGRA results have also been seen in the presence of other underlying 
conditions, including cancer and diabetes mellitus (Kobashi et al. 2012; Kwon et al. 2015; Lai 
197 
et al. 2011). Furthermore, concurrent malaria has been associated with impaired mitogen 
responses (Drabe et al. 2016). 
Given that a number of the factors that have been associated with false-negative and 
indeterminate IGRA results will be relevant in PNG, the possibility of false-negatives is 
particularly important in the context of the Balimo region population. A number of studies 
have described nutritional deficiencies in various groups in PNG, including mal- and under-
nutrition, particularly in children, as well as insufficient protein intake (Goris et al. 2017; 
Morita et al. 2015; Samiak & Emeto 2017; Wand et al. 2012). Malaria is endemic across 
many parts of PNG, and although Western Province has low endemicity, malaria cases have 
been seen in the province (Bande et al. 2014; Hetzel et al. 2015). 
The presence of other potentially immune-influencing factors should also be considered, 
such as parasite burden. Although burdens will undoubtedly vary over time and by region, 
various helminth species have been described in PNG. These include Necator americanus, 
Ascaris lumbricoides, Trichuris trichiuria, and Strongyloides fuelleborni kellyi (King & Mascie-
Taylor 2004; Shield & Kow 2013). Although research in this field is ongoing, helminth 
infection has been linked with indeterminate IGRA results (Banfield et al. 2012; Lucas et al. 
2010; Thomas et al. 2010). 
Earlier results presented in this thesis suggest that the prevalence of TB-HIV coinfection in 
the Balimo region may be low (see Section 3.3.8), however HIV is endemic in PNG, including 
in Western Province and the Gogodala region (Dundon 2010; McBryde 2012; National 
Department of Health 2010; World Health Organization 2018b). In addition to HIV, human T-
lymphotropic virus type 1 (HTLV-1) has been described as endemic in PNG and other 
countries in Melanesia (Asher et al. 1988; Cassar et al. 2007; Cassar et al. 2017; Kazura et al. 
1987; Yanagihara et al. 1990a; Yanagihara et al. 1990b). HTLV-1 is primarily linked with adult 
T-cell leukaemia and HTLV-associated myelopathy/tropical spastic paraparesis (Willems et al. 
2017), but studies have also linked the virus with conditions with diverse presentations, 
including uveitis, scabies, invective dermatitis, depression, and fibromyalgia (Blattner et al. 
1990; Brites et al. 2002; Cruz et al. 2006; de Oliveira et al. 2005; Mochizuki et al. 1992; 
Stumpf et al. 2008). 
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Overall, there are numerous factors that should be considered in the context of false-
negative IGRA results, particularly in a setting in which a variety of potentially 
immunosuppressing conditions are present. However, it is notable that in this study cohort, 
there was very little population-level evidence of immunosuppression. In the QFT®-Plus IGRA 
assay, the maximum concentration of IFN-ɣ is 10.0 IU/mL. In this study, three of the 114 
general population participants had an IFN-ɣ concentration below 3.0 IU/mL in the analysis 
of the mitogen tubes, with the remainder having a mitogen response greater than 10.0 
IU/mL (see Figure 7.4). Furthermore, there were only three indeterminate results overall – 
two in current TB patients and one in a TB investigation participant. Lower mitogen 
responses (below 8.0 IU/mL of IFN-ɣ) were measured in three IGRA-positive TB patients and 
two IGRA-negative TB patients; and in two IGRA-positive TB investigation participants and 
one IGRA-negative TB investigation participant. Thus, indeterminate and lower mitogen 
responses were seen more often in TB patients and TB investigation participants when 
compared to the general population, which is not surprising given that by definition they 
were more likely to be unwell at the time of the study. Although conditions such as 
malnutrition, parasites, and to a limited extent HIV are present in the Balimo region, and 
there is evidence of immunosuppression among people who are unwell or who have TB, the 
results of this analysis do not provide evidence of generalised immunosuppression in this 
population in the absence of broader immunological investigation. 
The final consideration regarding IGRA-negative results in extrapulmonary TB patients is the 
possibility that some patients in this group did not actually have TB, even if symptoms 
resolved following therapy. Although the population-level results support the accuracy of 
clinical TB diagnoses in this region, there are almost certainly some misdiagnoses among 
clinically diagnosed TB patients. 
 
7.4.4. Limitations 
There are a number of limitations inherent in this study. Relatively low numbers of 
participants were investigated, particularly in the non-general population groups. It was not 
possible to bacteriologically confirm the majority of diagnosed TB patients, and thus the 
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majority of participants in the TB patient group were clinically diagnosed. Although the 
results support statistical differences between the patient and non-patient groups, the 
results should still be interpreted with caution. 
This study also identified statistically significant differences in the analysis of the paired TB1 
and TB2 tubes for the non-patient and extrapulmonary TB patient groups. This result 
conflicts with those expected by the assay, which is suggested to have a greater likelihood of 
an elevated TB2 response in active TB, based on more frequent detection of ESAT-6 and CFP-
10 specific CD8+ cells in people with active TB compared to latent TB (Day et al. 2011; 
Nikolova et al. 2013; QIAGEN 2016; Rozot et al. 2013). However, this result may be 
influenced by the low sample numbers, particularly due to the substantially lower numbers 
of extrapulmonary TB participants when compared to the non-patient group. It should also 
be noted that there is other research that has not identified a difference between the TB1 
and TB2 tube IFN-ɣ concentrations in latent and active TB (Hofland et al. 2018). 
Finally, a number of studies have discussed the sources of variability that may influence the 
results of IGRA tests, with variability introduced in a number of the testing stages. In reviews 
of various IGRA tests, Banaei et al. (2016) and Pai et al. (2014) have described a number of 
sources of variability that could be important factors in the Balimo setting. These include 
blood collection time, adequacy of skin disinfection, blood volume, shaking of the blood 
tubes, time to incubation, and imprecision in the performance of the assay. Analytical 
factors are particularly notable close to the assay threshold, as they can give rise to 
discordant IGRA-positive and -negative results (Banaei et al. 2016). A number of studies 
using the earlier QFT-GIT assay have examined results close to the 0.35 IU/mL threshold. In 
one study, 19% of participants who underwent serial testing had discordant IGRA results, 
with IFN-ɣ variations as great as 11.1 IU/mL described (Detjen et al. 2009). Another study 
found 7% of participant samples that underwent duplicate testing had discordant results, 
with conversions (negative to positive) and reversions (positive to negative) significantly 
more likely in the borderline range of 0.25 – 0.80 IU/mL (Metcalfe et al. 2013). This study 
also suggested that variability of ±0.24 IU/mL could be expected for participants whose 
results fell in the borderline range (Metcalfe et al. 2013). In our study, some discordant 
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results were identified (see Section 7.2.4), and thus the possibility of result variability and 
false-positives and -negatives should be considered. 
 
7.5. Conclusion 
This study identified an unexpectedly low proportion of latent TB in the Balimo setting. 
Furthermore, there was little evidence of immunosuppression in the region’s general 
population, based on the results of the mitogen control tubes in the IGRA tests. There was a 
high proportion of IGRA-negative, clinically diagnosed TB patients in the Balimo setting. 
However, on a population level extrapulmonary TB patients were more likely than the 
general population to be IGRA-positive, with an odds ratio of 2.8. The results provide 
evidence of MTBC infection in at least half of the extrapulmonary TB patients diagnosed in 
this setting. Although not definitive in the confirmation of extrapulmonary TB diagnoses, 
these results provide insight into the clinical identification of extrapulmonary TB in this 
setting. 
The results emphasise the heavy burden of disease that is due to extrapulmonary TB in the 
Balimo region. Although extrapulmonary TB has limited influence on the transmission of TB, 
the large proportion of extrapulmonary TB patients in the Balimo region is a substantial 
contributor to the already considerable burden placed on health staff and facilities at BDH. 
As a result, reducing TB transmission is essential to the control of both pulmonary and 
extrapulmonary TB.  
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GENERAL DISCUSSION 
 
Tuberculosis (TB) in the Balimo region is contextualised by a number of health system factors 
– no resident physician, limited laboratory diagnostic facilities, and a high proportion of 
clinical diagnoses. These factors, while defining the TB epidemic in Balimo, also play a role in 
how TB patients are diagnosed, and the index of clinical suspicion with which symptomatic 
people are approached. These contextualising factors emphasise three defining aspects of 
the Balimo TB epidemic: (1) the influence of clinical non-laboratory confirmed diagnoses of 
TB, (2) the high proportion of extrapulmonary TB patients, and (3) the challenges associated 
with access to TB services. 
 
8.1. Challenges in Clinical Tuberculosis Diagnosis at Balimo District Hospital 
At BDH, a lack of advanced diagnostic facilities, as well as a high degree of suspicion of TB, 
likely contribute to the high proportion of clinical TB diagnoses. In this study, more than 90% 
of extrapulmonary TB diagnoses and about 20% of pulmonary TB diagnoses were clinical, 
based solely on presenting signs and symptoms. This situation is compounded by the 
inability to also identify other prevalent conditions that may present similarly to TB, such as 
HIV, malaria, and melioidosis. Rapid diagnostic kits for HIV are available in Balimo, although 
their use is complicated by the need for appropriate testing and counselling facilities that 
ensure patient privacy (McBryde 2012). Other febrile conditions have been identified in 
Western Province, including malaria, dengue fever, and Japanese E encephalitis (Bande et al. 
2014; Mackenzie et al. 1998), and the province has faced other health challenges, including 
cholera (Horwood et al. 2014). The possibility of infection with non-tuberculous 
mycobacteria (NTM) should also be considered. Although only a small number of NTM have 
been identified in Papua New Guinea (PNG) to date (Aia et al. 2016; Ley et al. 2015), their 
presentation with TB-like symptoms including lymphadenitis should be considered in this 
setting where a high proportion of extrapulmonary TB has been described (Griffith et al. 
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2007; Haverkamp et al. 2004). Furthermore, melioidosis is endemic in the Balimo region 
(Diefenbach-Elstob et al. 2015; Warner et al. 2007; Warner et al. 2008), and can present 
similarly to TB (Warner et al. 2010). However, the laboratory resources required to identify 
melioidosis are only sporadically available (Figure 8.1), and differential diagnosis of other 
conditions is not likely to be achieved given the limited laboratory facilities (Saweri et al. 
2017). 
 
 
Figure 8.1: Laboratory identification of Burkholderia pseudomallei, the causative agent of 
melioidosis, in the BDH laboratory. (Image credit: Jeffrey Warner) 
 
A reliance on clinical diagnoses of TB and treatment outcomes leads to important challenges 
in the context of drug resistance, particularly for patients who are smear-negative for TB, or 
for whom clinical samples are not able to be obtained. For such patients, it will be impossible 
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to differentiate between DR-TB and other potential conditions without the patient attending 
elsewhere for investigation – creating challenges for both the patient and health provider. In 
settings where laboratory-based diagnosis of TB is limited, it is not unusual for clinicians to 
use a treatment-as-confirmation-of-diagnosis approach, where patient improvement 
following initiation of a treatment regimen is considered to provide evidence of an accurate 
TB diagnosis, as has been described elsewhere in PNG (Kasa Tom et al. 2018). However, 
there is considerable uncertainty associated with this approach, especially given there are 
other conditions that may present similarly to TB with respiratory symptoms or 
lymphadenopathy, some of which will be self-limiting and resolve without treatment, and 
others which will respond to treatments such as rifampicin (Colebunders & Bastian 2000; 
Gaddey & Riegel 2016; Pandit et al. 2014; Thakkar et al. 2016). 
 
8.1.1. Diagnosis of smear-negative pulmonary tuberculosis 
In this region, bacteriological confirmation of TB, based on smear microscopy, occurred for a 
high proportion of about 65% of pulmonary TB patients recorded in the TB register. 
However, analysis of laboratory-based data, where microscopy and molecular results were 
compared for the same sample, found diagnostic sensitivity of the smear microscopy 
method to be only 50% (see Section 6.3.2). As already noted, a number of peripheral health 
facilities present in the Balimo region are able to clinically diagnose TB and commence 
people on TB treatment. The majority of these facilities maintain their own TB registers, 
which were not available for this study. These are small facilities, supplied with medication 
by BDH, and are thus unlikely to register a substantial number of TB patients. Furthermore, 
with the exception of very remote facilities such as Wawoi Falls, people with potential 
pulmonary TB should attend at Balimo for sputum examination (Figure 8.2). Therefore, 
although some smear-negative patients will be recorded elsewhere, the number is not likely 
to be substantial, and external registration of smear-positive patients will also occur. Hence, 
the data are unlikely to be substantially skewed by capture of a small proportion of TB 
patients outside of BDH. 
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Figure 8.2: Sister Bisato Gula, myself, Sister Keyanato Siwaeya, and Mr Robert Dowi, 
preparing to travel to a Gogodala-region village for a TB patrol, including collection of 
sputum samples. (Image credit: Mauri Amadu) 
 
There is still a question of under-diagnosis of smear-negative pulmonary TB – an issue which 
has been raised in our earlier research in the Balimo region (Guernier et al. 2018). Although 
less infectious, smear-negative patients are still capable of transmitting infection at least 
intermittently, and are thus of concern if they are frequently missed and not commenced on 
treatment (Behr et al. 1999; Hernández-Garduño et al. 2004; Tostmann et al. 2008). There 
are clear implications for ongoing transmission of MTB in the region when considering a 
potentially substantial proportion of undiagnosed pulmonary TB. 
 
8.2. Extrapulmonary Tuberculosis in the Balimo Region 
The patterns of TB seen in the Balimo region, including factors such as the high proportion of 
extrapulmonary TB patients, the large proportion of childhood cases, and the approximately 
equal proportions of male and female TB patients, will reflect sociocultural, structural, 
geographic, and biomedical influences that are specific to the Balimo region. Understanding 
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the patterns of disease in relation to these influences will lead to a more informed TB 
control program. 
Living in a rural setting with limited health facilities, people in the Balimo region have an 
increased likelihood of suffering from a variety of conditions that may increase susceptibility 
to infection or disease. These include immune-compromising conditions endemic to PNG 
such as mal- or under-nutrition, helminth and other parasite infections, and viral infections 
such as HIV and HTLV-1 (Asher et al. 1988; Dundon 2010; Goris et al. 2017; Kazura et al. 
1987; McBryde 2012; Morita et al. 2015; Samiak & Emeto 2017; Wand et al. 2012; 
Yanagihara et al. 1990a; Yanagihara et al. 1990b). Although research is ongoing, all of these 
conditions have suggested links with TB, particularly in the case of HIV (Elias et al. 2006; 
Grassi et al. 2016; Jaganath & Mupere 2012; Marinho et al. 2005; World Health Organization 
2014c). Other factors that may predispose to TB include exposure to smoke from cooking 
fires, and high housing density (i.e. high numbers of people per room), both of which have 
previously been associated with TB disease (Clark et al. 2002; Pérez-Padilla et al. 2001; 
Rahayu et al. 2015). 
In addition to susceptibility to Mycobacterium tuberculosis (MTB) infection, the high 
proportion of extrapulmonary TB raises the question of why people have increased 
susceptibility to disseminated disease. The mechanisms underlying the dissemination of TB 
bacilli to extrapulmonary sites are not yet clearly defined, but numerous immune system 
components are thought to be important in both control and containment of the MTB 
organism, including CD4 and CD8 T-cells, interferon (IFN)-ɣ, and tumour necrosis factor (TNF) 
(Kaufmann 2001; Patel et al. 2007; Pawlowski et al. 2012; Roberts et al. 2007). 
Extrapulmonary TB is linked with diminished immunocompetence, and has been associated 
with immune-suppressing conditions including HIV/AIDS (Bates et al. 2015; Gounden et al. 
2018). In the context of susceptibility to MTB infection and extrapulmonary dissemination of 
infection, immune dysregulation has been observed in many of the aforementioned 
conditions in the presence of MTB co-infection, including helminth infection, malaria, HIV, 
and HTLV-1 (Bastos et al. 2012; Carvalho et al. 2015; Chukwuanukwu et al. 2017; Day et al. 
2017; George et al. 2014). The investigation of blood-based T-cell markers in MTB infection is 
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a field of ongoing research by our group, as immune factors may well play a role in the 
epidemiology of TB in the Balimo region. 
 
8.2.1. Extrapulmonary tuberculosis in the context of clinical diagnoses 
The high proportion of extrapulmonary TB seen in the Balimo region led to the question of 
whether these diagnoses are accurate, especially in this setting where more than 90% of 
extrapulmonary TB patients are diagnosed clinically, based only on presenting signs and 
symptoms. Although some diagnoses will undoubtedly be incorrect, data from the IFN-ɣ 
release assays (IGRA), and analysis of treatment outcomes, suggest that there is evidence of 
accurate diagnoses for many clinically-diagnosed extrapulmonary TB patients. Regardless of 
over-diagnosis or under-diagnosis, a setting with no resident medical officer, and with 
limited laboratory facilities, may see increased TB diagnoses if the setting has a high TB 
burden and there is a strong index of suspicion in the approach to symptomatic patients. 
 
 
Figure 8.3: People travelling by dugout canoe in the Gogodala region of Western Province. 
(Image credit: David Plummer) 
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Given the difficulties associated with laboratory confirmation of extrapulmonary TB, as well 
as the non-specific nature of many extrapulmonary TB presentations, extrapulmonary TB 
cases are likely under-diagnosed in some settings. Indeed, the literature contains numerous 
case studies of extrapulmonary TB masquerading as other diseases for extended periods of 
time, particularly where the infection is localised to an unusual site. Examples include a case 
of pubic symphysis TB who was symptomatic for three years, as well as cases initially 
diagnosed as renal malignancy and leiomyoma (Kumar et al. 2014; Lal et al. 2013; Moore et 
al. 2008). 
There has been some research into the possibility of under-diagnosis of smear-negative and 
extrapulmonary TB. The results of one study from Mozambique indicated this to be the case, 
particularly in settings where the only diagnostic test available is smear microscopy, and 
where HIV is prevalent (Brouwer et al. 2013). Furthermore, an autopsy study conducted in 
South Africa identified a high proportion of TB infection in HIV patients who had died. 
Autopsies were undertaken on 34 patients, of whom 16 had evidence of TB infection. 
Extrapulmonary TB infection was identified in 14 of those 16, but only 10 of the 16 had been 
commenced on TB treatment prior to their death (Karat et al. 2016). In PNG, it has been 
noted that both under- and over-diagnosis of extrapulmonary TB are possible outcomes in 
settings where diagnoses are predominantly symptom-based (Karki et al. 2017). However, 
the identification and diagnosis of extrapulmonary TB is complicated due to the resource-
limited setting and lack of advanced specimen collection and diagnostic techniques. 
Unlike in Mozambique and South Africa, HIV appears to be less common in TB patients in the 
Balimo region, although further research is required to understand the true TB-HIV burden. 
In this study, co-infection was identified in 5.4% (95% CI 2.1 – 13.1) of tested patients. Across 
PNG, 7% of TB patients with a known HIV status were HIV-positive in 2016 (World Health 
Organization 2017a). However, a recent study undertaken in Eastern Highlands Province that 
screened for TB among people living with HIV identified active TB in 82/532 adult patients 
(15.4%) – evidence of a substantial burden of undiagnosed TB-HIV coinfection (Carmone et 
al. 2017) (Figure 8.4). By comparison, TB-HIV coinfection in tested patients in Mozambique 
and South Africa is estimated to be 44% and 59% respectively (World Health Organization 
2017a). However, in the Balimo region it is possible that HIV testing was more likely in 
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patients with certain risk factors, or increased clinical suspicion of HIV. These factors make it 
difficult to comment on the influence of HIV on TB, and particularly extrapulmonary TB, in 
this region. 
 
 
Figure 8.4: Educational poster from PNG focusing on TB and HIV. (Image credit: David 
Plummer) 
 
Figures from the World Health Organization (WHO) indicate that extrapulmonary TB occurs 
in 15% of notified TB patients globally, and only 8% of patients in the Western Pacific region, 
where PNG is located (World Health Organization 2017a). However, extrapulmonary TB 
proportions are known to be much higher in individual countries within the region, 
estimated at 46% in Vanuatu, 45% in Mongolia and New Zealand, 38% in the Solomon 
Islands, 37% in Australia, 33% in Cambodia, and 30% in Nauru (World Health Organization 
2017a). The relatively high proportion of extrapulmonary TB patients in the high-income 
countries of Australia and New Zealand is notable, although extrapulmonary TB has been 
recognised as a concern in other low-incidence settings (Peto et al. 2009; Sandgren et al. 
2013; Toms et al. 2017). However, Australia and New Zealand are not limited in laboratory 
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resources, and studies undertaken in Sydney and Auckland were able to confirm MTB 
infection based on bacteriology or histopathology in 78.6% and 97.0% of patients 
respectively (Herath & Lewis 2014; Pollett et al. 2016). However, the situation is likely to be 
different for the other countries listed with extrapulmonary TB proportions of 30% or more. 
Information about the proportion of laboratory-confirmed extrapulmonary TB cases was not 
able to be obtained for these countries, but it is likely that the proportion of laboratory-
confirmed cases would be low, as these are resource-limited settings. 
Published studies from other developing settings have found rates of extrapulmonary TB 
higher than expected based on comparison to countrywide proportions. Examples include 
49.4% of TB cases in Van, Turkey; and 54.9% of TB cases in Kabul, Afghanistan (Fader et al. 
2010; Sunnetcioglu et al. 2015). The authors of the Afghanistani study believed 
extrapulmonary TB to be erroneously over-represented in their study due to reporting 
anomalies (Fader et al. 2010). However, the authors of the Turkish study did not speculate as 
to the reason for their high proportion of extrapulmonary TB. There are additional 
characteristics of note in these studies. In the Turkish study, all cases were confirmed using 
laboratory methods and/or radiology (Sunnetcioglu et al. 2015). This result suggests that in a 
context where exhaustive diagnostic methods are available, cases of extrapulmonary TB may 
still be substantial. However, broader conclusions regarding the incidence of the two forms 
of active TB cannot be inferred from the study, as clinical diagnoses were not included. 
Clinical diagnoses of extrapulmonary TB were included in the study from Afghanistan (Fader 
et al. 2010). Contextual information in this study suggested many challenges similar to those 
found in Balimo. These include reporting difficulties, loss to follow-up of people following 
initial specimen collection and diagnosis, delays in recognition of potential extrapulmonary 
TB cases, uncertainty about age, and limited diagnostic facilities (Fader et al. 2010). In 
addition, HIV prevalence is thought to be low in the Afghanistani setting (Fader et al. 2010), 
as is also the case in Balimo. 
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8.3. The Influence of Health Systems and Access on Tuberculosis Diagnosis and 
Treatment 
The results presented in this thesis emphasise the challenges associated with TB 
management in rural and remote areas. Notified TB case density was lower in the peripheral 
regions, and treatment outcomes were poorer for people from the rural local level 
government (LLG) areas when compared to the Balimo Urban LLG. However, there are 
contextual factors that should be considered in relation to these results. Lower recorded 
case density in the peripheral regions may be due to registration and treatment of some TB 
patients at peripheral health facilities instead of at Balimo, or could be because TB density is 
in fact lower in rural areas. If it is the former reason, and a substantial number of patients 
are diagnosed at the peripheral health facilities, then the burden of TB in the Balimo region 
is even higher than the results in this thesis suggest. Even if TB density is lower in the 
peripheral regions, in this setting there are likely to still be complications in management 
and the risk of ongoing TB transmission due to potentially lengthy time periods before TB is 
diagnosed, as a result of access challenges in the region. The difficulties associated with the 
diagnosis and management of TB in rural settings will also be important in the context of 
drug resistance. Although risk will be variable based on local epidemiological factors, a study 
from Ethiopia identified living in a rural region as a risk factor for the development of 
multidrug-resistant TB (MDR-TB), and suggested links with access and education as possible 
reasons for this association (Desissa et al. 2018). These are factors that will also exist in the 
Balimo region. 
The diagnosis and treatment of TB in Balimo will be influenced by setting-specific factors, 
although there are a number of factors generalizable across PNG. The geographic diversity of 
PNG and large proportion of people living in rural and remote areas means that access 
challenges will be prevalent countrywide. There are challenges faced by PNG in the provision 
of health care services, with only 6.2 health workers (physicians, nurses, and midwives) per 
10,000 people countrywide (World Health Organization Regional Office for the Western 
Pacific 2017b). As a result, health facilities operating under a non-doctor-led model of care, 
operated by health extension officers (HEO) and nurses, are the norm in many rural and 
remote settings. 
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Based on a situation analysis undertaken in 2001, PNG has been described as having ‘a 
growing gap between the resources available for health personnel and the resources 
required to adequately staff health institutions and activities’, influencing the abilities of 
health workers to initiate and maintain care (Aitken & Kolehmainen-Aitken 2009). At the 
time of the situation analysis, PNG had a staff-to-patient ratio of 5.9 health workers 
(physicians, nurses, and midwives) per 10,000 people, and this ratio had increased to only 
6.2 per 10,000 people in 2010 (World Health Organization Regional Office for the Western 
Pacific 2017b). When also including HEOs, community health workers (CHW), dental officers, 
and other allied health workers, in 2008 the ratio was 18.3 per 10,000 people, still well 
below the WHO-recommended ratio of 23 health workers per 10,000 people (World Health 
Organization & National Department of Health 2012; World Health Organization Regional 
Office for the Western Pacific 2017b). However, the distribution of health workers is 
complex, and the full utilisation of health worker skills can be limited by a lack of health 
service resources (Aitken & Kolehmainen-Aitken 2009). Although difficult to quantify, TB 
epidemiology in the Balimo region (and undoubtedly other regions in PNG), will be 
influenced by the skills and experience of resident health workers, and by the availability of 
diagnostic tools and medications. 
 
 
Figure 8.5: Overlooking the Balimo lagoon at sunset. (Image credit: David Plummer) 
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8.4. Implications for Practice and Public Health 
The high burden of TB identified in the Balimo region emphasises the need for a rapid and 
achievable TB diagnostic that is capable of identifying both drug-susceptible and DR-TB. An 
example would be the implementation of a method such as the WHO-endorsed Xpert 
MTB/RIF. This approach would have the added benefit of contributing to the confirmation of 
some extrapulmonary TB diagnoses, as demonstrated in a number of studies using the Xpert 
MTB/RIF on non-sputum clinical samples (Denkinger et al. 2014; Hillemann et al. 2011; 
Marouane et al. 2016; Maynard-Smith et al. 2014; Suzana et al. 2016; Zeka et al. 2011). An 
essential component of implementation of the Xpert MTB/RIF would be the need for training 
and support for health workers in the Balimo region in the treatment of DR-TB. Expanding 
staffing at BDH to include a physician would also be essential, particularly in the context of 
the ongoing management of DR-TB patients. These recommendations are particularly 
important given that this study has identified rifampicin-resistant TB (RR-TB), with the 
possibility that MDR-TB is also present. The implementation of DR-TB diagnosis and 
treatment in Balimo would help to alleviate some of the TB burden seen at the hospital in 
Daru, which is the referral hospital for the province and that is known to face a considerable 
burden of DR-TB (Furin & Cox 2016; Kase et al. 2016; World Health Organization 
Representative Office: Papua New Guinea 2016). 
Expansion of TB services at BDH would necessitate improvements to the current facilities, 
particularly the laboratory and TB ward. Furthermore, this study has described a 
considerable burden of latent TB infection in BDH health workers (see Chapter 7), which 
emphasises the importance of well-managed facilities and infection control practices in 
reducing this risk (Verkuijl & Middelkoop 2016). It is also important to ensure that lay health 
workers such as community-based treatment supporters, who are an important part of the 
Western Province TB Program (World Vision TB DOTS Project 2013), receive appropriate 
health education regarding TB risk and infection control. Additional investment in facilities 
and personnel at the BDH laboratory is critical to maintaining and improving TB diagnostic 
capacity, as well as expanding diagnostic capability to accurately diagnose other diseases 
endemic in Western Province. 
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Results from Chapter 5 of this thesis highlighted the potentially substantial burden of 
undiagnosed TB in the Balimo region, based on analysis of a non-routine active TB case-
finding activity (see Section 5.4.3). This finding emphasises the need for finances and 
resources to undertake outreach activities. Given that increased active case-finding activities 
will lead to increased burden on the BDH health workers and facilities, the aforementioned 
investments in personnel, resources, and facilities would be necessary in combination with 
this approach. 
 
8.5. Future Research Directions 
This thesis has provided a broad description of the epidemiology of reported TB in the 
Balimo region. However, the limitations of the data, which have been described throughout 
this thesis, are an important consideration in the context of future research directions. These 
limitations highlight the importance of developing a greater understanding of TB in the 
Balimo region, and the representativeness of the data presented in this thesis. Further 
exploration in the near future of a number of aspects of this research would provide 
important additional detail to support TB control efforts in the region.  
As one of the defining outcomes of this study, the heavy burden of extrapulmonary TB, 
particularly in the context of under- or over-diagnosis and the accuracy of clinical diagnoses, 
warrants further investigation. This approach should include focused investigation of 
decision-making and diagnostic protocols to understand how extrapulmonary TB diagnoses 
are reached without the benefit of laboratory confirmation. 
The distribution of TB patients has highlighted the heterogeneity of case density across the 
Balimo region. It would be useful to undertake a more thorough investigation of select 
villages, particularly in the context of their proximity to peripheral sub-health centres and 
aid posts, to understand the influence of geography and access on TB distribution. In 
addition, investigation of TB in low- and high-burden villages could provide insights into 
structural and behavioural influences that influence the likelihood of developing TB. Analysis 
of the TB patient registers maintained at the peripheral health facilities would increase 
understanding of the epidemiology of TB in the Balimo region. 
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This study has described a number of influences that place people at greater risk of 
developing TB, or having poor TB treatment outcomes. These influences should be 
investigated, particularly regarding factors such as nutrition, cooking fires, housing density, 
and parasitic and viral infections. Furthermore, investigation of access-related challenges 
such as time to diagnosis and proximity to health services will be important to further the 
role of health promotion activities aimed at reducing TB transmission and enhancing 
community-based management of TB.  
It would be worthwhile developing a greater understanding of the burden of latent TB in this 
region, especially in rural and remote areas, given the unexpectedly low proportion of latent 
TB identified in this study in the context of the high active TB burden. If the regional latent 
TB burden is indeed low, this relatively isolated region may benefit from active case-finding 
alongside prophylactic treatment. Such a response may be a viable option in reducing the 
overall TB burden in the broader Gogodala region. 
 
 
Figure 8.6: Village houses located in the Aramia River floodplain area near Balimo. (Image 
credit: David Plummer) 
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8.6. Conclusion 
This research has described and characterised the TB epidemic in the Balimo region of 
Western Province, PNG. The findings provide important information in the context of TB 
management in the region, and in providing evidence of the critical importance of BDH in TB 
control. Given the heterogeneity of TB distribution across Western Province, understanding 
TB epidemiology in the Balimo region is particularly important to contribute to focused and 
efficient distribution of limited resources across the province. In describing the high ongoing 
burden of TB in the Balimo region, the results of this thesis highlight the importance of 
ensuring that staff, resources, and facilities at BDH are capable of responding to the heavy 
burden of TB, particularly in light of the growing evidence of drug resistance. In conclusion, 
TB in this region is at a critical juncture, with systematic, concerted efforts in research and 
control essential to address the TB epidemic in the region. 
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APPENDIX 1 
EXTRAPULMONARY TUBERCULOSIS DATA 
This appendix details extrapulmonary TB proportions from studies identified throughout the course of this research. The included data is 
neither systematic nor exhaustive, but simply reflects studies that were identified throughout this PhD. 
 
Appendix 1 - Table 1: Geographic locations, diagnostic methods, and proportions of extrapulmonary TB identified in setting-specific research. 
WHO region Country EPTB 
notification 
proportion@ 
Income 
group* 
Setting Years Diagnosis 
methods 
EPTB 
proportion^ 
Reference 
Africa Benin 10% Low Nationwide 2011 Laboratory and 
clinical 
9% (Ade et al. 2014) 
 Cameroon 17% Lower-
Middle 
Douala 2007-2011 Laboratory and 
clinical 
43% (Namme et al. 2013) 
 Ethiopia 32% Low Sidama Zone 2003-2012 Laboratory and 
clinical 
17% (Dangisso et al. 2014) 
 Ethiopia 32% Low Dilla Town, 
Gedeo Zone 
Nov 2012-
May 2013 
Laboratory and 
clinical 
12% (Gebrezgabiher et al. 2016) 
 Malawi 26% Low Nationwide 1994-2003 Not stated 23% (Nyirenda 2006) 
 South Africa 10% Upper-
Middle 
Durban Jan-Mar 
2016 
Laboratory and 
clinical 
43%# (Gounden et al. 2018) 
Americas Brazil 13% Upper-
Middle 
Nationwide 2007-2011 Not stated 13% (Gomes et al. 2014) 
 USA 21% High Houston, Texas 1995-1999 Laboratory and 
clinical 
29%# (Gonzalez et al. 2003) 
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 USA 21% High Minnesota 
(Somali-born) 
1993-2003 Not stated 49% (Rock et al. 2006) 
 USA 21% High North Carolina 1993-2006 Laboratory and 
clinical 
22%^ (Kipp et al. 2008) 
 USA 21% High Nationwide 1993-2006 Not stated 20%& (Peto et al. 2009) 
 USA 21% High Texas 2009-2015 Not stated 24%# (Qian et al. 2018) 
Eastern 
Mediterranean 
Saudi 
Arabia 
26% High Nationwide 2010-2011 Not stated 31% (Memish et al. 2014) 
Europe Austria 24% High Nationwide 2011 Not stated 20% (Solovic et al. 2013) 
 Czech 
Republic 
14% High Nationwide 2011 Laboratory and 
clinical 
13% (Solovic et al. 2013) 
 Estonia 7% High Nationwide 1991-2000 Laboratory and 
clinical 
12% (Pehme et al. 2005) 
 Germany 25% High Nationwide 1996-2000 Laboratory and 
clinical 
22% (Forssbohm et al. 2008) 
 Germany 25% High Nationwide 2011 Not stated 21% (Solovic et al. 2013) 
 Malta 26% High Nationwide 2011 Laboratory and 
clinical 
33% (Solovic et al. 2013) 
 Netherlands 46% High Nationwide 2011 Laboratory and 
clinical 
44% (Solovic et al. 2013) 
 Poland 5% High Nationwide 2011 Not stated 7% (Solovic et al. 2013) 
 Romania 16% Upper-
Middle 
Nationwide 2011 Not stated 14% (Solovic et al. 2013) 
 Slovakia 15% High Nationwide 2011 Laboratory and 
clinical 
16% (Solovic et al. 2013) 
 Slovenia 13% High Nationwide 2011 Guidelines 
require positive 
culture, but 
some not 
confirmed 
14% (Solovic et al. 2013) 
 Spain 28% High La Coruña, 
Galicia 
1991-2008 Laboratory and 
clinical 
38%& (García-Rodríguez et al. 2011) 
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 Sweden 34% High Nationwide 2011 Laboratory and 
clinical 
39% (Solovic et al. 2013) 
 Turkey 34% Upper-
Middle 
Kahramanmaras 2007-2012 Laboratory and 
clinical 
45%^ (Ates Guler et al. 2015) 
 Turkey 34% Upper-
Middle 
Kocaeli, 
Marmara 
1996-2000 Laboratory and 
clinical 
31%^ (Ilgazli et al. 2004) 
 UK (England 
and Wales) 
46% High Nationwide 1999-2006 Laboratory and 
clinical 
41% (Kruijshaar & Abubakar 2009) 
 UK 46% High Nationwide 2011 Not stated 48% (Solovic et al. 2013) 
South-East 
Asia 
Bhutan 49% Lower-
Middle 
Nationwide 2001-2010 Laboratory and 
clinical 
26-42%  
per year 
(Jamtsho et al. 2013) 
 India 16% Lower-
Middle 
Delhi 1996-2003 Laboratory and 
clinical 
20% (Arora & Gupta 2006) 
 India 16% Lower-
Middle 
Deralakatte, 
Karnataka 
2005-2011 Laboratory and 
clinical 
42% (Prakasha et al. 2013) 
 India 16% Lower-
Middle 
Kanpur, Kerala 2013-2015 Unknown 52% (Mavila et al. 2015) 
 India 16% Lower-
Middle 
Mumbai 2000-2002 Laboratory 22% (Gothi & Joshi 2004) 
 Myanmar 11% Lower-
Middle 
Nationwide, 
Myanmar 
Medical 
Association 
public-private 
mix clinics only  
2013 Unknown 9% (Thet Lwin et al. 2017) 
Western 
Pacific 
China 5% Upper-
Middle 
Tianjin 2006-2011 Laboratory 10% (Wang et al. 2014) 
 China 5% Upper-
Middle 
Nanshan 
district, 
Shenzhen 
2001-2016 Unknown 11% (Zhu et al. 2018) 
 Fiji 29% Upper-
Middle 
Nationwide 2002-2013 Laboratory and 
clinical 
25% (Pezzoli et al. 2016) 
260 
 Korea 
(Republic) 
19% High Nationwide 2013 Unknown 20% (Lee 2015) 
EPTB: extrapulmonary tuberculosis; UK: United Kingdom; USA: United States of America 
*Income groups are based on The World Bank list of economies for fiscal year 2018 (World Bank Group n.d.) 
@Based on the 2017 Global TB Report published by the World Health Organization (World Health Organization 2017a), with extrapulmonary TB 
proportion estimated to be 100% less the % pulmonary  
^Excludes patients with concurrent pulmonary and extrapulmonary infection, unless otherwise noted, and where these groups were defined in 
the study 
#Includes concomitant pulmonary and extrapulmonary infection 
&Includes disseminated infection, but not concomitant pulmonary and extrapulmonary infection.
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APPENDIX 2 
DETAILS OF PERIPHERAL HEALTH CENTRES IN THE BALIMO REGION 
Appendix 2 - Table 1: Peripheral health centre details for sites where TB can be diagnosed and/or treated in the Gogodala and Bamu regions. 
The details of these sites were obtained from Sister Bisato Gula. 
Location Type LLG Affiliation TB staff TB register Treatment Other staff 
and facilities 
Adiba Sub-HC Gogodala Rural ECPNG 1 x CHW No  
(record only) 
No (send to Balimo)  
Ali Aid post Gogodala Rural Government 1 x CHW Yes Yes  
Awaba HC Gogodala Rural ECPNG 2 x nurse Yes Yes TB ward 
ZN staining 
Bamio HC Bamu Rural Catholic 1 x nurse Yes Yes  
Emeti HC Bamu Rural Government 2 x CHW Yes Yes 1 x nurse 
Kamusie Clinic Bamu Rural Logging 
company 
1 x doctor 
1 x CHW 
Yes Yes 1 x CHW 
Mapodo HC Gogodala Rural ECPNG 2 x CHW Yes Yes 1 x nurse 
1 x CHW 
Pikiwa Treatment 
booth 
Gogodala Rural Logging 
company 
1 x tx 
supporter 
Yes No (send to Awaba)  
Sisiami Aid post Bamu Rural Government 1 x CHW Yes No (send to Bamio or Balimo)  
Tapila HC Gogodala Rural Government 1 x HEO Yes Yes 1 x nurse 
3 x CHW 
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Wasua HC Gogodala Rural ECPNG 1 x nurse 
1 x CHW 
Yes Yes 3 x CHW 
Wawoi Falls HC Bamu Rural ECPNG 1 x nurse Yes Yes 
(sputum not sent to Balimo) 
2 x CHW 
CHW: community health worker; ECPNG: Evangelical Church of Papua New Guinea; HC: health centre; HEO: health extension officer; LLG: local 
level government; TB: tuberculosis; tx: treatment; ZN: Ziehl-Neelsen 
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APPENDIX 3 
ANALYSIS OF BIAS IN REPORTING OF AGE 
 
Method: 
Potential bias in age was examined to determine whether reported ages were likely to be 
accurate. To do this, reported ages were recoded into each year of a decade. For example, 
all patients who reported their age as 10, 20, 30, 40, 50, 60, or 70 were recoded as 0; all 
patients who reported their age as 11, 21, 31, 41, 51, 61, or 71 were recoded as 1; and so on. 
Patients under the age of 10 were excluded from the analysis, as it was thought that age 
would be more likely to be correct in the early years of life. Age reporting was then 
examined using the Chi-square goodness of fit test, to determine if there was a significant 
difference between any of the reported years. 
 
Evidence of bias was identified in the reporting of age. Graphing of the recoded age groups 
showed ‘0’ and even-numbered age groups to be more frequently reported (Appendix 3 - 
Figure 1), and this result was statistically significant (X2 = 101.35, p < 0.01). 
The significant association continued when the ‘0’ age group was removed, with 
observations in the odd-numbered groups below the expected frequency, and observations 
in the even-numbered groups above the expected frequency (X2 = 22.08, p < 0.01). As a 
result, all further analyses involving age were based on the WHO age category groupings 
only, and no analyses were undertaken based on age as a continuous variable. 
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Appendix 3 - Figure 1: Graph of age group recoding, showing frequency of reported age in 
each year of a decade.  
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APPENDIX 4 
DETAILS OF RESIDENTIAL LOCATIONS AND LANGUAGE GROUPS 
 
Residential locations and derived language groups for patients recorded in the TB patient 
register. 
 
Appendix 4 - Table 1: Residential locations reported by TB patients (based on the first 
recorded address only). To ensure privacy only towns and villages with at least 10 TB cases 
are shown here. All locations with fewer cases are grouped under ‘Other villages’. 
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Appendix 4 - Table 2: Language groups spoken in residential locations reported by TB 
patients, based on the first residential address recorded. 
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APPENDIX 5 
DETAILS OF GEOGRAPHIC DATA 
Appendix 5 - Table 1: Geographic data and sources used for locations not listed in the census unit population data. 
Village Longitude Latitude Source 
Diwame 143.162994 -7.746011 http://placesmap.net/PG/Diwame-3213496/  
Kaniya 142.579102 -7.97672 http://placesmap.net/PG/Kaniya-9568/ 
Kubeai 143.044098 -7.306943 http://placesmap.net/PG/Kubeai-3160823/  
Lake Campbell / Kembi Lake 142.609 -6.74903 ArcGIS Online 
Madila 143.159 -7.99567 ArcGIS Online 
Panakawa 143.133 -7.68503 ArcGIS Online 
Parieme 142.973 -7.65253 ArcGIS Online 
Sasareme 142.867 -7.6167 http://www.aic.gov.pg/pdf/FinRpts/2012/AIC%2012-1005%20P2-
MCZ%20Final%20Report.pdf 
Saweta 142.655 -8.01297 ArcGIS Online 
Sogai 142.979 -7.60316 ArcGIS Online 
Waliyama 143.157 -8.28449 ArcGIS Online 
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APPENDIX 6 
COPY OF MANUSCRIPT PUBLISHED IN 
TROPICAL MEDICINE & INTERNATIONAL HEALTH 
AND PERMISSION FOR USE 
 
The majority of Chapter 3 of this thesis has been published in the journal of Tropical 
Medicine & International Health, with publication details as follows: 
Diefenbach-Elstob T, Graves P, Dowi R, Gula B, Plummer D, McBryde E, Pelowa D, 
Siba P, Pomat W and Warner J (2018) The epidemiology of tuberculosis in the rural 
Balimo region of Papua New Guinea. Tropical Medicine & International Health. In 
Press. https://doi.org/10.1111/tmi.13118 © 2018 John Wiley & Sons Ltd 
 
Written permission to include the article in this thesis as well as the original licence 
agreement follow on pages 269 – 275. 
A copy of the published article is shown on pages 276 – 286. 
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APPENDIX 7 
STANDARD PERMISSIONS FOR USE OF 
ARCGIS ONLINE BASEMAPS AND GOOGLE MAPS 
 
The following pages provide copies of the permissions for use of ArcGIS Online (Esri) and 
Google maps. The guidelines shown here have been followed for the use and attribution of 
maps included in this thesis. 
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APPENDIX 8 
PUBLICATIONS, PRESENTATIONS, AND OTHER ACHIEVEMENTS 
THROUGHOUT DOCTORAL STUDIES 
 
Publication: 
Diefenbach-Elstob T, Graves P, Dowi R, Gula B, Plummer D, McBryde E, Pelowa D, Siba P, 
Pomat W and Warner J (2018) The epidemiology of tuberculosis in the rural Balimo region of 
Papua New Guinea. Tropical Medicine & International Health. In Press. 
https://doi.org/10.1111/tmi.13118 
 
Conference presentations: 
‘Social and cultural determinants of TB treatment adherence in a remote region of Papua 
New Guinea’ (June 2015) AIMS Tropical Division Scientific Meeting, Townsville Australia 
– Oral presentation 
‘The sociocultural determinants of tuberculosis treatment adherence in the rural Balimo 
region of Papua New Guinea’ (September 2015) Australasian Tropical Health Conference, 
Palm Cove, Australia 
– Poster presentation 
‘Tuberculosis and drug resistance in the Balimo region of Papua New Guinea’ (September 
2015) Australasian Tropical Health Conference, Palm Cove, Australia 
– Oral presentation 
‘Tuberculosis and spatial epidemiology in the Balimo region of Papua New Guinea’ 
(December 2016) JCU CPHMVS 1st HDR Student Conference, Townsville, Australia 
– Oral presentation 
‘Tuberculosis in rural Papua New Guinea: towards enhancing clinical diagnoses in a resource-
limited setting’ (March 2017) 6th Conference of International Union Against Tuberculosis and 
Lung Disease, Asia Pacific Region, Tokyo, Japan 
– Poster presentation 
‘The epidemiology of presumptive tuberculosis cases in the rural Balimo district of Western 
Province, Papua New Guinea’ (September 2017) CBMDT & CBTID 2017 Annual Scientific 
Retreat, Cairns, Australia 
– Poster presentation 
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‘The epidemiology of tuberculosis in the Balimo district of Western Province, Papua New 
Guinea’ (September 2017) Australasian Tropical Health Conference, Cairns, Australia 
– Oral presentation 
‘The epidemiology of tuberculosis in the Balimo district of Western Province, Papua New 
Guinea’ (December 2017) PNG Impact, Port Moresby, Papua New Guinea 
– Oral presentation 
‘The epidemiology of tuberculosis in the Balimo district of Western Province, Papua New 
Guinea’ (December 2017) 2017 CPHMVS HDR Student Symposium, Townsville, Australia 
– Oral presentation 
‘Tuberculosis in the Balimo region of Western Province, PNG’ (May/June 2018) 7th 
Tuberculosis Control Symposium, TB-CRE, Sydney Australia 
– Oral presentation 
 
Other presentations and media: 
2016 JCU 3-Minute Thesis (3MT) competition – Title: TB or not TB: that is the question 
- College of Public Health, Medical and Veterinary Sciences – Finalist 
- Division of Tropical Health and Medicine – Finalist 
Brighter article: Battling a forgotten disease in remote Papua New Guinea – Available from: 
https://www.jcu.edu.au/brighter/articles/battling-a-forgotten-disease-in-remote-papua-
new-guinea  
 
Grants: 
Graduate Research Scheme Grants-In-Aid 2015, Round 2 - $3240 
Higher Degree by Research Enhancement Scheme – Grants-In-Aid 2016, Round 2 - $2500 
Higher Degree by Research Enhancement Scheme – Grants-In-Aid 2017, Round 1 - $3000 
